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ABSTRACT 
Muithi Mwanthi 
 
 
PAK1’S  REGULATION OF EOSINOPHIL MIGRATION AND IMPLICATIONS 
FOR ASTHMATIC INFLAMMATION 
 
More than 300 million people world-wide suffer from breathlessness, wheezing, 
chest tightness, and coughing characteristic of chronic bronchial asthma, the 
global incidence of which is on the rise. Allergen-sensitization and challenge 
elicits pulmonary expression of chemoattractants that promote a chronic 
eosinophil-rich infiltrate. Eosinophils are increasingly recognized as important 
myeloid effectors in chronic inflammation characteristic of asthma, although few 
eosinophil molecular signaling pathways have successfully been targeted in 
asthma therapy. p21 activated kinases (PAKs),  members of the Ste-20 family of 
serine/threonine kinases, act as molecular switches in cytoskeletal-dependent 
processes involved in cellular motility. We hypothesized that PAK1 modulated 
eosinophil infiltration in an allergic airway disease (AAD) murine model. In this 
model, Pak1 deficient mice developed reduced inflammatory AAD responses in 
vivo with notable decreases in eosinophil infiltration in the lungs and broncho-
alveolar lavage fluids (BALF). To test the importance of PAK1 in hematopoietic 
cells in AAD we used complementary bone marrow transplant experiments that 
demonstrated decreased eosinophil inflammation in hosts transplanted with Pak1 
deficient bone marrow. In in vitro studies, we show that eotaxin-signaling through 
 
vi 
PAK1 facilitated eotaxin-mediated eosinophil migration. Ablating PAK1 
expression by genetic deletion in hematopoietic progenitors or siRNA treatment 
in derived human eosinophils impaired eotaxin-mediated eosinophil migration, 
while ectopic PAK1 expression promoted this migration. Together these data 
suggest a key role for PAK1 in the development of atopic eosinophil inflammation 
and eotaxin-mediated eosinophil migration. 
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BACKGROUND AND SIGNIFICANCE 
 
Asthma 
Approximately 250 million people world-wide suffer from breathlessness, 
wheezing, chest tightness, and coughing characteristic of chronic bronchial 
asthma. Asthma’s staggering 12% US population prevalence continues to rise, 
paralleling hospitalizations for severe asthmatic attacks, especially in women, 
children, minority, and low-income populations [1, 2].  Asthma increases 
morbidity and health care costs, and, in severe cases, causes death.  Chronic 
asthma also synergizes with comorbid cardiopulmonary diseases, significantly 
compromising the patient’s respiratory system [3]. While patients need essential 
education on allergen–avoidance, the management of asthma primarily centers 
on pharmacotherapy. The 2009 Asthma Insight and Management survey of 
treatment modalities in the US reveals unsatisfactory asthma control assessment 
and implementation of current treatment guidelines [4]. Current global 
management of asthma symptoms with corticosteroids and β2 agonists has done 
little to stop disease morbidity or thousands of annual asthma attack fatalities 
(WHO) and clinical asthmatic care and outcomes in the US have idled in the past 
decade [5]. General immunosuppressive strategies which cause adverse 
systemic effects or novel therapies with narrow target population specificity, fail 
to effectively deal with the heterogeneity among asthma patients.  This 
therapeutic stagnation warrants focused investigation into deregulated 
inflammatory pathways within effector cells central to asthma pathogenesis. The 
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mitogen-activated protein kinases and their effector molecules like the p-21 
activated kinases (PAKs) are molecular switches that amplify intracellular 
proinflammatory signals in immune cells that may provide promising targets to 
modulate asthmatic inflammation. 
 
Bronchial asthma is a clinically heterogeneous disease with broad impact, multi-
factorial origin, and varied manifestation. Clinically, asthma is characterized by 
airway hyper-responsiveness (AHR) to muscarinic agonists, reversible airway 
obstruction, chronic airway inflammation, and excessive mucus production [6, 7]. 
Atopic asthma is triggered by exogenous antigens. Clinicians delineate atopic 
asthmatic subtypes based on the cell infiltrate nature, triggering factors, and 
response to corticosteroid treatment [6, 7]. Asthmatic inflammatory processes 
occur in three recognized phases. On allergen exposure the patient experiences 
rapid onset of local early-phase chest tightness, wheezing, and breathlessness 
(1-30 minutes) mediated by mast cell degranulation in airway epithelium and 
smooth muscle. The allergen-challenged individual subsequently suffers 
prolonged obstructive and pruritic late-phase symptoms (2-9 hours) provoked by 
systemic lipid mediators [8]. Repeated and continuous allergen-exposure 
establishes a chronic inflammatory lung environment exhibiting pathognomonic 
structural changes: distended airways with mucus plugs, eosinophil infiltration, 
charcot-laden crystals (CLCs), basement membrane fibrosis, airway smooth 
muscle (ASM) hypertrophy, hyperplasia, and mucus airway epithelium 
metaplasia (weeks, months, and years) [6]. These morpho-pathological findings 
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implicate deregulated intercellular interactions among multiple hematopoietic cell 
lineages and pulmonary environment cell types critical to pathogenesis [9, 10].   
 
Development of murine models of allergic airway inflammation 
Animal model design mimics the recognized features of human disease, 
highlights disease mechanisms, and drives the development of therapeutics. 
Several animal species including rats, guinea pigs, and even several non-human 
primate species have provided informative models for allergic airway disease. 
However, most current field-advancing asthma research is performed in mice 
primarily because of the ease of genetic manipulation, availability of a broad 
variety of immunological assays, and practical merits of murine colony 
management [11]. Initial murine allergic airway disease models developed to 
investigate hyper-reactive smooth muscle mediated bronchoconstriction, as well 
as hyperpnea promoted the use of β2 agonists for asthma treatment [12]. For the 
last three decades, allergic airway disease (AAD) animal models reflect the 
increased recognition of the role chronic inflammation plays in the pathogenesis 
of the human disease of asthma. This recognition initiated the dichotomy of AHR 
versus inflammatory murine models of allergic airway inflammation (AAI).  
 
Murine ovalbumin (OVA)-sensitization and challenge provides a model to study 
specific cell and cytokine regulation of allergic airway inflammation and has 
informed the development of many specific therapies. The OVA murine model 
has been the linchpin in studying the initial development of allergic airway 
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inflammation [7]. Lessons learned via the OVA model of allergic airway 
inflammation have provided insights resulting in oral and inhaled corticosteroids 
complementing β2 agonists in human bronchial asthma management [13-16]. 
Currently β2 agonist monotherapy without corticosteroids is uncommon practice 
[17]. On the other hand, in murine models corticosteroids have also been shown 
to cause significant immunosuppression and osteoporosis [16, 18]. Moreover, 
corticosteroids do not alter the natural course of the disease [19].  The OVA 
model, however, is limited by inaccuracy in recapitulating chronic inflammation 
and tissue remodeling, along with an allergen-induced tolerance induced by 
chronic OVA challenge that are not characteristic of human asthma [20, 21]. 
However, the OVA murine AAD model has several limitations as a tool for 
studying human asthma.  Unlike many human allergens, pure OVA lacks intrinsic 
protease activity and contaminating environmental adjuvants like house dust mite 
extracts; therefore OVA is commonly used in conjunction with the adjuvant 
aluminum hydroxide/ALUM or low LPS levels in mice to bolster the inflammatory 
AAD response [22-25]. Similarly age, gender, strain, and OVA-dose concerns 
also beleaguer the utility of any murine AAD model [26-29].  
 
Development of murine allergic airway inflammation 
Allergic airway inflammation, an adaptive immune response, entails antigenic 
sensitization and subsequent challenge of the immune system. Allergens, 
innocuous environmental antigens, sensitize the immune system of atopic 
individuals. In airway sensitization, allergens degrade epithelial tight junctions, 
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enhance epithelial blood flow or penetrate the airway epithelial barrier by other 
mechanisms [30-32]. Tobacco smoke, other air pollutants, genetic factors, and 
infectious agents may also compromise the integrity of the airway epithelial 
barrier exposing immunosurveillant airway dendritic cells (DCs) to higher doses 
of environmental allergens [22, 33-35]. At the basolateral surface of the 
epithelium, airway DCs usually sample and induce immune tolerance to airway-
invasive allergens in adjacent lymph nodes. However, some antigens can 
activate airway DCs by pattern recognition receptors and protease-activated 
receptors to induce a potent adaptive immune response [36-38]. Activated airway 
DCs secrete IL-4 that directs the maturation of naïve T cells to a Th2 phenotype 
[39]. Airway DCs also secrete chemokines like CCL17 and CCL22 that attract 
Th2 cells to the lung to orchestrate AAI [40]. A schematic of cellular interactions 
in the development of human asthmatic inflammation is illustrated in Figure 1. 
 
For decades, researchers studying atopy have considered CD4+ T-helper II 
(Th2) cell polarization as the central cell dysregulation in allergic diseases and 
asthma although the crucial role of the inflammatory environment is increasingly 
gaining recognition [7, 8, 25, 41, 42]. The mature Th2 cell synthesizes and 
secretes IL-3, IL-4, IL-5, IL-9, IL-13, and granulocyte-macrophage colony 
stimulating factor (GM-CSF); these molecules direct asthmatic inflammation [43]. 
Moreover, depletion of murine CD4+ T cells prevents development of AAI and 
only adoptive transfer of Th2 cells restores allergic inflammatory phenotype [44-
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47]. However, specific IL-4, IL-5, and IL-13 anti-therapies have shown varied and 
limited efficacy in clinical trials [41].  
 
Atopic asthma, a type I hypersensitivity, classically centers around the Th2 cell 
regulation of B cell antibody isotype switching to antigen-specific IgE molecules 
[41, 48].  Th2 derived IL-4 and IL-13 promote B cell maturation to allergen-
specific IgE secreting plasma cells and memory cells, while,  IL-3, IL-4, and IL-13 
govern basophil maturation as well as mast cell maturation and pulmonary 
recruitment [7, 49, 50] . Allergen-specific IgE can then bind to the high affinity Fc 
epsilon receptor type I (FcεRI) on basophils and mast cells and subsequent 
allergen exposure crosslinks the IgE-bound receptors inducing immediate 
degranulation [8]. The mast cell preformed degranulation mediators, histamine, 
proteoglycans, and serine proteases rapidly increase vascular permeability and 
bronchoconstriction provoking the characteristic obstructive symptoms of the 
early phase of asthma [8]. IgE also negatively feeds back on IgE production and 
signaling via CD23 (FcεRII) crosslinking on B and non-B cells [49-51]. Moreover, 
AAD studies in immunoglobulin deficient (JHD) mice show B cells play an 
immunotolerizing role to allergens [52]. Additionally, anti-IgE treatment in mice 
reduces several hallmarks of AAI [53]. Mast cell deficient mice (KitW/W-v & KitW-
sh/W-sh) have a significantly attenuated overall airway inflammatory response 
indicating mast cells are not only crucial in the early-phase but also the late and 
chronic phases of asthma [54]. Similarly, c-kit silencing in mice ablated this 
airway inflammation [55]. IgE-bound FcεRI crosslinking also initiates mast-cell 
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and basophil synthesis of lipid mediators important in the late phase of an 
asthmatic attack [8].  
 
Another player, the airway epithelium fuels asthmatic inflammation by secreting 
critical factors to chronic inflammation [25]. Airway epithelium–Th2 interactions 
are pivotal in chronic airway remodeling characteristic of human bronchial 
asthma. Th2 IL-13 induces goblet cell metaplasia, airway epithelial hyperplasia, 
increased epithelial secretions, and ASM hyper-responsiveness [56-60]. In 
contrast to its barrier function, the airway epithelium also secretes cytokines and 
growth factors that actively contribute to the development of chronic asthmatic 
inflammation. Epithelial cell-derived cytokines and growth factors IL-25, IL-33, 
thymic stromal lymphopoeitin (TLSP), GM-CSF, and eotaxins promote the 
development of chronic asthmatic inflammation [25]. Epithelial TLSP secreted in 
response to ligation of pathogen-associated molecular pattern (PAMP) receptors 
amplifies the Th2 response directly, by enhancing antigen presentation, or by 
acting on other hematopoietic cells [25, 61-64]. Epithelial IL-25 stimulates Th2 
cytokine secretion from both T cells and non-T cells and induces goblet cell 
metaplasia and eosinophilia [65-68]. Similarly, IL-33 activates hematopoietic cells 
and can generate Th2 cells by toll-like receptor, ST2, ligation independent of 
STAT 6. Furthermore, OVA-sensitized and challenged ST2 deficient mice have 
decreased parameters of inflammation [69-71]. Critically, epithelial GM-CSF and 
eotaxins promote development, trafficking, and lipid mediator synthesis of 
eosinophils  
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Figure 1 
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Figure 1: Schematic illustrating cellular interactions promoting chronic 
inflammation and remodeling in asthma. Th2 cytokines regulate the 
inflammatory changes in multiple hematopoietic and airway cell types. Th2-
eosinophil-airway tissue interactions critically promote chronic asthmatic 
inflammation and promote airway hyper-reactivity, cytokine expression, injury, 
smooth muscle hypertrophy and consequent airway remodeling. This figure 
summarizes content from Galli, Nature reviews, 2008 [8]. 
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The eosinophil and the inflammatory environment in asthma 
As current understanding of allergic mechanisms does not fully account for the 
great variety in asthmatic phenotype, human asthma persists as a clinically-
defined disease of elusive mechanistic complexity.  Traditionally asthmatic 
inflammation was regarded primarily as a Th2 cell mediated hypersensitivity. 
Mounting evidence, however, suggest fundamental modulatory roles for other 
myeloid cells, and the airway environment [7, 25, 41, 72]. Granulopoiesis 
accelerates because of cytokine secretion during asthmatic inflammation [73, 
74]. All major myelocytes (neutrophils, mast cells, and especially eosinophils) are 
reported to modulate asthmatic inflammation [25, 75]. Clinically, atopic asthma 
with predominant eosinophil lung infiltration and inflammation is the most 
common asthmatic subtype [6] in which eosinophils are the most numerous cell 
type recruited to the asthmatic lung [76]. 
 
Tissue eosinophils are found in the gastrointestinal tract, bone marrow, blood, 
and other tissues, excluding the lung under non-inflammatory homeostatic 
conditions. Recent reports, however, demonstrate eosinophil-lineage committed 
cells undergo proliferation locally in the inflamed asthmatic lung [74]. However, 
eosinophils have classically been considered effectors of Th2 cell inflammation. 
Th2 eosinophilopoietins (GM-CSF, IL-3, and critically IL-5) direct differentiation 
and maturation of eosinophil progenitor cells in the bone marrow as well as 
mobilization of eosinophils and eosinophil progenitors into the blood [77-79]. 
Bone marrow of the eosinophil lineage is coordinately controlled by GATA-1 and 
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PU.1 [80]. GATA-1 drives CCR3, major basic protein (MBP) and IL-5Rα 
eosinophil-specific gene expression, and functional deletion of GATA (dlb GATA) 
or transgenic co-expresssion of GATA with diphtheria toxin (PHIL) ablates the 
eosinophil lineage and AAD hallmarks in allergen-sensitized mice [81-83]. 
Similarly, PU.1 regulates expression of many eosinophil cationic proteins [84].  
 
Repeated allergen-challenge promotes a chronic eosinophil-rich pulmonary 
infiltrate in humans and mice. GM-CSF, IL-3, and IL-5 in concert with allergen-
induced Th2 cell, ASM, and airway epithelial-derived eotaxins elicit rapid 
eosinophil vascular egression and selective pulmonary trafficking of eosinophils 
via CCR3 G-protein signaling [76, 78, 85-87]. Moreover, IL-5 deficient mice and 
patients with a genetic polymorphism decreasing eotaxin expression 
demonstrate decreased allergen–induced eosinophilic lung infiltration [84, 88]. 
On the contrary, CCR3 ligation by inhibitory ligand can inhibit migration [89]. 
Emerging evidence further suggests that allergen incited inflammatory cytokines 
recruit hematopoietic progenitor cells from bone marrow to the lung where they 
can undergo further proliferation and final maturation, intensifying the degree of 
tissue inflammation [74]. While the genetic evidence for IL-5 and eotaxin control 
of eosinophil lung accumulation in AAD is compelling, anti-IL-5 therapy in asthma 
patients reduced eosinophilia and eosinophil TGFβ expression in the lung, but 
only modestly reduced AHR [90]. In contrast to these studies, other evidence 
suggests eosinophil infiltration of tissues can be T-helper cell-independent. 
Helper T cells were dispensable in eosinophil infiltration in a non-AAD murine 
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model [91]. Rather, eosinophil transfers were necessary to restore Th2 cytokine 
secretion in IL-5 and eotaxin deficient mice [92].  
 
Granulocyte trafficking from bone marrow to sites of inflammation involves 
relative eosinophil-endothelial rolling, adhesion, and transmigration. CCR3: 
chemokine-induced eosinophil adhesion and transmigration depends on 
interactions between eosinophil and the vessel wall. Expression and ligation of 
eosinophil alpha class of integrins LFA-1, VLA-4, α4β7, and Mac1 by endothelial 
ICAM, VCAM, and MadCAM are implicated in eosinophil accumulation in vivo 
[93-95]. In addition, Siglec F seems critical to egression and survival of 
eosinophils at sites of eosinophil inflammation [96]. A coordinated balance 
among adhesive, motile, and structural forces in the eosinophil are responsible 
for its consequent diapedesis through vascular epithelium and infiltration of local 
sites of airway inflammation. These processes are illustrated in Figure 2. While 
eosinophil infiltration is crucial to the development of asthmatic inflammation, the 
exact intrinsic eosinophil mechanisms by which eosinophils traffic to the lung in 
asthma and AAD remain incompletely understood. 
 
Accumulating evidence suggests eosinophils can regulate production and 
secretion of a variety of immunomodulatory molecules. Critically, eosinophil 
mediators, cytokines, and growth factors modulate asthmatic late phase and 
chronic airway inflammation. Eosinophils are the main source of cysteinyl 
leukotrienes that amplify the late phase response [97]. In concert with Th2 
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cytokines, lipid mediators promote exacerbated systemic vascular leak and 
pulmonary inflammation [8]. Moreover, currently prescribed cysteinyl leukotriene 
receptor blockers and phosphodiesterase inhibitors have been moderately 
successful at attenuating asthma [41]. Eosinophil granules contain toxic cationic 
proteins that cause tissue injury, remodeling and chronic inflammation in the 
asthmatic lungs [90, 98]. Airway tissue samples from asthmatic patients 
frequently demonstrate eosinophil degranulation products in CLCs [99]. The 
cationic granule proteins, MBP, eosinophil peroxidase (EPO), eosinophil cationic 
protein (ECP) and eosinophil-derived neurotoxin (EDN) wound airway epithelial 
cells, parasympathetic nerve endings, basement membrane, and smooth muscle 
promoting airway remodeling [100-104]. Degranulation products discovered 
around vagal nerve ganglia that innervate smooth muscle are hypothesized to 
cause AHR [105]. A piece-meal exocytotic mechanism governs release of human 
eosinophil preformed granule proteins and mediators, which allows for selective 
mobilization of granule proteins [106, 107]. Eosinophil degranulation and 
mediator release is controlled by cytoskeleton-facilitated Soluble N-
ethylmaleimide-sensitive factor Attachment Protein Receptor (SNARE)/Vesicle-
associated membrane protein (VAMP) interactions and intracellular trafficking 
[103]. Additionally on allergen-sensitization, eosinophils synthesize and secrete 
cytokines, chemokines, and growth factors. These pro-inflammatory molecules 
including IL-25, TGFα, TGFβ, metalloproteinases, pro-fibrotic, and angiogenic 
factors establish a chronic inflammatory milieu in the airway epithelium and 
facilitate injury and remodeling in asthma [90, 108-112]. 
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Figure 2 
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Figure 2: Schematic illustrating selective eosinophil interactions in bone 
marrow eosinophilopoiesis, egress into the blood, transmigration into the 
asthma-inflamed lung, and inflammation. Eosinophil lineage differentiation 
and maturation is coordinately controlled by GATA-1, PU.1, and c/EBP driven 
eosinophil gene expression as well as IL-3, IL-5, and GM-CSF signaling (top 
panel). Mature eosinophils or committed progenitors are mobilized in response to 
IL-5. Eotaxin concentration gradients induce the relative adhesion and 
diapedesis of eosinophils through the leaky endothelial wall (middle panel). 
Eotaxin-stimulated eosinophils release cationic proteins, cytokines, and 
inflammatory mediators that modulate chronic airway inflammation and 
remodeling. This figure was adapted and simplified from a review published by 
Rothenberg and Hogan in Annu. Rev. Immunol. 2006 [103, 113].  
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Identifying novel asthma targets 
While we are also beginning to understand the intercellular cytokine and 
mediator signaling cascades in asthma, no new drugs have been developed to 
replace corticosteroids in managing bronchial asthma. This stagnation in 
effective new asthma therapy warrants a broader investigative approach that 
seeks to identify putative molecular instigators of inflammation in multiple 
inflammatory processes. The mitogen-activated protein kinases (MAPKs) are 
kinases that modulate and amplify many intracellular signals important to the 
inflammatory process in multiple cell lineages. Moreover, mice treated with 
inhaled inhibitors of p38 MAPK have shown promising attenuation of eosinophilic 
inflammation [39, 114, 115]. Furthermore p38 MAPK, ERK, and JNK inhibitors 
have shown some efficacy at inhibiting eosinophil chemotaxis and pro-
inflammatory mediator synthesis and release [116-118]. p38 MAPK are known to 
modulate cytoskeletal remodeling and cell motility [119, 120]. p38 MAPK 
transduces migratory signals from multiple upstream molecular switches. PAKs, 
one such group of kinases, indirectly activate p38 MAPK and induce 
hematopoietic and endothelial cell migration [121, 122]. PAKs, modulators of p38 
MAPK and other MAPK proteins, may also promote chronic asthmatic 
inflammation and provide attractive alternative therapeutic targets. 
 
The Rho-family of GTPase proteins, the classic activators of PAKs, are 
implicated in the pathophysiology of bronchial asthma. Rac GTPase levels and 
activity and Rho-kinase (ROCK) activity are both elevated in smooth muscle 
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hyper-responsiveness and eosinophilia in models of chronic AAI [123-125]. 
Furthermore, Simvastatin decreases human AHR by inhibiting Rac1 [126]. In a 
murine model of AAD, ROCK small molecule inhibitors attenuated asthmatic 
eosinophilia and AHR [127]. Racs also modulate SCF-kit induced mast cell 
migration [128, 129]. Moreover, expression of a dominant negative construct of 
Rac 1 decreases mast cell synthesis and secretion of cysteinyl-leukotrienes to 
IgE stimulation [130].  
 
 
p-21 activated Kinases (PAKs) 
PAKs, members of the Ste-20 family of serine/threonine kinases, regulate many 
cellular physiological processes. Human tissues vary widely in their expression of 
the six isoforms of PAKs [131].  PAK1-3, Group 1 PAKs are structurally 
comprised of an N-terminal p21-binding domain, an overlapping regulatory region 
that includes an autoinhibitory domain, and a C-terminal catalytic kinase domain. 
They exist as auto-inhibited trans-homodimers under basal conditions [132-135].  
 
First described as binding partners of the Rho-family proteins CDC42 and Racs 
in murine brain tissue, Group 1 PAKs were found at  68, 65, and 62 kDa and 
were later designated PAK1 (α-PAK), PAK3 (β-PAK), and PAK2 (γ-PAK) 
respectively [134]. Their activation requires the CDC42/Racs-dependent 
dismantling of the inhibited dimeric complex into active monomeric units [136]. 
Classically, the active GTP-bound Rho-family GTPases, CDC42 or Rac, bind and 
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remove the CDC42/Rac binding domain (CRIB/PBD), that liberates the kinase 
domain’s autocatalytic function, and induces a complex conformational change 
that permits further phosphorylation events [136-140]. The autophosphorylated 
PAK1 intermediate is phosphorylated at several residues including the signal 
residue threonine 423 [141, 142]. Many further phosphorylation events 
disassemble the dimeric complex into two active monomers of PAK1. A general 
schematic of these events is depicted in Figure 3. 
 
Independent and distinct from GTPase activation, sphingosine and other cell 
membrane lipids important in asthma can directly activate PAK1 and are 
implicated in AAI [138, 143, 144]. Nck and Grb2 adaptor proteins can chaperone 
inactive PAK1 to the cortical membrane where Rho-family GTPases enhance 
PAK1 catalytic activity up to 20-fold [138, 145-147]. 
 
PAK2, another isoform of PAKs and member of Group I PAKs, is ubiquitously 
expressed in human tissue including hematopoietic cells [134]. PAK2 shares 
77% protein sequence homology with PAK1 [148]. PAK2 in addition to GTPase-
dependent activation can additionally undergo proteolytic cleavage and activation 
by caspase 3 during apoptosis [149]. Both PAK2 and PAK1 are expressed in 
human and murine hematopoietic cells. However, while PAK1 has largely a 
similar substrate specificity and function to PAK2 in vitro [150], the differential 
roles of PAK1 and PAK2 in hematopoietic function are incompletely understood.  
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Figure 3. adapted from Eswaran, J et al., Trends Biochem Sci, 2008 
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Figure 3: Schematic showing the activation of p-21 activated Kinase 1 
protein. A. PAK1 exists as a trans-inhibited homodimer associated at their CRIB 
domains (shown in orange).  GTP-bound CDC 42 or Rac binding activates this 
complex by reorientating the dimeric complex and disinhibiting the kinase activity 
of the catalytic subunits (shown in brown). The activated catalytic domains are 
phosphorylated at many residues including the signal pT423 residue. This figure 
was adapted from the version first published by Eswaran et al in Trends Biochem 
Sci, 2008 [151].   
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PAK1 in cytoskeletal regulation and cell motility 
PAKs modulate many cellular processes by regulating cytoskeletal function. 
PAK1 modulates remodeling of the F-actin cytoskeleton involved in cell 
migration. On cell stimulation, PAK1 relocates to various F-actin cytoskeletal 
structures. PAK1 localizes to focal adhesion complexes at leading cell edges 
[133, 152-154], lamellipodia [155], filopodia, membrane ruffles,  retracting cell 
edges [156], and vesicles [157]. Furthermore, PAK1 assists in recycling focal 
adhesions and actin stress fibers [156, 158]. In lower organisms, embryological, 
neurogenic, and metabolic evidence supports a role for PAKs homologs in 
modulating the actin cytoskeleton [159-165].  
 
PAK1 modulates cytoskeletal remodeling by both kinase-dependent and -
independent mechanisms. In general, PAK1 binds CDC42/Racs, mediating 
activation of its catalytic activity, whereas PAK1 binding of adaptor proteins like 
PI mediates its translocation and binding to several transmembrane receptors 
[166]. Reports utilizing ectopically expressed activating and deactivating mutant 
constructs of PAK1 have clarified some of these effects [133, 142, 167]. Full 
length PAK1 as well as a constitutively active kinase mutant, L107F, promote F-
actin turnover and cell motility, whereas a kinase dead mutant of PAK1, K299R, 
suppressed these phenotypes [156, 158, 168].  
PAK1 catalytically modulates F-actin remodeling in events essential to cell 
motility through multiple downstream effectors as summarized in Figure 4. PAK1 
activates the LIM Kinase inhibiting ADF/cofilin (cofilin) and allowing for the 
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persistence of polymerized actin filaments in cell protrusions and other actin sub-
cellular structures [169]. Cofilin severs F-actin filaments, generating free actin 
barbed ends, the building blocks for polymerizing new filaments of actin [170]. 
Genetic and overexpression studies support a role of cofilin in F-actin dependent 
cell motility [171-173]. PAK1 regulates cofilin activity both directly and by 
downstream effectors; however, this temporal-spatial cofilin control is 
incompletely understood [174-176].  
Importantly this kinase also localizes with, binds, phosphorylates, and activates 
p41-ARC, a subunit of the ARP2/3 complex in vivo and in vitro [177]. This 
complex directs nucleation and branching of new filaments of actin by using 
filaments with free barbed ends [178, 179]. Additionally ARP2/3 contributes to F-
actin motility structures and force-generation at the cell’s cortical membrane, and 
consequent cell migration; however, its exact regulation of motility is incompletely 
understood [145, 177, 180, 181]. 
Recent work that we have done suggests that PAK1 regulates Ezrin’s actin 
regulation. Ezrin/Radixin/Moeisin (ERM) proteins act as linkers for polymerizing 
F-actin to multiple transmembrane receptors [182, 183]. Ezrin and the other ERM 
proteins exist under homeostatic conditions in a closed autoinhibited 
conformation with tight binding between its N-terminal plasma membrane 
associated (FERM) and C-terminal ERM-association (C-ERMAD) domains. 
Receptor tyrosine kinase induced signaling events break the association 
between these domains and facilitate binding of the underlying actin cytoskeleton 
[182]. Ezrin has no intrinsic enzymatic activity but draws the actin cytoskeletal 
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signaling complexes in close apposition to membrane-bound receptors facilitating 
signal transduction [182, 183].  As such, Ezrin’s importance has been 
demonstrated in actin reorganization necessary for apical-basal organization of 
epithelia, T-cell immunological synapse, and hematopoietic cell adhesion to the 
extracellular matrix [184-187]. Moreover, tissue-specific murine Ezrin deficiency 
has been linked to defects in epithelial morphogenesis [188, 189]. Several 
studies link Ezrin deregulated expression and activation with metastatic invasion 
in human epithelial-derived and hematopoietic cancers [190, 191]. Our work 
demonstrates for the first time that PAK1 in mast cells regulates F-actin 
depolymerization in IgE/DNP-mediated degranulation [192].  
 
PAK1 also phosphorylates and activates Filamin A, an actin binding protein. 
Filamin A crosslinks F-actin into networks and anchors the actin cytoskeleton to 
transmembrane proteins in cellular adhesion, morphology, and motility.  Studies 
in Filamin A/FLNA deficient embryos and human cell-lines demonstrate an 
important role for Filamin A in cellular migration and maintenance of intercellular 
junctions in organogenesis [193, 194]. PAK1 can elicit cortical actin assembly by 
direct phosphorylation of Filamin A [195]. In cancer cell-lines, PAK1 transduces 
signals through Filamin A crucial for lamellipodia formation and cell migration 
[196, 197]. In muscle, PAK1 additionally phosphorylates and inhibits myosin light 
chain kinase decreasing the actin-myosin filament mediated cell tension [198, 
199]. PAK1 can further modify the tubulin cytoskeleton by phosphorylating and 
deactivating Op18/Stathmin at Serine 16, stabilizing microtubules [200, 201].   
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Figure 4 
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Figure 4: PAK1 regulation of cytoskeletal processes by downstream 
cytoskeletal binding and remodeling effector proteins. PAK1 directly 
phosphorylates p41ARC of the ARP2/3 complex, LIM Kinases (LIMKs), Filamin A 
Myosin Light Chain Kinase (MLCK), and Op18/Stathmin. PAK1 also indirectly 
induces phosphorylation changes in cofilin, p38 MAPK and Ezrin/Moeisin/Radixin 
(ERM) proteins. 
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PAK1 as a potential target in allergic airway disease 
PAK1 and other isoforms regulate chemoattractant-directed cell migration, a 
process that heavily involves the actin cytoskeleton. Inhibiting PAK1 kinase 
activity in NIH-3T3 fibroblasts alters cell motility, whereas enhancing PAK1 
activity by expression of a PAK1 L107F plasmid construct increased fibroblast 
migration to collagen [155]. Moreover, other constitutively active Pak1 constructs 
rescue decreased chemoattractant-induced formation of lamellipodia and 
cytoskeletal rearrangement in Akt-/- fibroblasts [202]. PAK1 also modulates 
human endothelial cell, macrophage, and neutrophil motility [203, 204]. 
Dysregulated PAK1, which promotes cell motility and tissue invasion in cancer 
metastasis, localizes at the protrusions on migrating COS-7 cancer cells in situ 
[205]. 
 
PAK1 is a well-known regulator of the F-actin cytoskeleton and cell migration, 
although work has not been done in eosinophils. p38 MAPK one putative 
downstream effector of PAK1 has been implicated in migration and F-actin 
modulation and motility in multiple hematopoietic cells. In contrast, although 
cofilin, ARP2/3, and Ezrin are individually implicated in F-actin remodeling in 
other cell systems, their role in eosinophil F-actin-mediated processes remains 
unexplored.  
 
PAKs dysregulation in multiple human cancer types is well-documented. 
Uncontrolled PAK1 signaling in human breast adenocarcinoma confers tamoxifen 
resistance [206-208]. PAK1 levels are also elevated in colonic adenocarcinoma 
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[209], ovarian carcinoma [210, 211], and renal cell carcinoma [212]. Similarly, 
Pak1 gene amplification has been detected in transitional cell carcinoma [168], 
high-grade ovarian carcinoma [211, 213, 214] and T cell lymphoma [215, 216]. 
Our multi-disciplinary research group has recently shown that PAK1 modulates 
mast cell pro-inflammatory functions in neurofibromatosis 1 [121]. Few studies, 
however, have focused on the effect PAK1 has in chronic AAD. 
 
Our collaborators and others have delineated the PAKs-F-actin cell-physiological 
changes in contracting ASM [217-219]. Their data suggest that dysregulated 
PAK1 signaling permits cellular processes culminating in AHR [219-222]. We 
have recently established that genetic deletion of Pak1 attenuates the SCF/c-kit 
induced migration of mast cells [121]. Furthermore, PAK1 is important in 
immediate allergen/IgE induced calcium-flux changes and F-actin cytoskeletal-
mediated depolymerization in mast cell degranulation [223].These reports taken 
together support studies investigating the role PAK1 plays in allergic airway 
disease. We hypothesized that a Racs/CDC42/PAK1 signaling axis modulates 
the development of chronic AAI by modifying cytoskeletal dependent cellular 
processes.   
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THESIS OVERVIEW 
 
In sum, existing therapeutic modalities with adverse systemic effects or new 
drugs with narrow target population specificity, fail to effectively impact the 
increasing asthma incidence and morbidity. Current management of asthma 
symptoms with corticosteroids and β2 agonists has done little to stop the natural 
progression and lung remodeling of asthma. In response to allergen-induced 
eotaxins and other chemoattractants, eosinophils infiltrate the allergen-sensitized 
and challenged airways en masse and promote this remodeling. Furthermore, 
Th2-airway tissue-eosinophil reciprocal signaling and interactions orchestrate the 
development of asthmatic inflammation. Directed research into these synergistic 
cell signaling networks can identify specific targets involved in multiple processes 
in this inflammatory cell environment.  
 
PAK1 classical activators Racs, as well as PAK1-interacting MAPK proteins both 
regulate eosinophilia in animal models as well as eotaxin-mediated eosinophil 
migration in vitro. However, genetic studies testing the mechanism by which 
PAK1 may regulate eotaxin-mediated eosinophil pro-inflammatory functions have 
not been explored. In these studies, we formally assess PAK1 as a novel anti-
eosinophil inflammation target. We use a Pak1 deficient AAD model to test 
PAK1’s role in eosinophil inflammation characteristic of asthma. Furthermore, we 
utilize bone-marrow derived eosinophils to evaluate the consequence of Pak1 
deletion on eotaxin-mediated eosinophil adhesion, migration, and degranulation.  
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MATERIALS AND METHODS 
 
Animals used 
Pak1-/- mice were generated by Dr. Jonathan Chernoff’s laboratory at Fox Chase 
as described [223] and  were backcrossed at an Indiana University Laboratory 
Animal Research Center facility for nine generations onto a C57BL/6 strain 
background using mice obtained from Jackson Laboratories.  
 
Ezrin flox/flox mice on a 129/SV strain background were generated by Dr. Andrea 
McClatchey’s laboratory at Harvard Medical School as described [188] and bred 
with Mx1Cre transgenic (MxCre+) mice on a C57BL/6J strain background to yield 
Mx1Cre+ and Mx1Cre- Ezrin flox/+  mice. These F1 mice were bred to yield stable 
Mx1Cre+ and Mx1Cre- Ezrin flox/flox breeders and experimental mice. The Ezrin 
flox/flox and Mx1Cre alleles are genotyped to yield 251 and 217 base pair bands 
respectively in reactions as previously described [188, 224, 225].  
 
Mice were housed in pathogen-free conditions at Indiana University School of 
Medicine according to the Institutional Animal Care and Use Committee and 
Institutional Review Board guidelines. 
 
Mx1Cre induction 
Poly I poly C (PolyIC), a synthetic dsRNA analog, induces IFN-β production and 
release in vivo.  Downstream JAK-STAT signaling acting at the Mx1 gene 
promoter induces Cre expression in Mx1Cre+ mice. Hematopoietic stem and 
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progenitor cells from Mx1Cre+ mice express Cre following polyIC administration 
[226]. Ezrin deletion (Ezrin-/-) was achieved in Mx1Cre+  Ezrin flox/flox mice after 
the administration of five intraperitoneal injections of polyIC (Sigma, Saint Louis, 
MO) dissolved in sterile PBS. Minimal in vivo adverse effects from PolyIC 
treatment were achieved using a tapered dosing scheme as follows; two 15 µg, 
two 20 µg, and one 25 µg injections per gram of body weight Poly IC injections 
on alternate days over a ten day period. MxCre- Ezrin flox/flox control mice for these 
experiments also received the same doses of PolyIC prior to experimentation. 
 
Eosinophil infiltration murine models 
Cohorts of age and sex matched Pak1-/- and Pak1+/+ mice were injected with a 
1 mL intraperitoneal dose of 2 µg murine recombinant eotaxin (‘mreotaxin’, R&D 
systems) or PBS. Two hours later, mice were euthanized by CO2 asphyxiation 
and their peritoneal cavities lavaged with 5 mL PBS to retrieve peritoneal cells as 
described [227]. Total cells were counted by hemocytometer, cell populations 
visualized by giesma-stained slides, and eosinophils quantified by fluorescent 
cytometry of CCR3.  
 
Alternatively, cohorts of age and sex matched anesthetized Pak1-/- and Pak1+/+ 
mice were injected with a 25µL intratracheal dose containing 10µg mreotaxin 
(Peprotech) or saline as described [228, 229]. The mice were maintained under 
anesthesia for four hours [228].The mice were euthanized by CO2 asphyxiation 
 
31 
and broncho-alveolar lavage fluid (BALF) collected at 4°C for hemocytometer 
counts, giesma staining, and fluorescence cytometric analysis of eosinophils. 
 
OVA-induced allergic airway disease model 
Cohorts of male 10-14 week Pak1-/- and Pak1+/+ mice were sensitized and 
challenged in a murine model of allergic airway inflammation (AAI). Mice of both 
genotypes were sensitized by two intraperitoneal injections, seven days apart 
with 100 μg purified Ovalbumin (‘OVA’/ Sigma) adsorbed to 2 mg of the adjuvant 
Aluminum hydroxide (‘Alum’/ Sigma). On the 14th day, OVA-sensitized mice 
were anesthetized using aerosolized isoflurane (Webster Veterinary) daily for five 
consecutive days to prepare them for intranasal OVA challenge. Anesthetized 
mice were intranasally challenged with 50 μg of OVA in solution with saline for 
five consecutive days. Twenty-four hours after the last intranasal challenge (day 
19), AAD mice were euthanized by a 60 μg/g body weight lethal intramuscular 
injection of pentobarbital, their tracheas cannulated using a 20G 11/4 inch 
veterinary I.V. catheter, and broncho-alveolar lavage (BAL) samples collected at 
4°C. Some of these murine tracheas and lungs for histological analysis were 
inflated to 20-25 cm of H2O and fixed in formalin while tissue for cellular analysis 
was washed and collected in saline at 4°C.  
 
All BAL were centrifuged at 1500 X g for 5 minutes and the first 0.5 mL rinse 
stored at -80°C for cytokine analysis by ELISA. The BAL cells from the rinses 
were resuspended and pooled then red blood cells lysed in 300 μl of RBC lysis 
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buffer (Qiagen) until the cell pellet blanched at room temperature. Cell pellets 
recovered from each mouse were resuspended in 100 µL of FACS buffer (2% 
BSA solution with PBS and 0.09% NaN3) and 10 µL aliquots taken for 
hemocytometer BAL cell counts and slide preparation. Resuspended cell aliquots 
were counted in duplicate in solutions of  1 part cells diluted in 10 or 20 parts 
trypan blue (Mediatech, Inc.) by hemocytometer. Pak1-/- and Pak1+/+ total BAL 
cell counts were compared for significant differences. BAL cell aliquots for slide 
preparation were diluted in PBS, spun onto glass slides at 1200 rpm for 10 
minutes, and Giesma-stained (HEMA-TEK 2000, Bayer). Representative digital 
pictures per sample were taken by a digital camera slide microscope system 
(SPOT, Diagnostic Instruments, Inc.). 
 
Peripheral immune responses in Pak1+/+ and Pak1-/- OVA- sensitized and 
challenged mice were evaluated by OVA-specific splenocyte cytokine analysis.  
Splenocytes were harvested from mice of both genotypes and challenged with 
100 µg/ml OVA for 72 hours as previously described [230]. Cell-free 
supernatants were collected and analyzed for cytokines by multiplex ELISA 
(reagents from Millipore). 
 
Histological analysis and inflammation scores 
Fixed lung tissue was embedded in paraffin, and cut into 4-8 µm sections by our 
histology core. Paraffin-embedded tissue sections were mounted onto glass 
slides and stained with Hematoxylin and Eosin (‘H&E’, Sigma), Masson's 
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Trichrome (Fisher Scientific), and Periodic acid-Schiff using standard histological 
techniques. Slides were visualized by light microscopy, and representative 20 
and 40X images captured with a digital camera (SPOT, Diagnostic Instruments, 
Inc.). In addition, blinded observers assigned inflammation scores to H&E tissue 
sections from 0-4 with 0 being uninflamed lung and 4 severely inflamed lung. 
Inflammation scores were compared for both genotypes and treatments and 
differences determined.  
 
Fluorescence cytometric analysis of cell populations 
Aliquots from BAL samples were pooled to provide at least 106 cells per cell 
sample for control staining. At least 105 cells for each sample were probed with 
leukocyte antigen conjugate fluorescent antibodies at final concentrations of 5 
µg/mL anti-CD45, a generic leukocyte antigen, 2  µg/mL B220-FITC, 10 µg/mL 
CD3-FITC, 0.625 µg/mL CCR3-PE (R&D systems), 2.5 µg/mL MHCII-PerCP, and 
2 µg/mL CD11c-APCcy7 as well as 6 μg/mL anti mouse CD16/32, Fc receptor 
blocking antibody [230, 231]. Alternatively, 10 µg/mL CD4-FITC, and 10 µg/mL 
CD8-FITC were used instead of CD3-FITC, 10 µg/mL SiglecF-PE instead of 
CCR3-PE, and 10 µg/mL APCcy7 CD11b instead of CD11c-APCCy7. All 
antibodies were obtained from BD pharmingen unless otherwise indicated in 
parenthesis. All control and test samples were incubated with antibodies for at 
least 30 minutes in the dark at 4°C before a wash and resuspension in FACS 
buffer for cell population data acquisition (BD FACSCalibur) using CellQuest (BD 
Immunocytometry Systems). On analysis, leukocyte population gates (all CD45+) 
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were set to distinguish the following populations: Eosinophils, FSClo B220/CD3 (-
), CCR3/SiglecF (+), Neutrophils, FSClo B220/CD3 (-) CCR3/SiglecF(-), 
Lymphocytes FSClo B220/CD3 (+), CCR3/SiglecF (-), and alveolar macrophages, 
FSChi, CDIIc or CD11b (+), MHCII (+). Total leukocyte population numbers were 
computed from the analysis percentages and significant differences (p<0.05) 
between Pak1-/- and Pak1+/+ populations compared. 
 
Adoptive bone marrow transplantation model 
For bone marrow transplantation assays, low density bone marrow mononuclear 
cells were harvested from CD45.2 Pak1-/- and Pak1+/+ mice on a C57BL/6J 
strain background as described in “Bone marrow isolation of LDMNCs”. These 
cells were transplanted into Pak1+/+ F1 mice which expressed both CD45.1 and 
CD45.2 common leukocyte antigens (CD45.1/2+) obtained from the Indiana 
University School of Medicine In Vivo Therapeutics Core as described [232]. 
Briefly, approximately two million viable Pak1-/- and Pak1+/+ bone marrow cells 
were injected with a 30 gauge 0.5 inch needle into the lateral tail vein of lethally-
irradiated (1100 cGy, split dose [700cGy and 400cGy with a 5 hour interval], 
cesium isotope source) CD45.1/2+ Pak1+/+ mice. Transplanted mice were 
housed in a pathogen-free environment to allow for stem and progenitor cell 
engraftment. Mice were assessed for hematopoietic reconstitution at six months 
post-transplantation by quantifying peripheral blood CD45.2 versus CD45.1/2 
chimerism. Mice were utilized in an OVA-induced allergic airway disease model. 
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Orthotopic left-lung transplantation model 
For lung transplantation assays, whole left lungs from donor mice were 
transplanted into 8-12 week old male recipient mice using non-suture 
microvascular anastomoses which reduces granulation tissue as previously 
described [233-235]. These state-of-the-art transplantation experiments were 
done in collaboration with Dr. David Wilkes’ lab, where this model is 
discriminately available. Pak1+/+ recipient mice received Pak1-/- lungs while 
Pak1-/- mice received Pak1+/+ lung grafts. Following a 7-day recovery period, 
transplanted mice were utilized in an OVA-induced AAD model as described 
above. The lung grafts were procured for cell suspension preparation and 
analyzed for eosinophil percentages by fluorescent cytometry for murine siglec 
F+ eosinophil in contrast to other populations. Total eosinophils were computed 
and compared between transplanted groups. 
 
Cell suspension preparation from murine lungs 
Whole lungs were collected from sensitized Pak1-/- and Pak1+/+ mice or lung 
transplant mice in cold PBS (4°C). Single cell suspensions were prepared for 
MACS separation using a gentle-MACS dissociation protocol (Miltenyi Biotec). 
Briefly, single mouse lungs or left-lungs were individually washed, and 
dissociated in HEPES buffer ph 7.4 (Sigma) supplemented with 2mg/mL 
collagenase D (Sigma) and 10U/mL DNAse I (Sigma) in 10mL C-tubes (Miltenyi). 
Total cell in these lungs were dissociated in a gentle-MACS dissociator (Miltenyi) 
using proprietary programming, hybridized while rotating in an oven at 37°C, and 
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further dissociated from parenchymal tissue. The solution was filtered through a 
70µm mesh, washed in PBS, cells labelled with anti-CD45 magnetic beads, and 
leukocytes positively selected by passing these cells through a magnetic column 
using standard Miltenyi protocol (#130-052-301). These cells were stained with 
antibodies against lineage antigens and analyzed by fluorescence cytometry. 
 
Multiplex ELISA assays 
Several allergen-induced murine cytokines and growth factors were assayed with 
multiplex simultaneous quantification of fluorescent antibody capture beads 
directed against eotaxin-1/CCL11, RANTES, IL-4, IL-5, IL-10, IL-13, IL-17, and 
IFNγ. BAL samples from OVA-sensitized and challenged Pak1-/- and Pak1+/+ 
mice and supernatants from OVA-stimulated ex vivo T-cell cultures were thawed, 
vortexed, and 25 µL transferred to custom ordered multiplex plates with analyte 
capture antibodies (Millipore Milliplex, Billerica, MA).  The multiplex assay was 
performed according to the manufacturer’s protocol with each sample tested in 
duplicate. Briefly, samples were incubated with analyte antibody for two hours, 
washed three times, incubated with streptavidin conjugated fluorescent 
secondary antibody, washed three additional times and suspended in 100 μL 
saline, and analyzed on a Luminex 200 cytometer with StarStation software 
(Luminex Corp, Austin, TX). Standard curves were computed using a cubic 
spline fit, according to the manufacturer’s instruction. The quantities of cytokines 
were computed relative to the standard curve generated, replicates averaged, 
and cytokines for each group tested compared.  
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Bone Marrow Isolation of low density mononuclear cells (LDMNCs) 
Whole bone marrow was harvested from pelves, femurs, and tibias of cohorts of 
10-16 week old mice in Iscove’s Modified Dulbecco’s Media (IMDM, 
Gibco/Invitrogen), supplemented with 2% fetal bovine serum (FBS, Hyclone, 
ThermoScientific) using a 20-gauge one inch needle. The flushed bone marrow 
was resolved to obtain LDMNCs on a density gradient (Histopaque Sigma 
11191) as described [121, 223]. Briefly, harvested cells were carefully layered 
onto an equivalent volume of Histopaque (Sigma) and centrifuged for 30 minutes 
at 1750 rpm on a gh-3.8 rotor (Beckman Coulter). Cells in the intermediate layer 
were collected washed in IMDM or other media, and enumerated as appropriate, 
before experimentation. 
 
Bone Marrow IL-5 methylcellulose cultures 
Non-adherent LDMNCs Pak1+/+ and Pak1-/- (N=3) were cultured in 35 X 10 mm 
diameter tissue culture dishes (Fisher Scientific) in culture medium, which was 
made up of 0.9% methylcellulose (Methocult H4100, Stem Cell Technology) 
enriched with 20% FBS and Iscove’s Dulbecco’s medium (with 1% penicillin-
streptomycin, 0.35% 2-ME, and 0.1% BSA) supplemented with rmIL-5 (1, 10 
ng/ml/ R&D systems) with 2 × 105 LDMNCs/ml of culture media at 37°C. After 5 
and 10 days, total IL-5 colonies were counted using inverse microscopy as 
previously described [236]. Each mouse was assessed in triplicate for each 
cytokine concentration and the total number of IL-5 colonies was compared 
between Pak1+/+ and Pak1-/- groups.  
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pCL11eGFP PAK1 mutant generation 
The pCL11eGFP lentiviral construct was a kind gift of Helmut Hannenberg at the 
Indiana University School of Medicine. This construct contains an eGFP cassette 
and a multiple cloning site (MCS) downstream of the (HPGK) promoter, which 
drives transcription in eukaryotic cells. The kinase-dead PAK1 mutant, K299R 
and the constitutively active mutant, L107F, (Addgene) were NOT1-adapted and 
inserted into the NOT1-cut and Klenow-blunted pCL11eGFP vector in frame at 
the C-terminus of the eGFP cassette using molecular cloning techniques. The 
integrity and orientation of the pCL11eGFPPAK1 mutant plasmid constructs were 
confirmed by restriction enzyme digestion and sequencing. 
 
Lentivirus generation 
To generate virus, NIH 293T cells at 60-70% confluence on 10 cm dishes were 
transfected with 10 µg of either pcl1PAK1eGFP, or pcl11PAK1K299R, or 
pcl11PAK1L107, 5 µg gag-pol expressing helper plasmid (pCD/NL-BH), and 1 µg 
foamy viral envelope plasmid (pcoPE01) in 6 mL Dulbecco’s Modified Eagle 
Media (DMEM, Gibco/Invitrogen) containing 10% FBS and 0.0075 mg/mL 
polyethyleneimine (PEI, Sigma). After overnight transfection at 37°C, transfection 
media was aspirated and replaced with 5 mL fresh DMEM containing 10% FBS, 
50 U/mL penicillin, 50 μg/mL streptomycin, and 2 mM L-Glutamine. After 24 
hours, all supernatants were collected, pooled (to 50 mL maximum), filtered 
through a 0.22 μm polyethersulfone (PES) membrane Stericup unit (Millipore, 
Billerica, MA), and centrifuged at 16,000 x g at 4°C for 2 hours in a polycarbonate 
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Oak Ridge centrifuge tube (Nalgene, Rochester, NY). Supernatant was 
decanted, bleached, and disposed in biohazardous waste, and the viral pellet 
resuspended in 1 mL IMDM containing 20% FBS. Virus was stored in 1mL 
aliquots at -80°C and all thawed samples were either immediately used or 
appropriately discarded.  
 
Viral titer (infectious particles per mL) was determined by percent GFP-positivity 
of serially transduced HT1080 cells, plated at 100,000 per well of a six-well plate 
in 1 mL DMEM/10% FBS. The serial dilution started at 10-2 dilution from viral 
frozen stock and ended with 10-8 dilution. Viral titer was determined by the 
following equation: 
 
ܶ݅ݐ݁ݎ	 ൬	݂݅݊݁ܿݐ݅݋ݑݏ	݌ܽݎݐ݈݅ܿ݁ݏ݉ܮ ൰ ൌ
%	ܩܨܲା݈݈ܿ݁ݏ	 ൈ 10ହ	ݐ݋ݐ݈ܽ	݈݈ܿ݁ݏ
1	݈݉	݉݁݀݅ܽ	 ൈ 10ି௫	݈݀݅ݑݐ݅݋݊	݂ܽܿݐ݋ݎ 
 
Lentiviral transduction 
CD117/c-kit + cells were magnetically isolated in a column following labeling 
Pak1+/+ and Pak1-/- LDMNCs with anti-c-kit/CD117 microbeads (Miletenyi 
Biotec). These cells enriched for stem and progenitor cells were transduced with 
viral supernatants as described [223]. Briefly, each well of a six-well plate was 
coated with 10 µg/cm2 of recombinant fibronectin (Retronectin, Takara) in 1 mL 
PBS, overnight at 4°C or for four hours at room temperature. This 
fibronectin/PBS solution was aspirated and replaced with 50-150 infectious 
particles per target c-kit+ cell, diluted in a 1 mL solution of IMDM containing 20% 
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FBS, 50 U/mL penicillin, 50 μg/mL streptomycin, 2 mM L-glutamine 
supplemented with either 100 ng/mL SCF, and 10 ng/mL IL-6. After one hour of 
virus/fibronectin incubation at 37°C, 1-2 million target cells were added in a 100 
μL volume of the aforementioned transduction media to each 1 mL solution 
containing well. After 16 to 24 hours of incubation at 37°C, the cells were 
harvested, washed in IMDM, and resuspended in eosinophil culture media. 
 
Eosinophil culture  
Bone marrow eosinophils (bmEos) were derived by culturing bone-marrow 
mononuclear cells ex vivo in eosinophil polarizing conditions. Briefly, LDMNCs 
were enumerated and cultured ex vivo in IMEM media (Gibco) with 20% fetal calf 
serum (Sigma), 1 U/mL penicillin/streptomycin (Lonza), glutamine (Lonza), 
supplemented with 1 ng/mL IL 5 (BD pharmingen), 0.25 ng/mL IL 3 (Peprotech), 
and 1 ng/mL GM-CSF(R&D systems) for 14 days at 37°C and 5% CO2 as 
described  [87, 237]. Cells were pelleted by centrifugation at 1500rpm for five 
minutes, and the media was changed every three days.  
 
Alternatively LDMNCs or c-kit+ virus-transduced cells were cultured at high IL-5 
concentrations to increase cell yields as described [238]. Cells were cultured at 
approximately 106 cells/mL in media containing RPMI 1640 (Gibco) with 20% 
FBS (Cambrex), 1 U/mL penicillin/streptomycin (Lonza), 2 mM glutamine 
(Lonza), 25 mM HEPES, 1 mM sodium pyruvate (Gibco), and 50 μM β-
mercaptoethanol (Sigma) and supplemented with 100 ng/mL stem-cell factor 
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(SCF/ PeproTech) and 100 ng/mL FLT3-Ligand (FLT3-L/ PeproTech) from day 0 
to day 4. On day 4, the media was replaced with eosinophil culture media 
supplemented with 10 ng/mL recombinant mouse interleukin-5 (rmIL-5/ R&D 
Systems) as the only growth factor. On day 8, the cells were moved to new flasks 
and maintained in fresh media supplemented with rmIL-5. On alternate days, 
from this point, one-half of the media was replaced with fresh media containing 
rmIL-5, and the cell concentration adjusted to 106 cells/mL. Cells were 
enumerated on day 0 and days requiring media replacement by hemocytometer. 
 
Assessment of eosinophil culture purity 
Eosinophil purity of ex vivo LDMC cultures was assessed on days 10, 12, 14 and 
16 by cell cytospin and flow cytometric analysis. Approximately 200,000 cells 
were washed with PBS and loaded onto a plastic slide funnel mounted on a glass 
slide and spun for 10 minutes at 1200 rpm (Beckmann Coulter). The cells affixed 
to these slides were Giemsa stained (Hema-Tek 2000, Bayer) and eosinophil 
percentage purity determined by counts under a light microscope.  
 
Approximately 500,000 cells from eosinophil cultures were washed and 
resuspended in 100 µL FACS buffer and incubated with 0.5 µg/mL PE-
conjugated anti-murine CCR3 (R&D Systems) or 0.5 µg PE-conjugated anti-
murine Siglec F (BD Biosciences) antibody for 30 minutes on ice as described 
[238]. Cells were washed in FBS/PBS and Phycoethrin (PE) intensity detected by 
fluorescent cytometer (FACS Calibur, BD). The data was analyzed in comparison 
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with PE conjugated isotype control (BD Biosciences) treated cells by Flowjo 
v7.6.5 software (Tree Star Inc.). 
 
Eosinophil adhesion assay 
Microfluidic 24-well plates (Fluxion Biosciences Inc.) were coated with 50 µg/mL 
fibronectin (Invitrogen) or gelatin for one hour at 37°C. Coating solution from 
each well was aspirated gently to avoid air bubble introduction and washed with 
300 µL of plain RPMI media (Gibco) with 0.5% BSA (Sigma). The wash solution 
was steadily pumped through the microfluidic chambers at 5 dynes/cm2 using a 
Bioflux 200 controller (Fluxion Biosciences Inc.). Fluid from both input and output 
channels was gently aspirated and cells added to each input well.  bmEos were 
washed and resuspended in RPMI/0.5% BSA media at a cell concentration of 2 x 
106 cells/mL. Approximately 4 x 106 eotaxin-treated or untreated Pak1+/+ and 
Pak1-/- bmEos were loaded at each input and flow initiated at 2 dynes/cm2 for 
two minutes to introduce a bolus of cells into the adhesion chambers, after which 
this volume rate was adjusted to 0.5 dynes/cm2 for 20 minutes to mimic capillary 
blood flow. The input well was cleared, washed with PBS, and flow initiated for 
two minutes at 2 dynes/cm2 to wash away non-adherent cells. Plates were fixed 
with paraformaldehyde (PFA) for imaging or stained with Coomassie blue for cell 
counts. 40X images of PFA stained cells were taken using (SPOT, Diagnostic 
Instruments, Inc.) and stained cells were counted by hemocytometer, and 
compared relative to genotype, treatment-group, and plate coating type. 
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Eosinophil migration assays 
Eosinophil migration to recombinant murine eotaxin-1/mCCL11 (‘rmEotaxin’/ 
Peprotech) was assessed using a transwell assay system. During the 10th-14th 
days of culture, bmEos were resuspended at cell concentrations of 2 x 106 
cells/mL in RPMI/0.5% BSA media. To assess if this transwell setup could 
distinguish eotaxin-induced chemotaxis from random chemokinesis a 
checkerboard scheme was followed where concentrations of rmEotaxin were 
loaded in top or bottom chambers alone, both chambers, or neither chamber 
preceding the migration experiment. 100 μl of resuspended bmEos were then 
seeded in the top three micron-meshed polycarbonate chamber of a 24-well 
transwell plate (Costar 3415) and the cells allowed to migrate to the bottom 
chamber where they were collected and enumerated by hemocytometer. All 
conditions of this checkerboard migration assay format were tested in duplicate 
or triplicate and the cell counts averaged per experiment. To calculate the 
chemotactic index, the number of cells that migrated in response to chemokines 
was divided by the number of spontaneously migrated cells [239]. Migrating cells 
were compared between the two genotypes and four conditions. bmEos cultures 
from Pak1+/+ mice were also pretreated for 1 hour at 37°C with small molecule 
inhibitors of PAKs, IPA3 (Chernoff, Fox Chase Cancer Center), and p38 MAPK, 
SB22025 (Sigma) then assayed for rmEotaxin-mediated chemotaxis. As a 
control, a trypan-blue exclusion count was performed on cell aliquots of bmEos 
pretreated with inhibitors to check for dead cell percentages.  
 
 
44 
Eosinophil degranulation assay 
Eosinophil degranulation to recombinant murine rmEotaxin (Peprotech) was 
assessed by a colorimetric assay measuring EPO activity in cell supernatants in 
lieu of eosinophil degranulation. On the 14th day of culture, bmEos were 
resuspended at cell concentrations of 1 x 106 cells/mL in HBSS media (Gibco). 
Cells were stimulated with 100-1000 ng/mL rmEotaxin for one hour at 37°C. Cells 
were gently centrifuged to separate supernatant and cell pellet and kept on ice.  
The cell pellet was permeabilized in 0.3% Triton-X (Sigma) for five minutes at 
room temperature and the cell lysate supernatant collected for each sample. 
100μl of cell supernatants and cell-pellet lysates were seeded in a round-bottom 
96-well plate. 100 µL of EPO substrate (consisting of a solution of 1 mM H2O2, 1 
mM O-phenylenediamine, and 0.1% Triton-X (all from Sigma) in 55 mM Tris 
buffer at pH of 8.0) was added to the seeded fluid and the reactants incubated in 
the dark for 30 minutes at 37°C. The reaction was terminated by adding 50 µL of 
4 M H2SO4, and absorbance read on a microplate luminometer at 490 nm (). 
Background absorbance readings (no eosinophil products) was subtracted from 
the absorbance readings of each well and the EPO degranulation of each 
supernatant expressed as a percentage of total cell EPO content according to 
the following equation:  
 
%	ܦ݁݃ݎܽ݊ݑ݈ܽݐ݅݋݊ ൌ ሺସଽ଴௡௠஺௕௦	஼௘௟௟	௦௨௣௘௥௡௔௧௔௡௧	ି	ସଽ଴௡௠஺௕௦	௕௔௖௞௚௥௢௨௡ௗሻሺସଽ଴௡௠஺௕௦	஼௘௟௟	௣௘௟௟௘௧	ି	ସଽ଴௡௠஺௕௦	௕௔௖௞௚௥௢௨௡ௗሻ ൈ 100% 
 
 
 
45 
HL-60 human eosinophil culture and differentiation 
HL-60 clone 15 cells (CRL-1964, American Type Culture Collection) were 
maintained in 1 U/mL Penicillin/Streptomycin (Lonza) and 2 mM glutamine 
(Lonza) containing RPMI-1640 medium (Gibco) supplemented with 10% FBS 
(Sigma) and 25 mM HEPES pH7.6 (Sigma), at cell concentrations between 0.5-2 
x 106 cells/mL at 37°C and 5% CO2. Approximately 0.5 x 106 cells/mL were 
differentiated to eosinophil-like cells (HL-60 Eos) by supplementing the media 
with 0.5mM n-butyrate (Sigma) dissolved in ethanol and cultured for five to seven 
days as described [240, 241]. HL-60 Eos were evaluated for differentiation by 
Giesma staining (HEMA-TEK 2000, Bayer) of cells affixed to a glass slide.  
 
In vitro HL-60 Eos PAK1 kinase assay 
HL-60 Eos were stimulated with 100 ng/mL human recombinant eotaxin 
(hmEotaxin/ R&D systems) in RPMI media (Gibco) with 0.5% BSA (Sigma) at 
37°C for 5, 15, and 30 minutes and the reaction terminated by addition of 1 mM 
Na3VO4 in 4°C PBS. 400 µg of whole cell lysate was prepared as previously 
described [242] reserving 10 µL aliquot of each sample for GAPDH detection as 
a loading control. The remainder of the lysate was immunoprecipitated with 2 
µg/mL α-PAK1 antibody (N20, Santa Cruz Biotechnology, Inc.) at 4°C for 18 
hours before incubation with protein A/G plus beads (Santa Cruz Biotechnology) 
for two hours. PAK1 phosphotransferase activity was assayed by incubating the 
immunobeads with 1 µg/reaction Mek (Millipore) and 250 µM ATP (Sigma 
Chemical) in 30 µL kinase buffer described [243]. Samples were separated by 
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10% SDS-PAGE, transferred to nitrocellulose, and probed with anti-Mek-
phospho-serine 298 (1:1000, Cell signaling). Phosphorylated Mek was used in 
lieu of PAK1 activation.  
 
PAK1 RNA interference in HL-60 eos 
PAK1 knockdown in HL-60 Eos was achieved by 72 hour incubation with human 
PAK1 siRNA constructs in siPORT NeoFx reagent (Ambion). siPORT™ 
NeoFX™ Transfection Agent was diluted (1:20) in 37°C Opti-Minimal Essential I 
medium (Opti-MEM) and the resulting solution incubated for 10 minutes at room 
temperature. Three PAK1 siRNA constructs (SASI_Hs01_00087968, 
SASI_Hs02_00334074, and SASI_Hs01_00087970 (Sigma MISSION® siRNA) 
were chosen based on rank order of efficacy postulated by a siRNA design 
algorithm (Rosetta InPharmatics) and tested. PAK1 siRNA or scramble siRNA 
constructs was diluted in Opti-MEM to 30nM and mixed with incubated siPORT 
NeoFx reagent. After a 10 minute incubation that permitted formation of 
transfection complexes, 2.3 mL of transfection solution was dispensed to each 
well of a 6-well plate.  Approximately 2 x 105 HL-60 cells in eosinophil 
differentiation media were overlaid on the transfection complexes and incubated 
at 37°C for 72 hours. HL-60 eos were enumerated, numbers standardized, lysed, 
and whole cell lysates prepared in SDS page for western blot analysis. Following 
optimization transfection experiments, SASI_Hs01_00087970 was chosen for 
further experimentation.  
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HL-60 Eos migration assay 
HL-60 Eos, siRNA-treated HL-60 Eos, or NeoFx-only treated HL-60 eos were 
utilized in migration assays to no stimulus or 100 ng/mL eotaxin. On the fifth day 
of differentiation in n-butyrate supplemented media, HL-60 eos were 
resuspended at cell concentrations of 1 x 106 cells/mL in RPMI/0.5% BSA media. 
Approximately 100 μL of these cells were seeded in the insert of an eight micron-
meshed polycarbonate chamber of a 24-well transwell plate (Costar 3422, 
Invitrogen) and the cells allowed to migrate to the bottom chamber where they 
were collected and enumerated by hemocytometer. All conditions of this 
checkerboard migration assay format were tested in duplicate and the cell counts 
averaged per experiment. To calculate the chemotactic index, the number of 
cells migrated in response to chemokines was divided by the number of 
spontaneously migrated cells. Migrating cells were compared among stimulus-
treated, siRNA-treated, and non-treated groups. 
 
Immunoblotting 
Whole cell bmEos lysates were prepared by addition of 1x SDS sample buffer 
supplemented with 1% 2-mercaptoethanol to 1 x 106 cells. Cell lysates were 
sonicated, clarified by centrifugation, and denatured at 100°C for 5 mins. 
Alternatively, cells lysed with ProteoJET Mammalian Cell Lysis Reagent 
(Fermentas), and clarified as above, were quantified by a BCA reagent assay 
(ThermoScientific). Samples were separated by SDS-PAGE on a 4-12% gradient 
or 6% acrylamide gels (Invitrogen) and transferred to PVDF membrane (Roche 
Diagnostics Corporation, IN). Membrane blots were probed with primary 
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antibodies to p-T423 PAKs, p-S3 cofillin, cofilin, p-S2152 filamin A, p-T567 
ERMs, Ezrin, p-S298 MEK, p-S16 Op/18 Stathmin (Abcam), and p34-ARC 
(Millipore) as well as GAPDH. All antibodies were obtained for Cell Signaling 
Technology, Inc. unless otherwise indicated. All blots were visualized using an 
HRP-conjugated anti-rabbit secondary antibody (1:5000, Amersham), and films 
developed using the West Dura luminal system (ThermoScientific). 
Immunoblotting was performed on at least three independent bmEos cultures 
and phosphorylated protein levels from representative blots quantified by 
subjecting representative autoradiographs to densitometry (NIH ImageJ). 
 
Deconvolution confocal microscopy 
For visualization, 10-14 day old cultures of Pak1-/- and Pak1+/+ bmEos were 
resuspended in RPMI with 0.5% BSA, 50 U/mL penicillin, 50 µg/mL streptomycin, 
and 2 mM L-Glutamine. Cells were standardized to a concentration of 2 x106 
cells/mL, and stimulated with 500 ng/mL rmeotaxin or no stimulation from 0-5 
minutes at 5% CO2/37°C. Cells were aliquoted to eppendorf tubes and the 
stimulation terminated by addition of 4% PFA for 15 minutes at room 
temperature. After fixation, cells were resuspended in 1 mL PBS. Approximately 
200,000 cells were then loaded in PBS onto a cytospin funnel mounted to a glass 
slide and spun for 10 minutes at 1200rpm. Following cytospin, cells affixed on 
slides were extracted by washing in 0.3% Triton-X (Sigma) for five minutes, 
blocked in 5% FBS for at least one hour, and incubated with primary antibody in 
0.1% BSA/PBS overnight at 4°C. The following morning, these cells were 
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washed three times in PBS, and subsequently incubated for one hour at room 
temperature with fluorophore-conjugated anti-mouse or anti-rabbit secondary 
antibodies (Molecular Probes, Invitrogen). After washing, one drop of a DAPI 
mounting solution (Molecular Probes, Invitrogen) was applied and a cover slip 
sealed over the samples using lacquer. Data were acquired and analyzed on a 
DeltaVision deconvolving microscopy system (Applied Precision, Washington). 
Typical controls included cells incubated with secondary (fluorophore-
conjugated) antibody but not primary antibody. Intensity and localization of cells 
from both genotypes were compared. 
 
Statistical analyses 
All statistical analyses were performed with GraphPad Prism 5.4. One- or two-
way ANOVA was performed, as appropriate, with Bonferroni post-hoc 
corrections. For two variable comparisons, unpaired two-tailed student’s t-tests 
were used. All tests, numbers of independent replicates, and significance levels 
are found within the figure legends in the results section. 
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RESULTS 
 
PAK1 in murine allergic airway inflammation 
We tested the role PAK1 played in a model of allergic airway murine 
inflammation using Pak1-/- mice. We used a murine allergic airway disease 
model employing OVA-albumin sensitization and challenge with adjuvant 
treatment. We supplemented these studies with two chimeric models. Using both 
adoptive bone marrow and orthotopic lung transplantation models, we tested the 
relative roles of hematopoietic and pulmonary contributions to this inflammation. 
 
Pak1 genetic disruption 
Our multi-disciplinary research group has previously generated a novel Pak1 
global knockout mouse and demonstrated that PAK1 notably modulates mast cell 
inflammatory processes. A schematic illustrating disruption of PAK1 in ES cells is 
shown in Figure 5. Southern blot analysis of murine Pak1-/- ES cells showed a 
disrupted Pak1 allele while western blot analysis of multiple tissues from these 
mice failed to detect PAK1 protein [223]. The resulting Pak1-/- mice are viable, 
undergo normal growth and development, are fertile, and have a normal lifespan. 
The mice used in our studies were backcrossed onto a C57BL/6J background for 
at least seven generations to achieve genetic uniformity with the wild-type 
(Pak1+/+) mice. The peripheral blood taken from these mice demonstrate normal 
blood cell composition and many cytokine levels were comparable to Pak1+/+ 
mice [223].  
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Figure 5  
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Figure 5: Schematic illustrating the genetic disruption of Pak1 in murine ES 
cells to ablate PAK1 expression. We generated a Pak1-/- mouse by targeted 
disruption of the Pak1 allele on chromosome 7 in embryonic stem (ES) cells. We 
first published this figure in its original form in Allen, J. et al. in BLOOD, 2008 
[223].  
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The Pak1-/- OVA-albumin allergic airway disease model 
Our initial goal was to establish a model to study PAK1’s effect on the 
development of allergen-induced airway inflammation. We utilized an ovalbumin 
(OVA)-sensitized and challenged murine model with aluminum hydroxide (Alum) 
adjuvant supplementation to elicit a potent Th2-mediated inflammatory airway 
response. Following optimization of the model in our mice, we employed the 
sensitization and challenge schedule illustrated in Figure 6. We utilized age-
matched, male mice in these experiments. We sensitized mice of both genotypes 
using two intraperitoneal injections of an amalgam of OVA and Alum and 
subsequently challenged the mice by intranasal inhalation for five days. OVA-
sensitized and challenged mice were utilized either for pulmonary function tests 
or for serum, BALF, and lung procurement to assess the inflammatory infiltrate.
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Figure 6 
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Figure 6: Schematic illustrating the Pak1-/- murine model of allergic airway 
inflammation. Age-matched male Pak1+/+ and Pak1-/- mice were OVA-
sensitized and challenged in a 19-day protocol and utilized for either pulmonary 
function tests for evaluation of AHR or cellular analysis for airway inflammation. 
Mice were sensitized to OVA by intraperitoneal injections on day 1 and day 8 and 
subsequently challenged by intranasal inhalation for five consecutive days before 
lungs tissue was harvested for H&E staining and analysis of leukocytes whereas 
BALF was assessed for leukocyte populations by fluorescent cytometry and 
cytokine content by ELISA. 
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Decreased airway eosinophil inflammation with Pak1 deletion in a murine 
model of AAD 
We sought to discern in vivo the role PAK1 played in a murine model of human 
bronchial asthma in which eosinophil infiltration critically contributes to the 
pathogenesis of the disease [9, 97]. To examine the role of the eosinophil, we 
scored lung eosinophilic inflammation by H&E-stained histological lung sections 
and eosinophil percentages by fluorescent cytometry from lung tissue harvested 
from Pak1+/+ and Pak1-/- OVA-sensitized and challenged as well as control 
mice. We found that Pak1-/- lung samples from AAD mice showed decreased 
inflammatory cell infiltrate around the small airways (Figures 7a-b), interstitial 
infliltration of cells (Figures 7c-d),  and eosinophilic infiltrate (Figures 7e-f) 
compared with sensitized Pak1+/+  lung tissue. We obtained leukocytes from 
lung samples of OVA-sensitized and challenged mice of both genotypes by 
connective tissue digestion and leukocyte magnetic bead separation, then 
quantified eosinophil percentages in inflamed lung tissue by fluorescence 
cytometry for eosinophil markers. Predictably, we found that percentages of non-
lymphocyte, non-monocyte CD45+, Siglec F+ cells increased with OVA-
sensitization and challenge in both genotypes, however this increase was 
modest in Pak1-/- relative to the robust eosinophil infiltrate in Pak1+/+ AAD mice 
(Figure 7g).  
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Pak1+/+ Pak1-/- 
 
 
 
   
Figures 7a-b 
Figures 7c-f 
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Figure 7g  
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Figure 7: PAK1 promotes eosinophil infiltration of lung tissue in a murine 
model of AAD. Pak1+/+ and Pak1-/- mice were sensitized and challenged with 
OVA to induce allergic airway inflammation or PBS for control. Lungs from these 
mice were fixed, sectioned, and stained with H & E. Micrographs are 
representative for at least five experiments (Figures 7a-f).   Lung leukocytes from 
these AAD mice were obtained following enzymatic digestion, mechanical 
dissociation, and magnetic separation from lung tissue. Leukocytes were 
assessed for lineage markers by multicolor fluorescence cytometry. On analysis, 
leukocyte population gates (all CD45+) were set to distinguish the following 
populations: Eosinophils, FSClo B220/CD3 (-), CCR3/SiglecF (+), Neutrophils, 
FSClo B220/CD3 (-) CCR3/SiglecF(-), Lymphocytes FSClo B220/CD3 (+), 
CCR3/SiglecF (-), and alveolar macrophages, FSChi, CDIIc or CD11b (+), MHCII 
(+). Population percentages were compared for significant differences (p<0.05) 
between Pak1-/- and Pak1+/+ samples N=6 (Figure 7g). Results are averaged 
from three experiments and compared. * p<0.05, using a two-tailed student’s t-
test. 
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Decreased BAL eosinophil numbers with Pak1 deletion in a murine model 
of AAD 
We retrieved BALF from mice of both genotypes from AAD induction and 
assessed cell populations by fluorescence cytometry and cytokines by multiplex 
ELISA. Consistent with our findings in the lung tissue, BALF obtained from OVA-
sensitized and challenged Pak1+/+ and Pak1-/- mice showed increases in 
cellularity and granulocyte composition. Granulocytes are depicted with red 
arrows (Figure 8a). These increases in cellularity and non-lymphocyte, non-
monocyte Siglec F+ leukocytes were dramatically reduced in Pak1-/- mice 
relative to Pak1+/+ AAD mice with induction of allergic airway inflammation 
(Figures 8 b-c).  BALF from AAD-induced mice from both genotypes however, 
showed comparable quantities of the eosinophil chemoattractant, eotaxin, 
suggesting a similar allergen-induced sensitization necessary for eosinophil 
recruitment to the inflamed lungs. 
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Figure 8a 
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Figure 8b 
  
Figure 8c 
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Figure 8d 
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Figure 8: PAK1 promotes eosinophil infiltration into broncho-alveolar 
lavage fluids (BALF) in a murine model of AAD. Pak1+/+ and Pak1-/- mice 
were sensitized and challenged with OVA to induce allergic airway inflammation 
or PBS for control. Broncho-alveolar lavage fluid was obtained from these mice 
following AAD induction, and an aliquot of these cells were cytospun and giesma-
stained (Figure 8a), and the total cells enumerated by hemocytometer (Figure 
8b). On analysis, leukocyte population gates (all CD45+) were set to distinguish 
the following populations: Eosinos, FSClo B220/CD3 (-), CCR3/SiglecF (+), 
Neutrophils, FSClo B220/CD3 (-) CCR3/SiglecF(-), Lymphocytes FSClo 
B220/CD3 (+), CCR3/SiglecF (-), and alveolar macrophages, FSChi, CDIIc or 
CD11b (+), MHCII (+). Eosinophil numbers were computed from fluorescence 
cytometry percentages (Figure 8c). Accellular fluid assessed for CCL11/eotaxin 
by ELISA (Figure 8d). Results in b-c are averaged from N=10-12 animals and 
compared. *** p<0.001, ****p<0.0001 using a two-tailed student’s t-test. 
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Normal OVA-specific T-helper cell cytokine secretion in Pak1-/- OVA-
sensitized mice 
 We also harvested spleens from Pak1+/+ and Pak1-/- OVA-sensitized and 
challenged mice. To compare peripheral T-helper cell responses we assessed 
cytokine secretion from splenocytes of both genotypes, we stimulated these cells 
ex vivo with OVA or plain media, and collected cell supernatants for cytokine 
analysis after 72 hours of culture. We assessed cytokine levels by multiplex 
ELISA using specific capture antibody beads. We found similar quantities of the 
T-helper cell cytokines IL-4, IL-5, IL-10, IL17, IFNγ, and RANTES (Figures 9a-f) 
in OVA-stimulated splenocyte supernatants from both genotypes. These data 
suggest preserved OVA-specific T-helper cell cytokine secretion in Pak1-/-. 
Taken together the data from this Pak1-/- murine model of AAD suggest a novel 
role for PAK1 in promoting eosinophil inflammation. 
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Figure 9: Pak1 genetic deletion does not affect OVA-specific splenocyte 
secretion of T-helper cell cytokines. Total splenocytes from OVA-sensitized 
and challenged Pak1+/+ and Pak1-/- mice were stimulated with OVA or plain 
media and cultured ex vivo for 72 hours. Cell-free supernatants were collected 
and stored for multiplex ELISA cytokine measurement of the following analytes: 
IL-4, IL-5, IL-10, IL-17, IFNγ, and RANTES (Figures 9a-f). Data from N=7-8 mice 
from each group were analyzed and compared between genotypes by a 
student’s t-test.  
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Decreased eosinophil inflammation in AAD-induced mice with 
hematopoeitic Pak1 deletion in an adoptive bone marrow transplant model 
Deregulated interactions of hematopoietic and non-hematopoietic tissues 
promote the development of allergic airway inflammation. To further dissect the 
hematopoietic and pulmonary contributions of PAK1 to this eosinophil 
inflammation, we performed adoptive bone marrow transplantation studies 
building upon this PAK1 AAD phenotype.  We transplanted C56BL/6J CD45.2+ 
Pak1+/+ or Pak1-/- LDMNCs into lethally-irradiated WT recipient mice that co-
express both isoforms of CD45.1 and CD45.2 (CD45.1/2+) common leukocyte 
antigen (Figure 10a). To complement these transplanted cohorts, we also 
transplanted CD45.1/2+ Pak1+/+ and CD45.2+ Pak1-/- LDMNCs into CD45.2+ 
Pak1-/- bone marrow ablated recipient mice. Following a five-month 
hematopoietic reconstitution, we assessed peripheral blood chimerism of CD45 
antigens and observed comparable and complete reconstitution in hosts from 
both cohorts (Figures 10 b-c). These transplanted mice were then sensitized and 
challenged to develop allergic airway inflammation. We observed that Pak1 
deficiency in the bone marrow decreased the eosinophil numbers in BAL 
retrieved from both Pak1+/+ (Figure 10d) and Pak1-/- (Figure 10e) recipient 
mice. We additionally observed that while bone marrow graft Pak1 deficiency in 
Pak1+/+ hosts modestly decreased eosinophil numbers in BAL compared to 
wildtype grafts, this deficiency markedly decreased BAL eosinophil numbers in 
Pak1-/- hosts. These data together suggest hematopoietic PAK1 modulates 
processes that incite eosinophil inflammation in this murine model of AAD.
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Figure 10a 
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Figure 10b 
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Figure 10c 
  
 
72 
 
Figure10d 
 
Figure 10e  
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Figure 10: Hematopoeitic Pak1 deletion decreases eosinophil inflammation 
in AAD-induced mice in an adoptive bone marrow transplant model. In an 
adoptive bone marrow transplant model, CD45.1/2+ WT recipient mice were 
lethally irradiated and transplanted with either CD45.2+ Pak1+/+ or Pak1-/- 
LDMNCs. After hematopoietic reconstitution these transplanted mice were 
utilized in a murine AAD model as shown (Figure 10a). Hematopoietic 
reconstitution was assessed for WT recipients that received Pak1+/+ versus 
Pak1-/- bone marrow at 6 months by fluorescence cytometry of peripheral blood 
leukocytes (94.39+/-0.46% versus 94.04+/-0.26%, [Figure 10a]). Bronchoalveolar 
cells were enumerated and analyzed for eosinophil markers and eosinophil 
numbers computed (Figure 10d). Conversely, CD45.2+ Pak1-/- recipients were 
lethally irradiated and transplanted with CD45.1/2+ Pak1+/+ or CD45.2+ Pak1-/- 
LDMNCs. Hematopoietic reconstitution was assessed for Pak1-/- recipients that 
received Pak1+/+ versus Pak1-/- bone marrow at 6 months by fluorescence 
cytometry of peripheral blood leukocytes (95.75+/-0.63% versus 95.23+/-1.27%, 
[Figure 10c]). Bronchoalveolar cells from animals in (c) were enumerated and 
analyzed for eosinophil markers and eosinophil numbers computed (Figure 10e). 
Graphs from (b) and (c) are representative of two experiments and results from 
(d) and (e) are averaged from four mice (N=4). * p<0.05, ** p<0.01, ***p<0.001 
using a two-tailed student’s t-test.  
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Decreased eosinophil inflammation in AAD-induced mice with 
hematopoietic Pak1 deletion in an orthotopic lung transplant model 
Bone marrow transplants, usually used to study hematopoiesis require ionizing 
radiation that irreparably disrupts the pulmonary resident cells and architecture in 
transplant recipient mice. To further investigate the hematopoietic and pulmonary 
contributions of PAK1 to allergic airway inflammation, we collaborated with Dr. 
David Wilkes’ lab to transplant left lung grafts into Pak1+/+ and Pak1-/- mice.  
We separately transplanted Pak1-/- lungs into Pak1+/+ mice and conversely 
Pak1+/+ left lungs into Pak1-/- recipient mice. Following a recovery period, we 
OVA-sensitized and challenged these transplanted mice in a murine AAD model 
(Figure 11a). 
 
We found that Pak1-/- transplanted lungs in Pak1+/+ recipient mice 
demonstrated more eosinophilic inflammation than Pak1+/+ transplanted lungs in 
Pak1-/-  recipients on H&E stained sections (Figures 11b-e) despite comparable 
goblet cell metaplastic changes characteristic of AAD between the two groups 
(Figures 11f-g). In these preliminary studies, three out of four (3/4) transplants in 
the groups of Pak1+/+ mice transplanted with Pak1-/- lungs had peribronchiolar 
eosinophil inflammation on histological inspection. Conversely, none of four (0/4) 
transplants in the group of Pak1-/- mice transplanted with Pak1+/+ lungs had 
these lesions. Likewise, slides from Pak1+/+ mice transplanted with Pak1+/+ 
lungs, but not Pak1-/- mice transplanted with Pak1-/- lungs demonstrated 
eosinophil lesions (Table 1). The chi-square association between transplanted 
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mice with Pak1+/+ versus Pak1-/- hematopoietic cells and peribronchiolar 
eosinophil lesions was statistically significant.  
 
In subsequent studies with separate cohorts of mice, we transplanted Pak1-/- left 
lung into Pak1+/+ mice and conversely Pak1+/+ left lungs into Pak1-/- recipient 
mice. We procured lung grafts from these mice, and enzymatically digested 
whole lung tissue to quantify eosinophils by fluorescence cytometry.  Consistent 
with results from our AAD model, we saw a trend towards decreased total BAL 
eosinophil numbers (Figure 11h) and percentages (Figure 11i) in Pak1-/- hosts 
relative to Pak1+/+ hosts. Leukocytes retrieved from native right lung (Figure 11j) 
and engrafted left lung (Figure 11k) revealed a trend towards decreased non-
lymphocyte, non-monocyte Siglec F+ cells in Pak1-/- hosts compared with 
Pak1+/+ hosts. Future studies are needed to resolve these trends by increasing 
the number of animals and the experimental power. However, taken together 
these histological and quantitative data suggest a role for host/hematopoietic 
PAK1 modulation in eosinophil inflammation in a murine model of AAD. 
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Figure 11a  
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Figures 11b-c   
Figures 11d-e 
 
Pak1+/+ Pak1-/- 
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Pak1+/+ Pak1-/-
Pak1+/+ 1/1 3/4
Pak1-/- 0/4 0/1
Grafts
H
os
ts
Table 1: Fraction of transplanted mice that demonstrated eosinophil 
infiltration on histology 
Table 2: Chi square comparison w/o Yates correction **p<0.01 comparing all 
Pak1+/+ and Pak1-/- hosts percentages that demonstrated eosinophil 
inflammation on histology 
Eosinophils No eosinophils Total
Pak1+/+  hosts 4 1 5
Pak1-/-  hosts 0 5 5
totals 4 6 10
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Figures 11f-g  
Pak1+/+ Pak1-/- 
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N=3 
t‐test P=0.16928, 
MW‐U p=0.2 
N=3 
t‐test p=0.16399 
MW‐U p=0.2 
Figures 11h-i 
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N=3 
t‐test p=0.129 
MW‐U p=0.2 
N=3 
t‐test p=0.08356 
MW‐U p=0.1 
Figures 11j-k 
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Figure 11: Hematopoeitic Pak1 deletion may decrease eosinophil 
inflammation in AAD-induced mice in an orthotopic lung transplant model. 
In an orthotopic lung transplant model, we transplanted lungs from Pak1-/- mice 
into Pak1+/+ host mice. Conversely we transplanted Pak1+/+ left lungs into 
Pak1-/- recipient mice as shown. Following a five day recovery, we utilized these 
mice in a murine model of allergic airway inflammation. We prepared H&E 
(Figures 11b-e) and PAS (Figures 11f-g) sections of left lung grafts from these 
mice. Micrographs from (b-g) are representative of four mice (N=4). On 
histological inspection of H&E stained micrographs presence of peribronchiolar 
eosinophilic lesions was scored (Table 1) and chi-square association computed 
for Pak1+/+ versus Pak1-/- hosts (Table 2) p<0.01.  
 
In a separate cohort, we collected, enumerated, and stained BAL cells from test 
transplanted and OVA-sensitized and challenged Pak1+/+ and Pak1-/- mice for 
eosinophil markers and obtained eosinophil percentages by fluorescence 
cytometry (Figures 11h-i). We also obtained total leukocytes from native right 
lungs and the engrafted left lungs and stained BAL cells from these mice for 
eosinophil markers and obtained eosinophil percentages by fluorescence 
cytometry (Figures 11j-k). Results from (h) through (k) are from three mice (N=3) 
and do not yet show statistical significance.  
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PAK1 in Eotaxin- mediated Eosinophil function 
Building upon our whole animal studies, we sought to determine PAK1’s 
functional and molecular role in regulating eosinophil function in allergic airway 
inflammation. Allergic sensitization induces expression and secretion of 
chemokines and cytokines that recruit hematopoietic cells eliciting inflammation 
in airways. Eotaxin expression in allergic airway inflammation potently recruits 
eosinophils en masse to the lung effecting chronic inflammation. Eotaxins also 
elicit eosinophil degranulation and cationic protein release mediating damage 
and remodeling in lung tissue. We hypothesized that PAK1 modulates eotaxin-
mediated eosinophil infiltration and degranulation. To investigate the role PAK1 
plays in these eotaxin-mediated eosinophil functions, we used two in vivo eotaxin 
infiltration murine models. We further evaluated the mechanism of PAK1-
dependent eosinophil recruitment in vitro using bone-marrow derived eosinophils.  
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Eotaxin-mediated Eosinophil infiltration in vivo is PAK1-dependent 
Given our previous findings in whole and chimeric animal AAD studies, we 
assessed isolated eotaxin recruitment of eosinophils in vivo to explain the 
apparent defect in eosinophil recruitment to the lungs in AAD Pak1-/- mice as 
compared to their wild-type counterparts. We injected a dose of intraperitoneal or 
intratracheal eotaxin in sedated Pak1+/+ and Pak1-/- mice and collected 
peritoneal or broncho-alveolar lavage fluids for cell population evaluation by 
fluorescent cytometry. We observed from giesma-stained slides of peritoneal 
lavage cells obtained from eotaxin-treated Pak1-/- mice an increase in eosin-
staining cells. Similarly, giesma-stained and quantified peritoneal lavages cells 
(Figures 12c-d) and fluorescence cytometry quantified CD45+, CD3/B220, 
SiglecF+ broncho-alveolar lavage fluid cells (Figures 12e-f) from Pak1-/- mice 
were increased with eotaxin treatment but decreased compared to cells in fluids 
retrieved from eotaxin-treated Pak1+/+ mice (Figures 12a-d).  
  
 
85 
 
Figure 12a 
 
 
 
 
 
Figure 12b 
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Figure 12: Eotaxin-mediated infiltration in vivo is PAK1-dependent. Pak1+/+ 
and Pak1-/- mice were treated with PBS and eotaxin by intraperitoneal or 
intratracheal injections. Leukocytes from the respective cavities were lavaged 
and assessed for eosinophil numbers after 2 and 4 hours according to the 
schemes above (Figures 12a-b). Eosinophils were identified by giesma-staining 
and total CCR3+ cells back calculated and compared between genotypes 
(Figures 12c-d). Similarly, non-lymphocyte and non-monocyte populations of BAL 
cells were analyzed for SiglecF expression and SiglecF+ cells calculated and 
compared between genotypes (Figures 12e-f). Results in (d) and (f) are 
averaged from 4-6 mice and representative of at least three independent 
experiments. p<0.05, ** p<0.01, using a two-tailed student’s t-test. 
   
 
89 
IL-5 LDMNC colony formation in vitro is not PAK1-dependent 
In order to study eosinophil function in vitro, we chose to differentiate eosinophils 
from bone marrow stem and progenitor cells as previously published [244, 245]. 
The impact of Pak1 deletion on stem and progenitor cell differentiation is 
incompletely understood and remains unexplored in eosinophil differentiation. IL-
5 critically coordinately controls murine eosinophil differentiation in vivo and in 
vitro and reproducibly drives the formation of murine eosinophil colonies in 
methocellulose agar [245, 246]. To assess the impact of Pak1 deletion on stem 
and progenitor capacity to form IL-5 colonies we performed an IL-5 colony 
forming assay using Pak1 sufficient and deficient bone marrow derived 
mononuclear cells. We plated mononuclear cells in methocellulose semi solid 
agar medium enriched with high and low concentrations of IL-5 as the only 
growth and differentiation factor, incubated these cells, and counted total 
colonies on the tenth day of culture as previously described [236]. We showed 
that IL-5 stimulation resulted in growth of both Pak1+/+ and Pak1-/- colonies. 
However we also observed no difference in total number of colonies between the 
two genotypes (Figure 13). These results suggest that IL-5 induced bone marrow 
mononuclear cell colony formation does not depend on PAK1.  
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Figure 13 
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Figure 13: IL-5 BMMC colony formation in vitro is not PAK1-dependent. We 
harvested Pak1+/+ and Pak1-/- bone marrow and isolated LDMNCs on a ficol 
gradient (N=3). We counted cells by trypan blue exclusion and plated 200,000 
LDMNCs of each genotype in methocellulose soft agar medium containing 20% 
FBS and supplemented with IL-5 as the only growth and differentiation factor. 
One ml of cell/media was plated on 6cm dishes and incubated at 37°C for 10 
days. Each animal for each concentration of IL-5 was assayed in triplicate. We 
counted the total number of colonies per plate on day 10 of culture, averaged the 
repeated measurements, and compared numbers of colonies at each IL-5 
concentration between genotypes by a student’s t-test (Figure 13).   
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Eosinophil expression of transmigration integrins as well as adhesion to 
fibronectin is not PAK1-dependent  
Reorganization of the cell cytoskeleton facilitates rolling, adhesion, and 
transmigration of leukocytes as they infiltrate sites of tissue inflammation. 
Effective transmigration requires coordination between adhesive and motile 
forces, which are controlled by extracellular matrix signals acting on the cell 
cytoskeleton. CDC42/Racs, activators of PAKs, are implicated in optimally 
balancing between these processes [247, 248].  Eotaxin acts as a potent 
chemoattractant for eosinophil infiltration in vivo as well as adhesion of 
eosinophils to fibronectin [249, 250]. We sought to determine the effect of Pak1 
deletion on expression of adhesive proteins and eotaxin-mediated eosinophil 
adhesion. We cultured Pak1+/+ and Pak1-/- bmEos and assessed the 
expression of eosinophil adhesive molecules important for endothelial 
transmigration by fluorescence cytometry. We observed no difference in the 
frequency of cells expressing these proteins, with greater than 95% of cells 
expressing CD11a/αL, Mac1/αMβ2, α4β7, and VLA4/α4β1 in both genotypes 
(Figures 14a-d). This global surface integrin expression was maintained following 
eotaxin stimulation (data not shown). Likewise, MFIs denoting surface expression 
of these integrins was comparable between genotypes. We used Pak1+/+ and 
Pak1-/- bmEos in a microfluidic chamber adhesion assay to fibronectin. We 
coated microfluidic plates with gelatin or recombinant fibronectin fragments for 
one hour. Eosinophils showed preferential eotaxin-induced adherence to 
fibronectin in contrast to gelatin (Figure 14e).  A micro-fluid pressure-gradient 
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maintained steady-flow of Pak1+/+ and Pak1-/- bmEos in media through the 
fibronectin-coated chambers for 30 minutes. Micrographs (Figure 14f) and 
hemocytometer enumeration (Figure 14g) of total adherent cells both 
demonstrate indistinguishable eotaxin-mediated eosinophil adhesion between 
the two genotypes. These data warrant further functional characterization of 
PAK1’s role in modulating eotaxin-mediated eosinophil adhesion via CD11a/LFA-
1, Mac1, α4β7, and VLA4 interactions with recombinant fragments of the 
endothelium-expressed ICAM, VCAM, and MadCAM adhesive molecules [251-
253]. 
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Figure 14: Pak1 does not affect eotaxin-induced adhesion of eosinophils to 
fibronectin or surface expression of adhesion molecules. We cultured 
Pak1+/+ and Pak1-/- bmEos and utilized these cells in adhesion studies. First, 
we assessed the expression of αL of LFA-1, Mac1, α4β7, and VLA4 integrins in 
these bmEos by fluorescence cytometry of (Figures 14a-d). We tested for 
eotaxin-induced eosinophil adhesion on fibronectin and gelatin coated wells in a 
microfluidic adhesion assay (Figure 14e). Subsequently, we assessed eotaxin-
induced adhesion to recombinant fibronectin fragments in a fluid system. 
Micrographs that represent microfluidic chambers of adherent eotaxin-stimulated 
and control Pak1+/+ and Pak1-/- bmEos are shown (Figure 14f). We enumerated 
the total cells adherent to the microfluidic chambers after 20 minutes of 
stimulated flow (Figure 14g) and compared numbers from N=4 cultures for each 
genotype and eotaxin concentration.   
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Decreased eotaxin-mediated chemotaxis of murine eosinophils in vitro with 
Pak1 deletion 
We additionally evaluated PAK1’s role in this eotaxin-mediated chemotaxis by 
deriving bone marrow eosinophils (bmEos) from Pak1+/+ and Pak1-/- mice. We 
cultured bone marrow stem and progenitor cells harvested from Pak1+/+ and 
Pak1-/-  mice ex vivo in eosinophil polarizing conditions for 10-14 days and 
assessed eosinophil maturity by expression of CCR3, the eotaxin receptor. We 
cultured eosinophils deficient in PAK1 expression as determined by 
immunoblotting (Figure 15a). We observed no difference in CCR3 mean 
fluorescence intensity (MFI) of bmEos between the genotypes. This observation 
suggests a comparable surface expression density of CCR3 Pak1+/+ and Pak1-
/- bmEos (Figures 15b-c). This observation suggests that both Pak1+/+ and 
Pak1-/- bmEos have a similar opportunity to bind eotaxin ligand in solution. 
Furthermore cytospin analysis of these cells demonstrated approximately 80% 
purity red-granule staining cells on Giesma staining. This purity was at least 95% 
in both genotypes when assessed by Siglec F expression on fluorescence 
cytometry. (Figure 15d) 
 
In optimization studies that we performed with wild-type bmEos, we observed 
maximal migration as early as two hours and a significant difference in 
chemotaxis over control from mreotaxin concentrations of 500ng/mL and greater 
(data not shown). We then used Pak1+/+ and Pak1-/- bmEos in a checkerboard 
transwell-migration assay in which we separated or combined eotaxin and 
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bmEos in the top transwell chamber and allowed the cells to migrate for two 
hours according to the schematic below (Figure 15e). We collected the cells 
migrating to the bottom well in each condition and expressed migration as a 
chemotactic index of background. We only observed a significant difference in 
migration over background levels when we applied an eotaxin-gradient to the 
bmEos of both genotypes. Remarkably, Pak1-/- bmEos demonstrated 40% 
decreased chemotaxis compared with Pak1+/+ cells (Figure 15d).  These data 
taken together implicate eosinophil PAK1 in regulating infiltration by intrinsically 
promoting eotaxin- mediated eosinophil chemotaxis. 
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Figure 15: PAK1 promotes eotaxin-mediated chemotaxis in vitro. Pak1+/+/ 
Wild-type and Pak1-/- mice bmEos were cultured and assessed for PAK1 
expression by immunoblot (Figure 15a) and surface expression of CCR3 by 
fluorescent cytometry (Figure 15b). This surface CCR3 bmEos expression was 
compared between genotypes (Figure 15c). The percentage of bmEos 
expressing Siglec F was assessed after 10 days of culture by fluorescence 
cytometry (Figure 15d) Eotaxin-mediated chemotaxis was evaluated using a 
transwell system Pak1+/+ and Pak1-/-  BmEos were compared in a checker-
board migration format. Checkerboard migration assays were conducted with no 
stimulus, with eotaxin in the top chamber only, both chambers as shown in the 
schematic (Figure 15e). The cells migrating to the bottom chamber only were 
enumerated by hemocytometer (Figure 15f). Results in (c and f) are an average 
of at least three experiments (N=3-4) while results in (d) are representative of at 
least five independent experiments. ***p<0.001 using a two-tailed student’s t-test. 
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Decreased eotaxin-mediated chemotaxis of HL-60 derived human 
eosinophils (HL-60 Eos) with PAK1 RNA Interference 
To assess the importance of PAK1 in a human eosinophil migration, we derived 
human eosinophils from a promyelocytic leukemia cell-line, HL-60. These cells 
acquire eosinophil characteristics when cultured in alkaline conditions in the 
presence of n-butyrate. We differentiated human eosinophils from this cell line 
and assessed for purity by giesma staining. We transfected cultured HL-60 
human eosinophils with siRNA against human PAK1 or scrambled siRNA and 
compared their chemotaxis. We successfully delivered siRNA into HL-60 derived 
eosinophils as assessed by color-tagged siRNA control experiments with greater 
than 95% transfection efficiency (Figure 16a).  
 
In preliminary experiments we tested three siRNA constructs specific for human 
PAK1 and selected the construct showing greatest PAK1 knockdown. We 
selected construct #3 for subsequent transfection experiments (Figure 16b). After 
a 72 hour transfection with this siRNA construct, we demonstrated efficacious 
knockdown of PAK1 protein expression in these cells (Figures 16c-d). We 
compared the eotaxin-mediated chemotaxis of PAK1 siRNA treated eosinophils 
with scramble siRNA-treated eosinophils in a transwell chemotaxis assay for two 
hours. We found that PAK1 RNA silencing decreased eotaxin-mediated migration 
of human eosinophils compared to control (Figure 16e).  
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Figure 16c 
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Figure 16: PAK1 promotes decreases eotaxin-mediated chemotaxis in HL-
60 derived human eosinophils. We cultured HL-60 clone 15 cells in eosinophil 
differentiating conditions for three days and tranfected them with color-tagged 
sequence as a positive control, scramble siRNA, or three siRNA constructs 
against human PAK1.  Transfection efficiency was assessed using color-tagged 
siRNA (Figure 16a). Three PAK1 siRNA constructs were screened for PAK1 
knockdown by western blot and construct marked #3 selected for subsequent 
studies (Figure 16b). PAK1 siRNA (#3) transfected cells used in migration 
studies were assessed for PAK1 expression 72 hours after siRNA treatment by 
western blot (Figure 16c) and percentage knockdown quantified by densitometry 
(Figure 16d) for N=3 independent cultures. Migration of human eosinophil 
derived from HL-60 clone 15 cell line transfected with scramble or PAK1 siRNA 
were compared from N=5 independent cultures for each siRNA construct (Figure 
16e). Results in (d) are representative of at least three experiments. ** p<0.01, 
***p<0.001 using a two-tailed student’s t-test. 
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Restored and enhanced eotaxin-mediated eosinophil migration with 
ectopic expression of full length PAK1 but not kinase-dead mutant PAK1 in 
Pak1-/- eosinophils 
Gene ablation by homologous recombination can occasionally result in the 
disruption of surrounding genes. Since preliminary studies demonstrate that 
Pak1-/- eosinophils have impaired migration, we validated the specificity of this 
knockout by ectopically expressing PAK1 to restore eosinophil migration. We 
utilized a state-of-the-art lentiviral-mediated transgene expression system to 
overexpress PAK1, and a kinase-dead PAK1 mutant construct, K299R.  We 
adapted and ligated PAK1 cDNA into the pCL1eGFPGwo lentiviral backbone 
developed, optimized and kindly given to us by our collaborator Dr. Helmut 
Hanenberg as described [223].  
 
Likewise, we obtained the pCMV6M-Pak1 K299R deposited at Addgene as a 
generous gift by Dr. Jonathan Chernoff (Figure 17a). Using molecular techniques 
we NOTI-adapted and PCR-amplified Pak1 K299R yielding approximately a 1620 
base pair insert by gel analysis (Figure 17c). We used the PCL11eGwo lentiviral 
vector for this construct, another generous gift from Dr. Hanenberg. This vector 
utilizes an HPGK promoter that expresses both PAK1K299R and EGFP 
efficiently in myeloid cells. Following a NotI restriction enzyme digestion of the 
PCL11eGwo lentiviral vector, we blunted this vector and NotI-pak1K299R-NotI 
insert by Klenow treatment. We ligated vector and insert, transformed competent 
cells, and picked colonies for plasmid restriction digests. To confirm the 5’->3’ 
 
118 
orientation after ligation, we amplified these plasmids and subjected them to a 
restriction digest with AgeI and BstbI that yielding a DNA fragment spanning the 
eGFPPAK1 constructs. We obtained a DNA fragment of about 2000bp (Figure 
17d). To confirm translation of our construct in mammalian cells, we transfected 
HEK293T cells with these constructs and demonstrated the expression of eGFP 
fusion proteins approximately 85kDA (Figure 17e). We sequenced the lentiviral 
plasmid to confirm that Pak1 K299R cDNA is encoded, in frame and without 
further mutations.  
 
We generated viral particles in a HEK293T packaging cell line by co-transfecting 
our Pak1 plasmid constructs and a recombinant foamy virus envelope plasmid 
that enhances entry into both quiescent stem cells and proliferating progenitor 
cells as described [15]. We filtered and concentrated viral supernatant fifty times 
to yield viral titers of between 5 X107 to 5 X108 particles per milliliter.  
 
We magnetically sorted for c-Kit+ cells from LDMNCs for Pak1+/+ and Pak1-/- 
bone marrow to enrich for stem and progenitor cells. We transduced these cells 
with PCL11eGwo, PCL1Pak1, and PCL11Pak1K299R at multiplicities of infection 
(MOIs) of between 50 and 100 infectious particles per cell. The transduced cells 
were cultured in eosinophil polarizing conditions and allowed to express these 
transgenes. Seven days post-transduction, these cells were collected and sorted 
according to GFP or GFP-fusion protein expression. We obtained yields of 
approximately 10 to 20% GFP+ cells (Figure 17f). We continued culturing these 
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eosinophil precursors for three to five days post-FACS after which they were 
utilized in transwell migration assays.  These cells variably expressed Gr-1/Ly-6, 
but expressed CCR3 and almost invariably, SiglecF, surface markers of 
eosinophil maturity (Figure 17g).  
 
We noted that eGFPPAK1 ectopic expression in Pak1-/- eosinophils enhanced 
their eotaxin-induced chemotaxis (Figure 17h). This chemotactic index was 
greater than Pak1+/+ eosinophils transduced with PCL11eGFP. However, 
eGFPPAK1K299R ectopic expression did not change the chemotactic potential 
of Pak1-/- eosinophils (Figure 17h). These data complement and validate our 
findings in Pak1-/- eosinophils. Furthermore, these studies suggest that eotaxin-
mediated eosinophil migration is at least partly PAK1 kinase-dependent. 
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Figure 17: Ectopic expression of full length PAK1 but not kinase-dead 
PAK1 mutant in Pak1-/- eosinophils restores enhanced eotaxin-mediated 
migration. We Not1-adapted and amplified ~1620bp Pak1 K299R insert (Figure 
17c) from the PCMV6M-Pak1K229R vector (Figure 17a) and blunted it by 
klenow-fragment treatment. We digested PCL11 vector with Not1 and similarly 
blunted and CIAP treated it to prevent self-ligation. We ligated the Pak1 K299R 
insert into the cut PCL11eGwo vector to form an eGFPPak1K299R construct as 
shown (Figure 17b). We confirmed orientation of inserts in both PCL1eGFPPAK1 
and PCL11eGFPPAK1K299R by restriction enzyme digestion that would 
generate ~2000bp eGFPPAK1 and eGFPPAK1K299R DNA fragments (Figure 
17d). As expected, these plasmid constructs ectopically expressed ~85kDA 
eGFPPAK1 and eGFPPAK1K299R fusion proteins when transfected into 
HEK293T packaging cells. Pak1+/+ and Pak1-/- c-kit+ LDMNCs were transduced 
with PCL11eGwo only, PCL1eGFPPAK1 and PCL11eGFPPAK1K299R, 
fluorescently sorted (Figure 17f), cultured in eosinophil conditions and assessed 
for Gr-1, Siglec F and CCR3 surface expression (Figure 17g). We used cells 
transduced with these viral expressed constructs for eotaxin-mediated transwell 
chemotaxis studies (Figure 17h).    
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Eosinophil F-actin reorganization by Eotaxin: CCR3 signaling through 
PAK1 
Eotaxin signaling pathways through PAK1 in eosinophils have not been studied 
to date. Since our data indicate Pak1 deletion decreases eotaxin-mediated 
eosinophil F-actin polymerization and consequent migration, we sought to 
determine PAK1’s downstream molecular targets responsible for these changes. 
To elucidate F-actin dynamics in the eotaxin-stimulated eosinophil, we examined 
the phosphorylation of putative PAK1-dependent actin-regulating proteins by 
immunoblot from total cell extracts obtained from eotaxin-stimulated Pak1-/- and 
Pak1+/+ bmEos. First to show that eotaxin ligation of CCR3 induced PAK1 
activation, we used an in vitro kinase assay where we immunoprecipitated PAK1 
from HL-60 derived human eosinophils. Eotaxin-stimulation increased PAK1’s 
phosphorylation of MEK1 at its serine 298 residue (Figure 18a). PAK1’s kinase 
activation is a complex process that critically requires autophosphorylation of its 
threonine 423 (T423) residue [139]. Eotaxin-treatment of Pak1+/+ murine bmEos 
phosphorylated PAKs at threonine 423, their signal activation residue (Figure 
18b). Although work has not yet been done in eosinophils, PAK1 is known to 
regulate cell migration via the cytoskeleton. [155, 202, 205]. To test the role of 
PAK1 in cytoskeletal rearrangement, we cultured Pak1-/- and Pak1+/+ bmEos 
and examined F-actin dynamics by fluorescence cytometry. Eotaxin stimulation 
in bmEos of both genotypes caused initial polymerization and reorganization of 
F-actin, but this eotaxin-induced F-actin polymerization at 30 seconds was 
significantly diminished in Pak1-/- bmEos compared to Pak1+/+ (Figure 18c).  
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Furthermore eotaxin-stimulated Pak1-/- bmEos had altered cortical F-actin 
arrangement compared to WT bmEos (Figure 18f).  The F-actin and the tubulin 
cytoskeleton are coordinately controlled in migration. We examined tubulin and 
F-actin polymerization in eotaxin-treated bmEos of both genotypes and likewise 
observed perturbed tubulin polymerization. These data together suggest that 
eotaxin-mediated F-actin polymerization and organization in eosinophils is PAK1-
dependent. We hypothesized that these cytoskeletal dynamics perturbed in 
Pak1-/- eosinophils were associated with eotaxin-induced migration (Figure 18g). 
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Figure 18: PAK1 promotes F-actin reorganization induced by eotaxin 
signaling in eosinophils. HL-60 derived human eosinophils were generated in 
vitro and human PAK1 immunoprecipitated from eotaxin treated HL-60 Eos. 
PAK1’s kinase activity was assessed to its substrated purified MEK1 (Figure 
18a).  Pak1+/+ and Pak1-/- bmEos were cultured in vitro, treated with eotaxin, 
total cell extracts prepared and immunoprobed for PAKs and MEK1 
phosphorylation (Figure 18b). Results in (a-b) are representative of at least three 
independent experiments. Pak1+/+ and Pak1-/- BmEos were also cultured and 
stimulated with eotaxin over a two-minute duration for cytoskeletal studies. 
Eotaxin treated Pak1+/+ and Pak1-/- bmEos were fixed and relative (Figure 18c) 
and representative arbitrary (Figure 18d) mean fluorescent intensities (MFI) of 
phalloidin-tagged F-actin polymerization quantified by fluorescence cytometry, 
visualized by confocal microscopy (Figure 18e) and compared. Eotaxin-treated or 
untreated bmEos of both genotypes were also stained for tubulin and F-actin and 
visualized by deconvolution microscopy (Figure 18f).  Results in (c) are averaged 
from five experiments (N=5) while results in (d-f) are representative from at least 
five experiments. A schematic summarizing conclusions from this study is 
illustrated (Figure 18g) * p<0.05 using a two-tailed student’s t-test.  
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Eotaxin-induced eosinophil phosphorylation changes of cofilin as well as 
F-actin colocalization with p-34 Arc are PAK1-dependent  
Eotaxin signaling pathways through PAK1 in eosinophils have not been studied 
to date. PAK1 in many cell systems has been known to regulate several F-actin 
regulating proteins [150, 176, 254]. To elucidate F-actin dynamics in the eotaxin-
stimulated eosinophil, we examined the phosphorylation of putative PAK1-
dependent actin-regulating proteins by immunoblot from total cell extracts 
obtained from eotaxin-stimulated Pak1-/- and Pak1+/+ bmEos. We showed that 
eotaxin induced dephosphorylation of cofilin in bmEos occurs in a PAK1-
dependent manner (Figures 19a-b). Remarkably, Pak1-/- bmEos demonstrated 
impaired dephosphorylation of cofilin at serine 3 relative to Pak1+/+ bmEos 
(Figures 19a-b). PAK1 regulates cofilin in signaling events essential for F-actin 
cytoskeletal dynamics in cell migration [176, 195].  
 
Pak1 deficiency perturbed spatial eosinophil F-actin localization/reorganization 
30 seconds after eotaxin stimulation (Figure 18c-d). To further examine F-actin 
cytoskeletal events at this time point, we fluorescently tagged p34-ARC a subunit 
of the ARP2/3 protein complex. ARP2/3 is a known substrate of PAK1 that 
initiates new F-actin polymerization sites [177].  We found decreased 
colocalization of F-actin with this PAK1-regulated component of ARP2/3 in Pak1-
/- bmEos although p34ARC expression is comparable between the two 
genotypes (Figures 19c-d).  These data taken together suggest decreased de 
novo polymerization of actin-filaments in eotaxin-stimulated Pak1-/- bmEos.  
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Figure 19: Eotaxin induces PAK1-dependent phosphorylation changes of 
cofilin, filamin A and F-actin localization with p-34 ARC. Pak1+/+ and Pak1-/- 
bmEos were treated with eotaxin and fixed for immunocytochemical analysis or 
total cell extracts prepared for western blot. Cell extracts were immunoprobed for 
pS3-cofilin and total cofilin (Figure 19a) and levels of these proteins compared by 
densitometry (Figure 19b). Cell extracts from bmEos were immunoprobed for p-
34 ARC levels (Figure 19c). Fixed and permeabilized cells were probed for total 
p-34 ARC and F-actin (Figure 19d). Results in (a-c) are representative from at 
least three experiments. * p<0.05 using a two-tailed student’s t-test.  
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Eotaxin-induced phosphorylation of PAK2, Ezrin/ moeisin/ Radixin, Op18/ 
Stathmin, and p38 MAPK in the eosinophil is PAK1-independent 
To expand upon and explain PAK1-dependent F-actin polymerization, we also 
immunoblotted for phosphorylated PAK2, Ezrin/moeisin/Radixin, Op18/Stathmin, 
and p38 MAPK in total cell extracts from eotaxin-treated Pak1+/+ and Pak1-/- 
bmEos. PAK2, an isoform of PAK1, has been shown to have some redundant 
substrate specificities and function in vitro and in vivo [150]. PAK1 and PAK2 are 
both expressed in hematopoietic tissues although their redundant and disparate 
role in eosinophil function remain to be explored. We show that eotaxin 
stimulation induced PAK2 phosphorylation at the threonine 423 residue that is 
independent of PAK1 expression (Figures  20a-b). To further investigate the role 
of these two isoforms of PAKs in eosinophil migration we used, IPA3, an 
allosteric inhibitor of PAK1 that also inhibits PAK2. We pretreated Pak1+/+ 
eosinophils with IPA3 for 20 minutes prior to using these cells in a transwell 
migration assay. We observed that PAKs inhibition prevented eotaxin-mediated 
eosinophil migration (Figure 20c). Furthermore, IPA3 treatment significantly 
decreased spontaneous non-chemokine driven chemokinesis of eosinophils 
(Figure 20d) despite no profound effect on cell membrane compromise as 
assessed by trypan blue exclusion counts two hours after IPA3-incubation (not 
depicted). These findings suggest both PAK1 and PAK2 may have additive or 
synergistic effects on eotaxin-mediated eosinophil migration. 
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ERM, p38 MAPK, Filamin A, and Op18/Stathmin have been shown in other cell 
systems to regulate cytoskeletal remodeling downstream of PAK1 [121, 195, 
196, 200, 255]. We have previously observed that Pak1 modulates F-actin 
depolymerization and mast cell degranulation through Ezrin [192]. We show for 
the first time that eotaxin-treatment induced phosphorylation changes of p-T567 
ERM (Figures 20i-j). Phospho-T567 ERM also colocalized with F-actin in the 
eotaxin-polarized Pak1+/+ eosinophil (Figure 20e) so we hypothesized that a 
PAK1-ERM signaling axis is involved in eotaxin-induced F-actin changes and 
migration. To test this hypothesis, we generated mice with conditional 
hematopoietic Ezrin deficiency. We crossed Ezrin floxed mice with mice 
expressing the Mx-1 Cre transgene that is expressed in hematopoietic and liver 
tissues in an inducible fashion (Figure 20f).  Approximately 25% of the second 
generation of pups yielded the desired Ezrin flox/flox Mx1Cre- (Ez-WT) and    
Ezrinflox/flox Mx1Cre+ (Ez-KO). We induced Mx-1 Cre expression by 
intraperitoneal administration of a tapered dose of PolyIC on alternative days 
standardized by mouse weight. We demonstrated hematopoietic ablation of Ezrin 
expression by western blot analysis of Ez-KO LDMNCs (Figure 20g). We 
cultured Ez-WT and Ez-KO bmEos and used them in eotaxin migration assays. 
We observed no difference between migration of Ez-WT and Ez-KO eosinophils 
(Figure 20h). These data together suggest eotaxin-induced phosphorylation of 
Ezrin is neither necessary for eotaxin-mediated eosinophil F-actin polymerization 
nor migration. Furthermore, these Ezrin changes are not PAK1-dependent.  
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p38 MAPK is known to regulate the cell cytoskeleton and cell migration via its 
downstream effector HSP27 [122, 245]. In hematopoietic cells, SCF-mediated 
mast-cell migration is in part PAK1-dependent [121]. We postulated that PAK1-
p38-dependent signaling may also be important in eotaxin-mediated eosinophil 
migration. To examine p38 MAPK’s role in PAK1-dependent eotaxin-mediated 
eosinophil migration, we used chemical inhibition of p38 MAPK activity in 
transwell migration assays as well as western blot analysis of eotaxin-treated 
bmEos. p38 MAPK inhibition by SB 203580 decreased eotaxin-mediated wild-
type eosinophil migration by greater than 40% in a similar manner as PAK1 
(Figure 20k). We also measured and quantified eotaxin-induced phosphorylation 
of p38 MAPK and observed phosphorylation of T180/Y182 p38 MAPK. However, 
the eotaxin-mediated phosphorylation of p38 MAPK did not appear to be PAK1-
dependent in the initial eotaxin-mediated PAK1 signaling (Figures 20i-j).  
 
PAK1 also phosphorylates Filamin A at its serine 2152 residue. Filamin A 
anchors integrins and transmembrane receptor complexes to the cell 
cytoskeleton modulating cell shape. Moreover, studies in FLNA knockout 
systems demonstrate multiple defects with migrational etiology [193, 194]. We 
show that eotaxin-induces phosphorylation of Filamin A comparably in both 
Pak1+/+ and Pak1-/- bmEos (Figures 20l-m). Additionally, PAK1 is known to 
phosphorylate Op18/stathmin at its serine 16 residue mediating tubulin and 
consequently F-actin reorganization. In our studies, while we show a novel 
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eotaxin-induced phosphorylation of Op18/Stathmin in eosinophils, this 
phosphorylation does not appear to be PAK1-dependent (Figures 20i-j). 
 
From the biochemical and microscopic data we report in Figures 19 and 20, we 
propose a model of eotaxin signaling in the eosinophil (Figure 20n). We show 
that eotaxin:CCR3 independently phosphorylates PAK1 and PAK2. We also 
show that PAK1 in the eosinophil mediates eotaxin-induced depolymerization of 
cofilin in modulating F-actin temporal-spatial polymerization. In so doing, PAK1 
may increase de novo polymerization of F-actin at new sites that are ARP2/3-
mediated. However, the intital eotaxin-induced phosphorylation of ERM, p38 
MAPK, filamin A, and Op18/Stathmin is PAK1-independent.  
  
 
146 
 
 
 
 
Figure 20a-b  
  
 
147 
 
Figure 20c 
 
 
 
Figure 20d   
 
148 
 
 
Figure 20e  
 
149 
 
 
Figure 20f  
 
150 
 
Figure 20g  
 
151 
 
Figure 20h  
 
152 
 
Figure 20i  
 
153 
 
Figure 20j 
 
  
 
154 
 
 
Figure 20k 
  
 
155 
 
 
 
Figures 20l-m  
 
156 
 
Figure 20n  
 
157 
Figure 20: PAK1-independent Eotaxin-induced phosphorylation of PAK2, 
Ezrin/moeisin/Radixin, Op18/Stathmin, and p38 MAPK in the eosinophil. 
Pak1+/+ and Pak1-/- bmEos were treated with eotaxin and total cell extracts 
prepared for western blot or fixed for immunocytochemical analysis. Cell extracts 
were blotted for p-T423 PAKs (Figures 20a-b), p-T567 ERM, p-T180/Y182 p38 
MAPK, Fillamin A, p-S16 Op18/Stathmin as well as GAPDH as a loading control 
(Figures 20i-m). Paraformaldehyde fixed bmEos were permeabilized and 
immunoprobed for p-T567 Ezrin and phalloidin-treated for F-actin visualization 
(Figure 20e). To assess migration inhibitor treated cells and cell deficient in Ezrin 
were utilized in transwell migration assays where bmEos migrating to the bottom 
chamber were enumerated by hemocytometer. Pak1+/+ bmEos were pretreated 
with inhibitors against PAKs, IPA3, and p38 MAPK, SB 203580, before being 
utilized in an eotaxin transwell migration assays, N=3-6 (Figures 20c-d, k). Ezrin 
floxed mice were crossed with mice expressing the inducible Mx-1 Cre 
transgene, to yield the desired F2 descendants according to this schematic 
(Figure 20f). Ez WT and Ez KO mice were injected with five doses of PolyIC on 
alternate days to induce expression of Mx-1 Cre in Ez KO bone marrow. Cell 
extracts from LDMNCs from four Ez WT and Ez KO mice, post-PolyIC treatment 
was immunoblotted for Ezrin (Figure 20g).  Ez WT and Ez KO eotaxin-mediated 
chemotaxis was evaluated using a transwell system, N=5 (Figure 20h). Our 
eosinophil migration studies, suggest a generalized schematic of PAK1-
dependent and -independent eotaxin-induced pathways (Figure 20n). *p<0.05, ** 
p<0.01, ***p<0.001 using a two-way ANOVA with Bonferroni post hoc.   
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Eotaxin-induced eosinophil degranulation in vitro is PAK1- independent 
Eosinophil degranulation and mediator release promote airway remodeling [90]. 
Based on the results from our murine asthma model that demonstrated 
decreased eosinophils in the BAL and lung tissue of Pak1-/- mice, we wanted to 
examine Pak1’s role in eotaxin-mediated murine eosinophil degranulation. 
Eotaxin is known to induce degranulation and granule protein release from 
human and murine eosinophils [117, 256, 257]. In a peritoneal eotaxin-mediated 
eosinophil infiltration model, we show eotaxin induces potent eosinophil 
recruitment and degranulation in vivo. Furthermore, this degranulation seems to 
be dependent on PAK1 with fewer degranulated eosinophils in Pak1-/- mouse 
peritoneal lavage Giesma-stained cytospins compared with Pak1+/+ (Figures 
21a-b). We sought to characterize the peritoneal lavage cell populations by 
FACS. We found consistent with previous studies that whereas granulated 
eosinophils were predominantly CCR3+, prolonged exposure to eotaxins cause 
degranulation and receptor internalization [236, 258]. Hence degranulated 
eosinophils were predominantly CCR3- (like neutrophils) and appeared to have 
without red granules on giesma staining (Figure 21c). This ablated CCR3 
expression makes fluorescence cytometric CCR3 assessment of eosinophils 
from peritoneal lavage fluid variable and unreliable. Our previous work supports a 
role for PAK1 in mast cell degranulation. Pak1-/- mast cell degranulation is 
decreased measured by β-hexoaminidase enzymatic activity [223]. Furthermore, 
transgenic lentiviral expression of PAK1 restored IgE/DNP-mediated mast cell 
degranulation in vitro (Figure 21d). Moreover, we observed that this PAK1-
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dependent degranulation is mediated in part by Ezrin [192]. Similar to Pak1 
deletion, Ezrin deficiency in mast cells decreased IgE/DNP-mediated 
degranulation (Figure 21e) and F-actin depolymerization (Figure 21f). We 
consequently hypothesized that PAK1 regulates eotaxin-mediated eosinophil 
degranulation and used a well-documented colorimetric assay quantifying 
supernatant EPO activity in lieu of granule release. We found that we could not 
elicit eotaxin-induced EPO degranulation over baseline despite strong in vivo 
degranulation. Furthermore, we could not distinguish between relative 
degranulation levels of Pak1-/- versus Pak1+/+ bmEos (Figure 21g). Similarly, 
further degranulation studies using Ez-KO bmEos revealed no difference in 
degranulation compared with Ez-WT (Figure 21h). Our inconclusive 
degranulation results suggest a need for a more sensitive system to study 
eotaxin-mediated degranulation in vitro. 
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Figure 21: Eotaxin-induced eosinophil degranulation in vitro. Cytospin slides 
from whole animal eotaxin-infiltration studies showed degranulation of 
eosinophils in vivo following PBS (Figure 21a) or eotaxin (Figure 21b) treatment. 
Black arrows indicate degranulated eosinophils (Figure 21b). FACS of Pak1+/+ 
peritoneal lavage cell populations followed by giesma-staining of different cell 
populations (EOS=eosinophil, NE=neutrophil, MONOS=mononuclear cells 
[Figure 21c]). Our previous work showed the effect of Pak1 deletion and ectopic 
transgene expression in bone-marrow mast cells on IgE/DNP-mediated 
degranulation and β-hexosaminadase activity, N=6 (Figure 21d).  Follow-up 
studies demonstrated the result of genetic deletion of a PAK1 downstream 
effector, Ezrin, on this mast cell degranulation, N=5 (Figure 21e) and F-actin 
depolymerization (Figure 21f). A colorimetric degranulation assay measuring 
released EPO activity measures eotaxin-mediated degranulation of Pak1+/+ and 
Pak1-/- (Figure 21g) and Ez WT and Ez KO (Figure 21h) eosinophils in vitro. 
Experiments in (b-h) are an average of at least three experiments, N=3-6.  
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DISCUSSION AND FUTURE EXPERIMENTS 
Eosinophils whose major function had largely been regarded as T-helper 2 cell 
effectors, are increasingly gaining recognition for their integral role in modulating 
airway hyperresponsiveness, inflammation, and remodeling through toxic 
degranulation products, lipid mediators, growth factors, and cytokines. In an 
OVA-albumin murine AAD model, eosinophil T-helper cell airway epithelial 
signaling networks establish self-perpetuating chronic inflammation in the airway 
that recapitulates human asthma. Identifying the mechanisms through which 
eosinophils infiltrate the lung in asthma would offer novel specific targets for 
therapeutic intervention. In these studies we have identified PAK1 as a key 
regulator of allergic airway eosinophil inflammation in vivo as well as eotaxin-
mediated eosinophil migration in vitro.  
PAK1 in murine allergic airway inflammation 
We have previously demonstrated that genetic ablation of Pak1 does not alter 
murine survival or in vivo hematopoietic lineage differentiation as assessed by 
peripheral blood differential leukocyte assessment [223]. Studies done with these 
Pak1-/- mice implicate PAK1 in migration and degranulation of mast cells [121, 
192, 218]. These pro-inflammatory processes drive allergic airway inflammation 
and depend heavily on stimulus-induced F-actin dynamics [192, 223]. While 
several studies propose a role for PAK1’s in force generation in airway smooth 
muscle hyperresponsiveness in AAD, no reports discuss PAK1’s potential role in 
allergic airway inflammation [218].  
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The data presented in our studies support a PAK1 kinase-dependent mechanism 
for eosinophil infiltration in vivo. Several Rho-family GTPase pathways have 
been associated with promoting allergic airway inflammation [125, 259]. Our data 
implicate PAK1, a known Rho-GTPase molecular substrate in eosinophil airway 
inflammation characteristic of AAD. We show for the first time an attenuated 
inflammatory cell response in a Pak1-/- OVA-albumin murine AAD model that 
recapitulates human eosinophil-rich airway inflammation in tissue (Figure 7) and 
BALF (Figure 8). The levels of eotaxin in the BAL and other T-helper cell derived 
cytokines from OVA-stimulated splenocytes of Pak1+/+ and Pak1-/- sensitized 
mice were indistinguishable (Figures 8d and 9) implying a preservation of T-cell 
responses in this Pak1-/- AAD model.  
This markedly depressed airway inflammation seems primarily hematopoietically-
derived and intrinsic to the eosinophil as both Pak1+/+ and Pak1-/- recipient mice 
transplanted with Pak1-/- bone marrow showed decreased eosinophil 
inflammation compared to their counterpart recipients transplanted with Pak1+/+ 
bone marrow (Figure 10). However, our data cannot rule out the possible role of 
other factors in the inflammatory environment in recruiting eosinophils to the lung 
in these sensitized mice as may be suggested by the adoptive bone marrow 
transplant results. We saw markedly suppressed eosinophil recruitment in BAL 
fluids from Pak1-/- mice transplanted with Pak1-/- bone marrow compared to BAL 
fluids from Pak1+/+ mice transplanted with Pak1-/- bone marrow (Figure 10d-e). 
Similar to our bone marrow transplantation studies, orthotopic lung transplants 
demonstrated a trend towards greater lung eosinophil inflammation in host mice 
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with a Pak1+/+ hematopoietic system as compared to Pak1-/- hosts (Figure 11), 
however, this trend needs to be clarified by increasing the number in subsequent 
cohorts of mice that are transplanted.  
The exact contribution of PAK1 to allergic airway inflammation remains largely 
unexplored. Our studies demonstrate PAK1’s integral role in eosinophil infiltration 
of the lungs following allergen-sensitization and challenge. However, PAK1 role 
in other cells in this allergic process remains understudied. Mast cell 
degranulation and SCF-mediated migration are impaired in Pak1-/- mice [121, 
223]. A role of PAK1 in neutrophil chemotaxis is also reported however studies in 
Pak1-/- mice are indicated to clarify its mechanism [260, 261]. One possibility is 
that PAK1 is selectively effective in promoting allergen-induced infiltration of 
inflammatory cells. The other possibility is that PAK1 promotes the motility of 
cells of multiple hematopoietic cell lineages in which case further studies are 
critical to fully characterizing the immune responses of Pak1-/- mice.   
Our data in this section are obtained from an OVA-Alum sensitization model that 
elicits a potent Th2-driven eosinophil response in vivo. While this model is a very 
useful tool in studying eosinophil infiltration, the model does not fully recapitulate 
human disease. In human bronchial asthma, mast cells inflammation plays a 
major role in eosinophil infiltration as well as the other hallmarks of asthma while 
the adjuvant Alum potentiates the Th2 response to override the mast cell effect 
on development of this allergic airway inflammation [54, 262]. Similarly, here we 
only examine acute eosinophil inflammation recruitment [21]. Future studies 
utilizing a chronic sensitization and challenge protocol for Pak1-/- mice would 
 
171 
complement and supplement our findings in a model that mimics the mast-cell 
involvement and chronic accumulation of eosinophils in vivo.  Since the exact 
effect of ionizing-radiation on the lung parenchyma from bone marrow 
transplanted mice is also unknown [259, 263] we also utilized complementary 
orthotopic lung transplantation studies. Our results from these studies indicate a 
need for increased numbers in cohorts used in future studies. Likewise, these 
prospective studies should include groups of isogeneic transplant animals as 
controls for the surgical procedure. Ultimately, AAD studies in genetic crosses 
between Pak1-/- and  KitW-sh/W-sh mice are warranted to study eosinophil 
inflammation in a mast-cell deficient context. These studies would clarify the 
distinct roles of PAK1 in mast cells, T-helper cell and eosinophils in AAD. 
The process of eosinophil migration and infiltration is critical to the development 
of chronic airway inflammation in asthma. Eosinophils take up residence in the 
lungs and modulate chronic inflammatory processes that cause airway tissue 
injury and remodeling. Our studies have identified PAK1 as a potential 
transducer of allergen-induced chemotactic signals in the migrating eosinophil. 
Although PAK1 is likely not the exclusive regulator of eotaxin-mediated migration, 
it is a promising targetable molecular switch for therapeutic intervention. Our 
work is a basis for future studies testing PAK1’s role in allergen recruitment of 
eosinophils.  
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PAK1 in Eotaxin- mediated Eosinophil function 
No published reports have examined the role of PAK1 in eosinophil function to 
date. Building upon our robust in vivo AAD model of eosinophil recruitment, we 
sought to understand the mechanism by which PAK1 modulated eosinophil 
function. We hypothesized based on our transplant data, that PAK1 plays a role 
in intrinsic eosinophil activity. We test this question in two in vivo murine 
infiltration models where we standardized the concentration of eotaxin, a potent 
eosinophil chemoattractant. Our results suggest a role for PAK1 in eotaxin-
mediated infiltration of eosinophils in vivo (Figure 12). In previous eotaxin 
infiltration studies, eotaxin preferentially recruited eosinophils relative to other cell 
lineages to the peritoneum [227, 228]. Both studies identify the importance of a 
readily available pool of circulating or tissue eosinophils to respond to this 
eotaxin signal, consequently the degree of eosinophil accumulation in vivo was 
dependent on allergen-sensitization or IL-5 in transgenic mice. Our studies in the 
non-sensitized animal could therefore be complemented by repeating these 
studies in the OVA-sensitized mice.  
We obtained further evidence on PAK1’s role in eotaxin-mediated eosinophil 
function from bmEos and HL-60 Eos. We demonstrated for the first time that 
eotaxin phosphorylated and activated PAK1 in murine and HL-60 derived 
eosinophils (Figures 19a-b). We subsequently sought to generate Pak1 deficient 
eosinophils and were able to demonstrate a comparable potential of Pak1-/- stem 
and progenitor cells to generate colonies from IL-5 the major eosinophilopoietic 
cytokine (Figure 14). Pak1-/- bmEos generated using IL-5 also demonstrated 
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indistinguishable expression of CCR3, siglec F as well as many adhesive 
molecules compared to Pak1+/+ bmEos. Since eosinophil infiltration involves 
margination, adhesion, and transmigration we assessed PAK1’s role in adhesive 
and motive eosinophil processes. First we assessed PAK1’s effect on eotaxin-
mediated eosinophil adhesion. Previous studies have shown the importance of 
eotaxin-mediated adhesion to eosinophil migration to sites of inflammation. 
These studies have frequently used recombinant fibronectin to mimic adhesion of 
eosinophils to the endothelial wall [192, 250, 264]. Adhesion in eotaxin-
stimulated eosinophils is mediated by integrin association with neighboring cell 
integrins. We examined the effect Pak1 deletion had on surface expression of 
CD11a/αL, Mac1/αMβ2, α4β7, and VLA4/α4β1, integrins well-documented to 
play important roles in eosinophil trafficking in various body organs [265]. We 
found comparable percentages of cells expressing similar densities of these 
integrins (Figures 16a-d). These data suggest that Pak1 deletion does not affect 
the surface expression of the important adhesive eosinophil integrins. We 
subsequently performed functional adhesive studies on fibronectin coated plates 
in a microfluidic system that recapitulates capillary flow. We confirmed in our 
studies, that eosinophil preferentially adhered to fibronectin compared to gelatin 
coated plates, and this adhesion was eotaxin-mediated (Figures 16e-f). However, 
the adhesion was not different between Pak1+/+ and Pak1-/- eosinophils (Figure 
14g). Our studies in adhesion are limited in that they are largely correlative in that 
functional adhesion of each integrin is not tested. In future studies, we will 
expand upon these adhesion studies utilizing recombinant ICAM, VCAM, and 
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MadCAM, the interacting integrins on the endothelium that eosinophils can bind 
[265, 266].  
Our studies also propose a model of eotaxin-mediated eosinophil chemotaxis 
that depends on PAK1’s modulation of F-actin polymerization. Our data indicate 
that eotaxin: CCR3 signaling phosphorylates and activates PAK1 driving 
eosinophil chemotaxis (Figure 14). While Pak1-/- eosinophils ectopically 
expressing a full length PAK1 construct had enhanced chemotaxis, ectopic 
expression of catalytically inactive PAK1, K299R, did not affect Pak1-/- 
eosinophil migration (Figure 16). PAK1 regulates F-actin dynamics via distinct 
mechanisms [133, 167].  These results suggest an eotaxin-mediated PAK1 
kinase-dependent mechanism as opposed to a kinase-independent interaction 
with downstream proteins in the F-actin changes needed for eosinophil 
chemotaxis (Figure 16).   
Chemokine-induced hematopoietic cell movement depends on cycles of F-actin 
polymerization, depolymerization and reorganization [267-270]. Our results 
demonstrate that PAK1 regulates eotaxin-induced eosinophil F-actin 
polymerization. PAK1 can catalytically control cell motility via cofilin-dependent 
actin cytoskeletal changes as well as ARP2/3-mediated nucleation and branching 
of F-actin in different cell types. PAK1’s regulation of cofilin in migrating cells is 
complex [174, 176] and cofilin phosphorylation in eotaxin-stimulated murine 
eosinophils appears to be spatial-temporally determined. Our data indicate that 
PAK1 facilitates dephosphorylation of cofilin which may be necessary for F-actin 
remodeling around the cell (Figure 19). PAK1 directly regulates the p41-Arc 
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subunit of the ARP2/3 F-actin nucleating complex independent of cofilin [177, 
271]. We show that Pak1 deletion decreases the co-localization of F-actin and 
the p-34-Arc subunit of this complex suggesting a role for PAK1 in ARP2/3-
mediated de novo F-actin polymerization. In contrast to these two F-actin binding 
protein partners of PAK1, p38MAPK, Ezrin/Radixin/Moesin, and Op18/Stathmin 
do not seem critical to PAK1-dependent eotaxin-mediated eosinophil chemotaxis 
despite their phosphorylation in the eotaxin-treated eosinophil (Figure 20). 
Furthermore, migration studies using Ezrin-/- eosinophils that showed no 
attenuated migration make Ezrin an unlikely downstream PAK1 effector critical to 
eotaxin-mediated eosinophil migration (Figure 20). These data taken together 
provide initial evidence for a model where eotaxin-induced activation of PAK1’s 
kinase activity results in the catalytic downstream regulation of cofilin and 
ARP2/3-mediated F-actin changes and eosinophil chemotaxis. 
One implication our studies have on the field is the use of small molecule 
inhibitors to target PAK1 kinase activity to attenuate eosinophil inflammation. The 
disparate roles of PAK1 and PAK2 in hematopoietic cells, however, remains 
incompletely understood. PAK1 and PAK2 are highly homologous and of similar 
substrate specificity in vitro [150]. We show that similar to PAK1, PAK2 is 
phosphorylated at its activation residue with eotaxin-stimulation (Figure 10). 
However, this activation does not seem critical to eotaxin-mediated eosinophil 
migration as is shown by our migration studies in Pak1-/- ectopically expressing 
K299R, a dominant negative form of PAKs (Figure 17). Nonetheless, we show in 
migration studies using IPA3 a pan-PAKs inhibitor severely hampered migration 
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(Figure 20). These data suggest that loss of Pak2 may potentiate the loss of 
eotaxin-mediated migration potential exhibited by Pak1-/- eosinophils. However, 
studies using ectopic expression of K299R and IPA3 are hindered by 
uncertainties of in vitro manipulation and non-selectivity. Other current PAK1 
selective inhibitors developed to target cell invasion and metastasis in cancer 
treatment are unable to select for PAK1 over its group I PAK isoforms PAK2 and 
PAK3 [244, 272]. Our studies identify a need to evaluate the differential versus 
redundant roles of PAK1 and its isoform PAK2 in eotaxin-mediated eosinophil 
migration and infiltration. To adequately address this issue in future studies, we 
would utilize Pak1-/- and Pak2 floxed mice crossed with Mx1Cre + mice we can 
begin to assess the differential role of these isoforms in eosinophil inflammation 
in vivo. The results of this study warrant further exploration of the anti-
inflammatory attributes of PAK1 inhibition on eosinophil inflammation in a mouse 
model of AAD.  
Lastly, we tested the effect PAK1 has on eotaxin-mediated eosinophil 
degranulation and mediator release, based on our definitive data in mast-cell 
degranulation [223]. In vivo, in our eotaxin mediated eosinophil peritoneal 
infiltration model we demonstrate an increased number of degranulated Pak1+/+ 
eosinophils compared to Pak1-/- eosinophils (Figures 21b-c) [273]. To build upon 
this in vivo phenotype, we used a colorimetric EPO quantifying assay. 
Surprisingly, we could not elicit increased degranulation over baseline using 
increasing doses of eotaxin alone (Figure 21g) neither could we demonstrate a 
difference in degranulation between Pak1+/+ and Pak1-/- nor EZ-WT and EZ-KO 
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eosinophils (Figures 21g-h). The in vivo system is significantly different for 
eosinophils in contact with other cells and the extracellular matrix when 
responding to eotaxin [250]. EPO is extremely adhesive and may not readily 
solubilize during the colorimetric reaction [274, 275]. Consequently, newer 
studies on eotaxin-mediated eosinophil degranulation utilize multiple 
degranulation assays [256]. In future degranulation studies we will utilize multiple 
end-point analysis including MBP, EPO, and β-hexosaminidase to assess 
degranulation. We will also include adhesive recombinant integrins like ICAM and 
VCAM or cytokines like IL-5 to potentiate eotaxin-mediated degranulation 
response.  
PAK1 acts as a molecular switch in many physiological cellular processes. In 
eosinophils our studies demonstrate that PAK1 modulates eosinophil function by 
transducing the eotaxin:CCR3 signal. We provide novel data implicating PAK1 in 
regulating actin-mediated inflammatory processes in eosinophil inflammation 
characteristic of AAD. Our findings have opened up a novel front exploring PAK1 
as a potential asthmatic therapeutic. These studies broaden the understanding of 
the molecular mechanisms underpinning eosinophil inflammation in AAD. Due to 
relatively innocuous consequences of Pak1 deletion coupled with its critical role 
in eosinophil migration, our findings warranted broader investigative exploration 
of PAK1’s role in allergic disease.  
  
 
178 
REFERENCES 
 
1. CDC/P. Asthma: A Presentation of Asthma Management and Prevention 
(Slide Presentation and Speaker Notes). 2009  [cited 2012 01/01]; 
Available from: http://www.cdc.gov/asthma/healthcare.html. 
2. WHO. Asthma: Factsheet No. 307. 2011; Available from: 
http://www.who.int/mediacentre/factsheets/fs307/en/index.html. 
3. CDC/P. Flu and People with Asthma. [Webpage] 2011  [cited 2012 01/01]; 
Available from: http://www.cdc.gov/flu/asthma/index.htm. 
4. Murphy, K.R., et al., Asthma management and control in the United 
States: results of the 2009 Asthma Insight and Management survey. 
Allergy and asthma proceedings : the official journal of regional and state 
allergy societies, 2012. 33(1): p. 54-64. 
5. Nathan, R.A., et al., Comparison of the Asthma in America and Asthma 
Insight and Management surveys: did asthma burden and care improve in 
the United States between 1998 and 2009? Allergy and asthma 
proceedings : the official journal of regional and state allergy societies, 
2012. 33(1): p. 65-76. 
6. Robbins, S.L., V. Kumar, and R.S. Cotran, Robbins and Cotran pathologic 
basis of disease. 8th ed. 2010, Philadelphia, PA: Saunders/Elsevier. xiv, 
1450 p. 
7. Buc, M., et al., Immunopathogenesis of bronchial asthma. Arch Immunol 
Ther Exp (Warsz), 2009. 57(5): p. 331-44. 
8. Galli, S.J., M. Tsai, and A.M. Piliponsky, The development of allergic 
inflammation. Nature, 2008. 454(7203): p. 445-54. 
9. Costa, J.J., P.F. Weller, and S.J. Galli, The cells of the allergic response: 
mast cells, basophils, and eosinophils. JAMA, 1997. 278(22): p. 1815-22. 
10. Bloemen, K., et al., The allergic cascade: review of the most important 
molecules in the asthmatic lung. Immunol Lett, 2007. 113(1): p. 6-18. 
11. Corry, D.B. and C.G. Irvin, Promise and pitfalls in animal-based asthma 
research: building a better mousetrap. Immunol Res, 2006. 35(3): p. 279-
94. 
12. Zuyderduyn, S., et al., Treating asthma means treating airway smooth 
muscle cells. Eur Respir J, 2008. 32(2): p. 265-74. 
13. Bates, J.H., M. Rincon, and C.G. Irvin, Animal models of asthma. Am J 
Physiol Lung Cell Mol Physiol, 2009. 297(3): p. L401-10. 
14. Kroegel, C. and H. Wirtz, History of guidelines for the diagnosis and 
management of asthma: from opinion to control. Drugs, 2009. 69(9): p. 
1189-204. 
15. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and 
Management of Asthma-Summary Report 2007. J Allergy Clin Immunol, 
2007. 120(5 Suppl): p. S94-138. 
16. Barnes, P.J. and I.M. Adcock, How do corticosteroids work in asthma? 
Ann Intern Med, 2003. 139(5 Pt 1): p. 359-70. 
 
179 
17. McIvor, R.A., et al., Potential masking effects of salmeterol on airway 
inflammation in asthma. Am J Respir Crit Care Med, 1998. 158(3): p. 924-
30. 
18. Weldon, D., The effects of corticosteroids on bone growth and bone 
density. Ann Allergy Asthma Immunol, 2009. 103(1): p. 3-11; quiz 11-3, 
50. 
19. Guilbert, T.W., et al., Long-term inhaled corticosteroids in preschool 
children at high risk for asthma. N Engl J Med, 2006. 354(19): p. 1985-97. 
20. Yiamouyiannis, C.A., et al., Shifts in lung lymphocyte profiles correlate 
with the sequential development of acute allergic and chronic tolerant 
stages in a murine asthma model. Am J Pathol, 1999. 154(6): p. 1911-21. 
21. Bates, J.H., et al., The synergistic interactions of allergic lung inflammation 
and intratracheal cationic protein. Am J Respir Crit Care Med, 2008. 
177(3): p. 261-8. 
22. Nygaard, U.C., A. Aase, and M. Lovik, The allergy adjuvant effect of 
particles - genetic factors influence antibody and cytokine responses. Bmc 
Immunology, 2005. 6: p. -. 
23. Ng, N., et al., House dust extracts have both T(H)2 adjuvant and 
tolerogenic activities. Journal of Allergy and Clinical Immunology, 2006. 
117(5): p. 1074-1081. 
24. Horner, A.A., et al., House dust extracts elicit toll like receptor dependent 
dendritic cell responses. Journal of Allergy and Clinical Immunology, 2005. 
115(4): p. 893-893. 
25. Barrett, N.A. and K.F. Austen, Innate cells and T helper 2 cell immunity in 
airway inflammation. Immunity, 2009. 31(3): p. 425-37. 
26. Melgert, B.N., et al., Female mice are more susceptible to the 
development of allergic airway inflammation than male mice. Clinical and 
Experimental Allergy, 2005. 35(11): p. 1496-1503. 
27. Hamada K, G.C., Goldman A, Kobzik L, Resistance of very young mice to 
inhaled allergen sensitization is overcome by coexposure to an air-
pollutant aerosol. Am J Respir Crit Care Med, 2000 Apr: p. 1285-93. 
28. Sakai, K., et al., Effect of different sensitizing doses of antigen in a murine 
model of atopic asthma. Clin Exp Immunol, 1999. 118(1): p. 9-15. 
29. Morokata, T., et al., C57BL/6 mice are more susceptible to antigen-
induced pulmonary eosinophilia than BALB/c mice, irrespective of 
systemic T helper 1/T helper 2 responses. Immunology, 1999. 98(3): p. 
345-51. 
30. Jeong, S.K., et al., Mite and cockroach allergens activate protease-
activated receptor 2 and delay epidermal permeability barrier recovery. J 
Invest Dermatol, 2008. 128(8): p. 1930-9. 
31. Shakib, F., A.M. Ghaemmaghami, and H.F. Sewell, The molecular basis 
of allergenicity. Trends Immunol, 2008. 29(12): p. 633-42. 
32. Antony, A.B., R.S. Tepper, and K.A. Mohammed, Cockroach extract 
antigen increases bronchial airway epithelial permeability. J Allergy Clin 
Immunol, 2002. 110(4): p. 589-95. 
 
180 
33. Bhalla, D.K., et al., Cigarette smoke, inflammation, and lung injury: a 
mechanistic perspective. J Toxicol Environ Health B Crit Rev, 2009. 12(1): 
p. 45-64. 
34. Samuelsen, M., U.C. Nygaard, and M. Lovik, Allergy adjuvant effect of 
particles from wood smoke and road traffic. Toxicology, 2008. 246(2-3): p. 
124-31. 
35. Vercelli, D., Discovering susceptibility genes for asthma and allergy. Nat 
Rev Immunol, 2008. 8(3): p. 169-82. 
36. Suarez, C.J., N.J. Parker, and P.W. Finn, Innate immune mechanism in 
allergic asthma. Curr Allergy Asthma Rep, 2008. 8(5): p. 451-9. 
37. Sandor, F. and M. Buc, Toll-like receptors. III. Biological significance and 
impact for human medicine. Folia Biol (Praha), 2005. 51(6): p. 198-203. 
38. Kiss, A., et al., A new mechanism regulating the initiation of allergic airway 
inflammation. J Allergy Clin Immunol, 2007. 120(2): p. 334-42. 
39. Barnes, P.J., Role of GATA-3 in allergic diseases. Curr Mol Med, 2008. 
8(5): p. 330-4. 
40. Perros, F., et al., Blockade of CCR4 in a humanized model of asthma 
reveals a critical role for DC-derived CCL17 and CCL22 in attracting Th2 
cells and inducing airway inflammation. Allergy, 2009. 64(7): p. 995-1002. 
41. Holgate, S.T. and R. Polosa, Treatment strategies for allergy and asthma. 
Nat Rev Immunol, 2008. 8(3): p. 218-30. 
42. Robinson, D.S., et al., Predominant TH2-like bronchoalveolar T-
lymphocyte population in atopic asthma. N Engl J Med, 1992. 326(5): p. 
298-304. 
43. Cousins, D.J., T.H. Lee, and D.Z. Staynov, Cytokine coexpression during 
human Th1/Th2 cell differentiation: direct evidence for coordinated 
expression of Th2 cytokines. J Immunol, 2002. 169(5): p. 2498-506. 
44. Cohn, L., J.S. Tepper, and K. Bottomly, IL-4-independent induction of 
airway hyperresponsiveness by Th2, but not Th1, cells. J Immunol, 1998. 
161(8): p. 3813-6. 
45. Gavett, S.H., et al., Depletion of murine CD4+ T lymphocytes prevents 
antigen-induced airway hyperreactivity and pulmonary eosinophilia. Am J 
Respir Cell Mol Biol, 1994. 10(6): p. 587-93. 
46. Cohn, L., et al., IL-4 promotes airway eosinophilia by suppressing IFN-
gamma production: defining a novel role for IFN-gamma in the regulation 
of allergic airway inflammation. J Immunol, 2001. 166(4): p. 2760-7. 
47. Cohn, L., et al., Induction of airway mucus production By T helper 2 (Th2) 
cells: a critical role for interleukin 4 in cell recruitment but not mucus 
production. J Exp Med, 1997. 186(10): p. 1737-47. 
48. Ishizaka, K., T. Ishizaka, and M.M. Hornbrook, Physicochemical properties 
of reaginic antibody. V. Correlation of reaginic activity wth gamma-E-
globulin antibody. J Immunol, 1966. 97(6): p. 840-53. 
49. Aubry, J.P., et al., CD23 interacts with a new functional extracytoplasmic 
domain involving N-linked oligosaccharides on CD21. J Immunol, 1994. 
152(12): p. 5806-13. 
 
181 
50. Gould, H.J. and B.J. Sutton, IgE in allergy and asthma today. Nat Rev 
Immunol, 2008. 8(3): p. 205-17. 
51. Yu, P., et al., Negative feedback regulation of IgE synthesis by murine 
CD23. Nature, 1994. 369(6483): p. 753-6. 
52. Tsitoura, D.C., et al., Critical role of B cells in the development of T cell 
tolerance to aeroallergens. International Immunology, 2002. 14(6): p. 659-
667. 
53. Coyle, A.J., et al., Central role of immunoglobulin (Ig) E in the induction of 
lung eosinophil infiltration and T helper 2 cell cytokine production: 
inhibition by a non-anaphylactogenic anti-IgE antibody. The Journal of 
experimental medicine, 1996. 183(4): p. 1303-10. 
54. Yu, M., et al., Mast cells can promote the development of multiple features 
of chronic asthma in mice. J Clin Invest, 2006. 116(6): p. 1633-41. 
55. Wu, W., et al., Silencing of c-kit with small interference RNA attenuates 
inflammation in a murine model of allergic asthma. International journal of 
molecular medicine, 2012. 30(1): p. 63-8. 
56. Skowron-zwarg, M., et al., Interleukin-13 interferes with CFTR and AQP5 
expression and localization during human airway epithelial cell 
differentiation. Exp Cell Res, 2007. 313(12): p. 2695-702. 
57. Gomperts, B.N., et al., IL-13 regulates cilia loss and foxj1 expression in 
human airway epithelium. Am J Respir Cell Mol Biol, 2007. 37(3): p. 339-
46. 
58. Laoukili, J., et al., IL-13 alters mucociliary differentiation and ciliary beating 
of human respiratory epithelial cells. J Clin Invest, 2001. 108(12): p. 1817-
24. 
59. Moore, P.E., et al., IL-13 and IL-4 cause eotaxin release in human airway 
smooth muscle cells: a role for ERK. Am J Physiol Lung Cell Mol Physiol, 
2002. 282(4): p. L847-53. 
60. Grunstein, M.M., et al., IL-13-dependent autocrine signaling mediates 
altered responsiveness of IgE-sensitized airway smooth muscle. Am J 
Physiol Lung Cell Mol Physiol, 2002. 282(3): p. L520-8. 
61. Soumelis, V., et al., Human epithelial cells trigger dendritic cell mediated 
allergic inflammation by producing TSLP. Nat Immunol, 2002. 3(7): p. 673-
80. 
62. Seshasayee, D., et al., In vivo blockade of OX40 ligand inhibits thymic 
stromal lymphopoietin driven atopic inflammation. J Clin Invest, 2007. 
117(12): p. 3868-78. 
63. Allakhverdi, Z., et al., Thymic stromal lymphopoietin is released by human 
epithelial cells in response to microbes, trauma, or inflammation and 
potently activates mast cells. J Exp Med, 2007. 204(2): p. 253-8. 
64. Zhou, B., et al., Thymic stromal lymphopoietin as a key initiator of allergic 
airway inflammation in mice. Nat Immunol, 2005. 6(10): p. 1047-53. 
65. Fort, M.M., et al., IL-25 induces IL-4, IL-5, and IL-13 and Th2-associated 
pathologies in vivo. Immunity, 2001. 15(6): p. 985-95. 
 
182 
66. Swaidani, S., et al., The critical role of epithelial-derived Act1 in IL-17- and 
IL-25-mediated pulmonary inflammation. J Immunol, 2009. 182(3): p. 
1631-40. 
67. Tamachi, T., et al., IL-25 enhances allergic airway inflammation by 
amplifying a TH2 cell-dependent pathway in mice. J Allergy Clin Immunol, 
2006. 118(3): p. 606-14. 
68. Hurst, S.D., et al., New IL-17 family members promote Th1 or Th2 
responses in the lung: in vivo function of the novel cytokine IL-25. J 
Immunol, 2002. 169(1): p. 443-53. 
69. Kurowska-Stolarska, M., et al., IL-33 induces antigen-specific IL-5+ T cells 
and promotes allergic-induced airway inflammation independent of IL-4. J 
Immunol, 2008. 181(7): p. 4780-90. 
70. Pecaric-Petkovic, T., et al., Human basophils and eosinophils are the 
direct target leukocytes of the novel IL-1 family member IL-33. Blood, 
2009. 113(7): p. 1526-34. 
71. Suzukawa, M., et al., An IL-1 cytokine member, IL-33, induces human 
basophil activation via its ST2 receptor. J Immunol, 2008. 181(9): p. 5981-
9. 
72. Korsgren, M., et al., Natural killer cells determine development of allergen-
induced eosinophilic airway inflammation in mice. J Exp Med, 1999. 
189(3): p. 553-62. 
73. Yoshizumi, M., et al., Relationships between Cytokine Profiles and 
Signaling Pathways (IkappaB Kinase and p38 MAPK) in Parainfluenza 
Virus-Infected Lung Fibroblasts. Frontiers in microbiology, 2010. 1: p. 124. 
74. Radinger, M., et al., Local proliferation and mobilization of CCR3(+) 
CD34(+) eosinophil-lineage-committed cells in the lung. Immunology, 
2011. 132(1): p. 144-54. 
75. Panopoulos, A.D. and S.S. Watowich, Granulocyte colony-stimulating 
factor: Molecular mechanisms of action during steady state and 
'emergency' hematopoiesis. Cytokine, 2008. 42(3): p. 277-288. 
76. Ponath, P.D., et al., Cloning of the human eosinophil chemoattractant, 
eotaxin. Expression, receptor binding, and functional properties suggest a 
mechanism for the selective recruitment of eosinophils. J Clin Invest, 
1996. 97(3): p. 604-12. 
77. Sanderson, C.J., Interleukin-5, eosinophils, and disease. Blood, 1992. 
79(12): p. 3101-9. 
78. Collins, P.D., et al., Cooperation between interleukin-5 and the chemokine 
eotaxin to induce eosinophil accumulation in vivo. J Exp Med, 1995. 
182(4): p. 1169-74. 
79. Gauvreau, G.M., A.K. Ellis, and J.A. Denburg, Haemopoietic processes in 
allergic disease: eosinophil/basophil development. Clinical and 
experimental allergy : journal of the British Society for Allergy and Clinical 
Immunology, 2009. 39(9): p. 1297-306. 
 
 
 
183 
80. Du, J., et al., Novel combinatorial interactions of GATA-1, PU.1, and 
C/EBPepsilon isoforms regulate transcription of the gene encoding 
eosinophil granule major basic protein. J Biol Chem, 2002. 277(45): p. 
43481-94. 
81. Zimmermann, N., et al., Analysis of the CC chemokine receptor 3 gene 
reveals a complex 5' exon organization, a functional role for untranslated 
exon 1, and a broadly active promoter with eosinophil-selective elements. 
Blood, 2000. 96(7): p. 2346-54. 
82. Lee, J.J., et al., Defining a link with asthma in mice congenitally deficient 
in eosinophils. Science, 2004. 305(5691): p. 1773-6. 
83. Walsh, E.R., et al., Strain-specific requirement for eosinophils in the 
recruitment of T cells to the lung during the development of allergic 
asthma. J Exp Med, 2008. 205(6): p. 1285-92. 
84. Gombart, A.F., et al., Regulation of neutrophil and eosinophil secondary 
granule gene expression by transcription factors C/EBP epsilon and PU.1. 
Blood, 2003. 101(8): p. 3265-73. 
85. Rankin, S.M., D.M. Conroy, and T.J. Williams, Eotaxin and eosinophil 
recruitment: implications for human disease. Mol Med Today, 2000. 6(1): 
p. 20-7. 
86. Zimmermann, N., et al., Chemokines in asthma: cooperative interaction 
between chemokines and IL-13. J Allergy Clin Immunol, 2003. 111(2): p. 
227-42; quiz 243. 
87. Rothenberg, M.E., et al., Characterization of a human eosinophil 
proteoglycan, and augmentation of its biosynthesis and size by interleukin 
3, interleukin 5, and granulocyte/macrophage colony stimulating factor. J 
Biol Chem, 1988. 263(27): p. 13901-8. 
88. Nakamura, H., et al., Variant eotaxin: its effects on the asthma phenotype. 
J Allergy Clin Immunol, 2001. 108(6): p. 946-53. 
89. Fulkerson, P.C., et al., CXCL9 inhibits eosinophil responses by a CCR3- 
and Rac2-dependent mechanism. Blood, 2005. 106(2): p. 436-43. 
90. Kay, A.B., S. Phipps, and D.S. Robinson, A role for eosinophils in airway 
remodelling in asthma. Trends Immunol, 2004. 25(9): p. 477-82. 
91. Shinkai, K., M. Mohrs, and R.M. Locksley, Helper T cells regulate type-2 
innate immunity in vivo. Nature, 2002. 420(6917): p. 825-9. 
92. Mattes, J., et al., Intrinsic defect in T cell production of interleukin (IL)-13 in 
the absence of both IL-5 and eotaxin precludes the development of 
eosinophilia and airways hyperreactivity in experimental asthma. The 
Journal of experimental medicine, 2002. 195(11): p. 1433-44. 
93. Wardlaw, A.J., Molecular basis for selective eosinophil trafficking in 
asthma: A multistep paradigm. The Journal of allergy and clinical 
immunology, 1999. 104(5): p. 917-26. 
94. Knol, E.F., et al., Comparison of human eosinophil and neutrophil 
adhesion to endothelial cells under nonstatic conditions. Role of L-
selectin. Journal of immunology, 1994. 153(5): p. 2161-7. 
 
184 
95. Bochner, B.S., Road signs guiding leukocytes along the inflammation 
superhighway. The Journal of allergy and clinical immunology, 2000. 
106(5): p. 817-28. 
96. Zhang, M., et al., Defining the in vivo function of Siglec-F, a CD33-related 
Siglec expressed on mouse eosinophils. Blood, 2007. 109(10): p. 4280-7. 
97. Bandeira-Melo, C. and P.F. Weller, Eosinophils and cysteinyl leukotrienes. 
Prostaglandins Leukot Essent Fatty Acids, 2003. 69(2-3): p. 135-43. 
98. Flood-Page, P.T., et al., Eosinophil's role remains uncertain as anti-
interleukin-5 only partially depletes numbers in asthmatic airway. Am J 
Respir Crit Care Med, 2003. 167(2): p. 199-204. 
99. Pantanowitz, L. and K. Balogh, Charcot-Leyden crystals: pathology and 
diagnostic utility. Ear Nose Throat J, 2004. 83(7): p. 489-90. 
100. Hisamatsu, K., et al., Cytotoxicity of human eosinophil granule major basic 
protein to human nasal sinus mucosa in vitro. J Allergy Clin Immunol, 
1990. 86(1): p. 52-63. 
101. Ackerman, S.J., et al., Comparative toxicity of purified human eosinophil 
granule cationic proteins for schistosomula of Schistosoma mansoni. Am J 
Trop Med Hyg, 1985. 34(4): p. 735-45. 
102. Wang, J. and A. Slungaard, Role of eosinophil peroxidase in host defense 
and disease pathology. Arch Biochem Biophys, 2006. 445(2): p. 256-60. 
103. Hogan, S.P., et al., Eosinophils: biological properties and role in health 
and disease. Clin Exp Allergy, 2008. 38(5): p. 709-50. 
104. Pegorier, S., et al., Eosinophil-derived cationic proteins activate the 
synthesis of remodeling factors by airway epithelial cells. J Immunol, 
2006. 177(7): p. 4861-9. 
105. Costello, R.W., et al., Localization of eosinophils to airway nerves and 
effect on neuronal M2 muscarinic receptor function. The American journal 
of physiology, 1997. 273(1 Pt 1): p. L93-103. 
106. Lacy, P., et al., Fusion protein vesicle-associated membrane protein 2 is 
implicated in IFN-gamma-induced piecemeal degranulation in human 
eosinophils from atopic individuals. The Journal of allergy and clinical 
immunology, 2001. 107(4): p. 671-8. 
107. Karawajczyk, M., et al., Piecemeal degranulation of peripheral blood 
eosinophils: a study of allergic subjects during and out of the pollen 
season. American Journal of Respiratory Cell and Molecular Biology, 
2000. 23(4): p. 521-9. 
108. Tanaka, H., et al., Role of interleukin-5 and eosinophils in allergen-
induced airway remodeling in mice. Am J Respir Cell Mol Biol, 2004. 
31(1): p. 62-8. 
109. Moqbel, R. and P. Lacy, New concepts in effector functions of eosinophil 
cytokines. Clin Exp Allergy, 2000. 30(12): p. 1667-71. 
110. Lacy, P. and R. Moqbel, Eosinophil cytokines. Chem Immunol, 2000. 76: 
p. 134-55. 
111. Burgel, P.R., et al., Human eosinophils induce mucin production in airway 
epithelial cells via epidermal growth factor receptor activation. Journal of 
immunology, 2001. 167(10): p. 5948-54. 
 
185 
112. Puxeddu, I., et al., Human peripheral blood eosinophils induce 
angiogenesis. The international journal of biochemistry & cell biology, 
2005. 37(3): p. 628-36. 
113. Rothenberg, M.E. and S.P. Hogan, The eosinophil. Annu Rev Immunol, 
2006. 24: p. 147-74. 
114. Duan, W., et al., Inhaled p38alpha mitogen-activated protein kinase 
antisense oligonucleotide attenuates asthma in mice. Am J Respir Crit 
Care Med, 2005. 171(6): p. 571-8. 
115. Chopra, P., et al., Therapeutic potential of inhaled p38 mitogen-activated 
protein kinase inhibitors for inflammatory pulmonary diseases. Expert Opin 
Investig Drugs, 2008. 17(10): p. 1411-25. 
116. Eynott, P.R., et al., Allergen-induced inflammation and airway epithelial 
and smooth muscle cell proliferation: role of Jun N-terminal kinase. British 
journal of pharmacology, 2003. 140(8): p. 1373-80. 
117. Kampen, G.T., et al., Eotaxin induces degranulation and chemotaxis of 
eosinophils through the activation of ERK2 and p38 mitogen-activated 
protein kinases. Blood, 2000. 95(6): p. 1911-7. 
118. Underwood, D.C., et al., SB 239063, a potent p38 MAP kinase inhibitor, 
reduces inflammatory cytokine production, airways eosinophil infiltration, 
and persistence. The Journal of pharmacology and experimental 
therapeutics, 2000. 293(1): p. 281-8. 
119. Gamell, C., et al., The p38/MK2/Hsp25 pathway is required for BMP-2-
induced cell migration. PLoS One, 2011. 6(1): p. e16477. 
120. Birukov, K.G., et al., Shear stress-mediated cytoskeletal remodeling and 
cortactin translocation in pulmonary endothelial cells. American Journal of 
Respiratory Cell and Molecular Biology, 2002. 26(4): p. 453-64. 
121. McDaniel, A.S., et al., Pak1 regulates multiple c-Kit mediated Ras-MAPK 
gain-in-function phenotypes in Nf1+/- mast cells. Blood, 2008. 112(12): p. 
4646-54. 
122. Rousseau, S., et al., CXCL12 and C5a trigger cell migration via a PAK1/2-
p38alpha MAPK-MAPKAP-K2-HSP27 pathway. Cellular signalling, 2006. 
18(11): p. 1897-905. 
123. Chiba, Y. and M. Misawa, The role of RhoA-mediated Ca2+ sensitization 
of bronchial smooth muscle contraction in airway hyperresponsiveness. J 
Smooth Muscle Res, 2004. 40(4-5): p. 155-67. 
124. Schaafsma, D., et al., Allergic sensitization enhances the contribution of 
Rho-kinase to airway smooth muscle contraction. Br J Pharmacol, 2004. 
143(4): p. 477-84. 
125. Taki, F., et al., Effects of Rho-kinase inactivation on eosinophilia and 
hyper-reactivity in murine airways by allergen challenges. Clin Exp Allergy, 
2007. 37(4): p. 599-607. 
126. Takeda, N., et al., Role of RhoA inactivation in reduced cell proliferation of 
human airway smooth muscle by simvastatin. Am J Respir Cell Mol Biol, 
2006. 35(6): p. 722-9. 
 
 
186 
127. Henry, P.J., T.S. Mann, and R.G. Goldie, A rho kinase inhibitor, Y-27632 
inhibits pulmonary eosinophilia, bronchoconstriction and airways 
hyperresponsiveness in allergic mice. Pulm Pharmacol Ther, 2005. 18(1): 
p. 67-74. 
128. Tan, B.L., et al., Genetic evidence for convergence of c-Kit- and alpha4 
integrin-mediated signals on class IA PI-3kinase and the Rac pathway in 
regulating integrin-directed migration in mast cells. Blood, 2003. 101(12): 
p. 4725-32. 
129. Yang, F.C., et al., Rac2 stimulates Akt activation affecting BAD/Bcl-XL 
expression while mediating survival and actin function in primary mast 
cells. Immunity, 2000. 12(5): p. 557-568. 
130. Cho, S.H., et al., Rac and protein kinase C-delta regulate ERKs and 
cytosolic phospholipase A2 in FcepsilonRI signaling to cysteinyl 
leukotriene synthesis in mast cells. J Immunol, 2004. 173(1): p. 624-31. 
131. Jaffer, Z.M. and J. Chernoff, p21-activated kinases: three more join the 
Pak. Int J Biochem Cell Biol, 2002. 34(7): p. 713-7. 
132. Zhao, Z.S., et al., A conserved negative regulatory region in alphaPAK: 
inhibition of PAK kinases reveals their morphological roles downstream of 
Cdc42 and Rac1. Mol Cell Biol, 1998. 18(4): p. 2153-63. 
133. Frost, J.A., et al., Differential effects of PAK1-activating mutations reveal 
activity-dependent and -independent effects on cytoskeletal regulation. J 
Biol Chem, 1998. 273(43): p. 28191-8. 
134. Manser, E., et al., A brain serine/threonine protein kinase activated by 
Cdc42 and Rac1. Nature, 1994. 367(6458): p. 40-6. 
135. Bagrodia, S. and R.A. Cerione, Pak to the future. Trends Cell Biol, 1999. 
9(9): p. 350-5. 
136. Lei, M., et al., Structure of PAK1 in an autoinhibited conformation reveals 
a multistage activation switch. Cell, 2000. 102(3): p. 387-97. 
137. Buchwald, G., et al., Conformational switch and role of phosphorylation in 
PAK activation. Mol Cell Biol, 2001. 21(15): p. 5179-89. 
138. Bokoch, G.M., et al., A GTPase-independent mechanism of p21-activated 
kinase activation. Regulation by sphingosine and other biologically active 
lipids. J Biol Chem, 1998. 273(14): p. 8137-44. 
139. King, C.C., et al., p21-activated kinase (PAK1) is phosphorylated and 
activated by 3-phosphoinositide-dependent kinase-1 (PDK1). J Biol Chem, 
2000. 275(52): p. 41201-9. 
140. Morreale, A., et al., Structure of Cdc42 bound to the GTPase binding 
domain of PAK. Nat Struct Biol, 2000. 7(5): p. 384-8. 
141. Gatti, A., et al., Multisite autophosphorylation of p21-activated protein 
kinase gamma-PAK as a function of activation. J Biol Chem, 1999. 
274(12): p. 8022-8. 
142. Chong, C., et al., The mechanism of PAK activation. Autophosphorylation 
events in both regulatory and kinase domains control activity. J Biol Chem, 
2001. 276(20): p. 17347-53. 
 
187 
143. Oskeritzian, C.A., S. Milstien, and S. Spiegel, Sphingosine-1-phosphate in 
allergic responses, asthma and anaphylaxis. Pharmacol Ther, 2007. 
115(3): p. 390-9. 
144. Rivera, J., R.L. Proia, and A. Olivera, The alliance of sphingosine-1-
phosphate and its receptors in immunity. Nat Rev Immunol, 2008. 8(10): 
p. 753-63. 
145. Buday, L., L. Wunderlich, and P. Tamas, The Nck family of adapter 
proteins: regulators of actin cytoskeleton. Cell Signal, 2002. 14(9): p. 723-
31. 
146. Puto, L.A., et al., p21-activated kinase 1 (PAK1) interacts with the Grb2 
adapter protein to couple to growth factor signaling. J Biol Chem, 2003. 
278(11): p. 9388-93. 
147. Lu, W., et al., Activation of Pak by membrane localization mediated by an 
SH3 domain from the adaptor protein Nck. Curr Biol, 1997. 7(2): p. 85-94. 
148. Mayhew, M.W., et al., Identification of phosphorylation sites in betaPIX 
and PAK1. J Cell Sci, 2007. 120(Pt 22): p. 3911-8. 
149. Rudel, T. and G.M. Bokoch, Membrane and morphological changes in 
apoptotic cells regulated by caspase-mediated activation of PAK2. 
Science, 1997. 276(5318): p. 1571-4. 
150. Bokoch, G.M., Biology of the p21-activated kinases. Annu Rev Biochem, 
2003. 72: p. 743-81. 
151. Eswaran, J., et al., UnPAKing the class differences among p21-activated 
kinases. Trends Biochem Sci, 2008. 33(8): p. 394-403. 
152. Sells, M.A., A. Pfaff, and J. Chernoff, Temporal and spatial distribution of 
activated Pak1 in fibroblasts. J Cell Biol, 2000. 151(7): p. 1449-58. 
153. Dharmawardhane, S., et al., Localization of p21-activated kinase 1 (PAK1) 
to pinocytic vesicles and cortical actin structures in stimulated cells. J Cell 
Biol, 1997. 138(6): p. 1265-78. 
154. Dharmawardhane, S., et al., Localization of p21-activated kinase 1 (PAK1) 
to pseudopodia, membrane ruffles, and phagocytic cups in activated 
human neutrophils. J Leukoc Biol, 1999. 66(3): p. 521-7. 
155. Sells, M.A., J.T. Boyd, and J. Chernoff, p21-activated kinase 1 (Pak1) 
regulates cell motility in mammalian fibroblasts. J Cell Biol, 1999. 145(4): 
p. 837-49. 
156. Sells, M.A., et al., Human p21-activated kinase (Pak1) regulates actin 
organization in mammalian cells. Curr Biol, 1997. 7(3): p. 202-10. 
157. Dharmawardhane, S., et al., Regulation of macropinocytosis by p21-
activated kinase-1. Mol Biol Cell, 2000. 11(10): p. 3341-52. 
158. Manser, E., et al., Expression of constitutively active alpha-PAK reveals 
effects of the kinase on actin and focal complexes. Mol Cell Biol, 1997. 
17(3): p. 1129-43. 
159. Hing, H., et al., Pak functions downstream of Dock to regulate 
photoreceptor axon guidance in Drosophila. Cell, 1999. 97(7): p. 853-63. 
 
 
 
188 
160. Chen, W., et al., The Caenorhabditis elegans p21-activated kinase 
(CePAK) colocalizes with CeRac1 and CDC42Ce at hypodermal cell 
boundaries during embryo elongation. J Biol Chem, 1996. 271(42): p. 
26362-8. 
161. Leberer, E., et al., Virulence and hyphal formation of Candida albicans 
require the Ste20p-like protein kinase CaCla4p. Curr Biol, 1997. 7(8): p. 
539-46. 
162. Weiss, E.L., et al., Chemical genetic analysis of the budding-yeast p21-
activated kinase Cla4p. Nat Cell Biol, 2000. 2(10): p. 677-85. 
163. Arias-Romero, L.E., et al., EhPAK2, a novel p21-activated kinase, is 
required for collagen invasion and capping in Entamoeba histolytica. Mol 
Biochem Parasitol, 2006. 149(1): p. 17-26. 
164. Klopocka, W., J. Moraczewska, and M.J. Redowicz, Characterisation of 
the Rac/PAK pathway in Amoeba proteus. Protoplasma, 2005. 225(1-2): 
p. 77-84. 
165. Nagel, M., et al., Role of p21-activated kinase in cell polarity and 
directional mesendoderm migration in the Xenopus gastrula. Dev Dyn, 
2009. 238(7): p. 1709-26. 
166. Manser, E., et al., PAK kinases are directly coupled to the PIX family of 
nucleotide exchange factors. Molecular cell, 1998. 1(2): p. 183-92. 
167. Adam, L., et al., Regulation of microfilament reorganization and 
invasiveness of breast cancer cells by kinase dead p21-activated kinase-
1. J Biol Chem, 2000. 275(16): p. 12041-50. 
168. Ito, M., et al., P21-activated kinase 1: a new molecular marker for 
intravesical recurrence after transurethral resection of bladder cancer. J 
Urol, 2007. 178(3 Pt 1): p. 1073-9. 
169. Delorme, V., et al., Cofilin activity downstream of Pak1 regulates cell 
protrusion efficiency by organizing lamellipodium and lamella actin 
networks. Dev Cell, 2007. 13(5): p. 646-62. 
170. Chan, A.Y., et al., Role of cofilin in epidermal growth factor-stimulated 
actin polymerization and lamellipod protrusion. The Journal of cell biology, 
2000. 148(3): p. 531-42. 
171. Kumar, G., et al., Over-expression of S4D mutant of Leishmania 
ADF/cofilin impairs flagellum assembly by affecting actin dynamics. 
Eukaryotic cell, 2012. 
172. Tang, W., et al., A PLCbeta/PI3Kgamma-GSK3 signaling pathway 
regulates cofilin phosphatase slingshot2 and neutrophil polarization and 
chemotaxis. Developmental cell, 2011. 21(6): p. 1038-50. 
173. Vartiainen, M.K., et al., The three mouse actin-depolymerizing 
factor/cofilins evolved to fulfill cell-type-specific requirements for actin 
dynamics. Molecular biology of the cell, 2002. 13(1): p. 183-94. 
174. Coniglio, S.J., S. Zavarella, and M.H. Symons, Pak1 and Pak2 mediate 
tumor cell invasion through distinct signaling mechanisms. Molecular and 
cellular biology, 2008. 28(12): p. 4162-72. 
 
189 
175. Starinsky-Elbaz, S., et al., The pre-GAP-related domain of neurofibromin 
regulates cell migration through the LIM kinase/cofilin pathway. Molecular 
and cellular neurosciences, 2009. 42(4): p. 278-87. 
176. Edwards, D.C., et al., Activation of LIM-kinase by Pak1 couples 
Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. Nature cell 
biology, 1999. 1(5): p. 253-9. 
177. Vadlamudi, R.K., et al., p41-Arc subunit of human Arp2/3 complex is a 
p21-activated kinase-1-interacting substrate. EMBO Rep, 2004. 5(2): p. 
154-60. 
178. Pantaloni, D., et al., The Arp2/3 complex branches filament barbed ends: 
functional antagonism with capping proteins. Nature cell biology, 2000. 
2(7): p. 385-91. 
179. Machesky, L.M., et al., Scar, a WASp-related protein, activates nucleation 
of actin filaments by the Arp2/3 complex. Proceedings of the National 
Academy of Sciences of the United States of America, 1999. 96(7): p. 
3739-44. 
180. Wu, C., et al., Arp2/3 is critical for lamellipodia and response to 
extracellular matrix cues but is dispensable for chemotaxis. Cell, 2012. 
148(5): p. 973-87. 
181. Mullins, R.D., J.A. Heuser, and T.D. Pollard, The interaction of Arp2/3 
complex with actin: nucleation, high affinity pointed end capping, and 
formation of branching networks of filaments. Proceedings of the National 
Academy of Sciences of the United States of America, 1998. 95(11): p. 
6181-6. 
182. Fehon, R.G., A.I. McClatchey, and A. Bretscher, Organizing the cell 
cortex: the role of ERM proteins. Nat Rev Mol Cell Biol, 2010. 11(4): p. 
276-87. 
183. McClatchey, A.I. and R.G. Fehon, Merlin and the ERM proteins--
regulators of receptor distribution and signaling at the cell cortex. Trends 
Cell Biol, 2009. 19(5): p. 198-206. 
184. Shaffer, M.H., et al., Ezrin and moesin function together to promote T cell 
activation. J Immunol, 2009. 182(2): p. 1021-32. 
185. Shaffer, M.H., et al., Ezrin is highly expressed in early thymocytes, but 
dispensable for T cell development in mice. PLoS One, 2010. 5(8): p. 
e12404. 
186. Belkina, N.V., et al., LOK is a major ERM kinase in resting lymphocytes 
and regulates cytoskeletal rearrangement through ERM phosphorylation. 
Proceedings of the National Academy of Sciences of the United States of 
America, 2009. 106(12): p. 4707-12. 
187. Brown, K.L., et al., Regulation of hyaluronan binding by F-actin and 
colocalization of CD44 and phosphorylated ezrin/radixin/moesin (ERM) 
proteins in myeloid cells. Experimental cell research, 2005. 303(2): p. 400-
14. 
188. Saotome, I., M. Curto, and A.I. McClatchey, Ezrin is essential for epithelial 
organization and villus morphogenesis in the developing intestine. Dev 
Cell, 2004. 6(6): p. 855-64. 
 
190 
189. Bonilha, V.L., et al., Microvilli defects in retinas of ezrin knockout mice. 
Exp Eye Res, 2006. 82(4): p. 720-9. 
190. Curto, M. and A.I. McClatchey, Ezrin...a metastatic detERMinant? Cancer 
Cell, 2004. 5(2): p. 113-4. 
191. Monni, R., et al., Ezrin is a target for oncogenic Kit mutants in murine 
erythroleukemia. Blood, 2008. 111(6): p. 3163-72. 
192. Staser, K., et al., A Pak1-PP2A-ERM signaling axis mediates F-actin 
rearrangement and degranulation in mast cells. Exp Hematol, 2012. 
193. Feng, Y., et al., Filamin A (FLNA) is required for cell-cell contact in 
vascular development and cardiac morphogenesis. Proceedings of the 
National Academy of Sciences of the United States of America, 2006. 
103(52): p. 19836-41. 
194. Cunningham, C.C., et al., Actin-binding protein requirement for cortical 
stability and efficient locomotion. Science, 1992. 255(5042): p. 325-7. 
195. Vadlamudi, R.K., et al., Filamin is essential in actin cytoskeletal assembly 
mediated by p21-activated kinase 1. Nature cell biology, 2002. 4(9): p. 
681-90. 
196. Maceyka, M., et al., Filamin A links sphingosine kinase 1 and sphingosine-
1-phosphate receptor 1 at lamellipodia to orchestrate cell migration. 
Molecular and cellular biology, 2008. 28(18): p. 5687-97. 
197. Rider, L. and M. Diakonova, Adapter protein SH2B1beta binds filamin A to 
regulate prolactin-dependent cytoskeletal reorganization and cell motility. 
Molecular endocrinology, 2011. 25(7): p. 1231-43. 
198. Dummler, B., et al., Pak protein kinases and their role in cancer. Cancer 
Metastasis Rev, 2009. 28(1-2): p. 51-63. 
199. Sanders, L.C., et al., Inhibition of myosin light chain kinase by p21-
activated kinase. Science, 1999. 283(5410): p. 2083-5. 
200. Takahashi, K. and K. Suzuki, Membrane transport of WAVE2 and 
lamellipodia formation require Pak1 that mediates phosphorylation and 
recruitment of stathmin/Op18 to Pak1-WAVE2-kinesin complex. Cellular 
signalling, 2009. 21(5): p. 695-703. 
201. Wittmann, T., G.M. Bokoch, and C.M. Waterman-Storer, Regulation of 
microtubule destabilizing activity of Op18/stathmin downstream of Rac1. 
The Journal of biological chemistry, 2004. 279(7): p. 6196-203. 
202. Somanath, P.R. and T.V. Byzova, 14-3-3beta-Rac1-p21 activated kinase 
signaling regulates Akt1-mediated cytoskeletal organization, lamellipodia 
formation and fibronectin matrix assembly. J Cell Physiol, 2009. 218(2): p. 
394-404. 
203. Kiosses, W.B., et al., A role for p21-activated kinase in endothelial cell 
migration. J Cell Biol, 1999. 147(4): p. 831-44. 
204. Smith, S.D., et al., PAK1-mediated activation of ERK1/2 regulates 
lamellipodial dynamics. J Cell Sci, 2008. 121(Pt 22): p. 3729-36. 
205. Parrini, M.C., et al., Dissecting activation of the PAK1 kinase at 
protrusions in living cells. J Biol Chem, 2009. 284(36): p. 24133-43. 
 
191 
206. Balasenthil, S., et al., p21-activated kinase-1 signaling mediates cyclin D1 
expression in mammary epithelial and cancer cells. J Biol Chem, 2004. 
279(2): p. 1422-8. 
207. Holm, C., et al., Association between Pak1 expression and subcellular 
localization and tamoxifen resistance in breast cancer patients. J Natl 
Cancer Inst, 2006. 98(10): p. 671-80. 
208. Mira, J.P., et al., Endogenous, hyperactive Rac3 controls proliferation of 
breast cancer cells by a p21-activated kinase-dependent pathway. Proc 
Natl Acad Sci U S A, 2000. 97(1): p. 185-9. 
209. Carter, J.H., et al., Pak-1 expression increases with progression of 
colorectal carcinomas to metastasis. Clin Cancer Res, 2004. 10(10): p. 
3448-56. 
210. Davidson, B., M. Shih Ie, and T.L. Wang, Different clinical roles for p21-
activated kinase-1 in primary and recurrent ovarian carcinoma. Hum 
Pathol, 2008. 39(11): p. 1630-6. 
211. Schraml, P., et al., Combined array comparative genomic hybridization 
and tissue microarray analysis suggest PAK1 at 11q13.5-q14 as a critical 
oncogene target in ovarian carcinoma. Am J Pathol, 2003. 163(3): p. 985-
92. 
212. O'Sullivan, G.C., et al., Modulation of p21-activated kinase 1 alters the 
behavior of renal cell carcinoma. Int J Cancer, 2007. 121(9): p. 1930-40. 
213. Brown, L.A., et al., Amplification of EMSY, a novel oncogene on 11q13, in 
high grade ovarian surface epithelial carcinomas. Gynecol Oncol, 2006. 
100(2): p. 264-70. 
214. Brown, L.A., et al., Amplification of 11q13 in ovarian carcinoma. Genes 
Chromosomes Cancer, 2008. 47(6): p. 481-9. 
215. Mao, X., et al., Genomic alterations in blastic natural killer/extranodal 
natural killer-like T cell lymphoma with cutaneous involvement. J Invest 
Dermatol, 2003. 121(3): p. 618-27. 
216. Mao, X., et al., Amplification and overexpression of JUNB is associated 
with primary cutaneous T-cell lymphomas. Blood, 2003. 101(4): p. 1513-9. 
217. Gerthoffer, W.T., Actin cytoskeletal dynamics in smooth muscle 
contraction. Can J Physiol Pharmacol, 2005. 83(10): p. 851-6. 
218. McFawn, P.K., et al., Calcium-independent contraction and sensitization of 
airway smooth muscle by p21-activated protein kinase. Am J Physiol Lung 
Cell Mol Physiol, 2003. 284(5): p. L863-70. 
219. Gunst, S.J. and W. Zhang, Actin cytoskeletal dynamics in smooth muscle: 
a new paradigm for the regulation of smooth muscle contraction. Am J 
Physiol Cell Physiol, 2008. 295(3): p. C576-87. 
220. Tang, D.D. and S.J. Gunst, The small GTPase Cdc42 regulates actin 
polymerization and tension development during contractile stimulation of 
smooth muscle. J Biol Chem, 2004. 279(50): p. 51722-8. 
221. Tang, D.D., Y. Bai, and S.J. Gunst, Silencing of p21-activated kinase 
attenuates vimentin phosphorylation on Ser-56 and reorientation of the 
vimentin network during stimulation of smooth muscle cells by 5-
hydroxytryptamine. Biochem J, 2005. 388(Pt 3): p. 773-83. 
 
192 
222. Wu, Y., et al., Integrin-linked kinase regulates smooth muscle 
differentiation marker gene expression in airway tissue. Am J Physiol Lung 
Cell Mol Physiol, 2008. 295(6): p. L988-97. 
223. Allen, J.D., et al., p21-activated kinase regulates mast cell degranulation 
via effects on calcium mobilization and cytoskeletal dynamics. Blood, 
2009. 113(12): p. 2695-705. 
224. Sauer, B., Inducible gene targeting in mice using the Cre/lox system. 
Methods, 1998. 14(4): p. 381-92. 
225. Kuhn, R., et al., Inducible gene targeting in mice. Science, 1995. 
269(5229): p. 1427-9. 
226. Kiel, M.J., et al., Hematopoietic stem cells do not depend on N-cadherin to 
regulate their maintenance. Cell Stem Cell, 2009. 4(2): p. 170-9. 
227. Das, A.M., R.J. Flower, and M. Perretti, Eotaxin-induced eosinophil 
migration in the peritoneal cavity of ovalbumin-sensitized mice: 
mechanism of action. Journal of immunology, 1997. 159(3): p. 1466-73. 
228. Rothenberg, M.E., et al., Eotaxin triggers eosinophil-selective chemotaxis 
and calcium flux via a distinct receptor and induces pulmonary 
eosinophilia in the presence of interleukin 5 in mice. Molecular medicine, 
1996. 2(3): p. 334-48. 
229. Fukuyama, S., et al., Effect of eotaxin and platelet-activating factor on 
airway inflammation and hyperresponsiveness in guinea pigs in vivo. 
American journal of respiratory and critical care medicine, 2000. 161(6): p. 
1844-9. 
230. Chang, H.C., et al., The transcription factor PU.1 is required for the 
development of IL-9-producing T cells and allergic inflammation. Nat 
Immunol, 2010. 11(6): p. 527-34. 
231. van Rijt, L.S., et al., A rapid flow cytometric method for determining the 
cellular composition of bronchoalveolar lavage fluid cells in mouse models 
of asthma. J Immunol Methods, 2004. 288(1-2): p. 111-21. 
232. Yang, F.C., et al., Nf1-dependent tumors require a microenvironment 
containing Nf1+/-- and c-kit-dependent bone marrow. Cell, 2008. 135(3): 
p. 437-48. 
233. Jungraithmayr, W.M., et al., A mouse model of orthotopic, single-lung 
transplantation. J Thorac Cardiovasc Surg, 2009. 137(2): p. 486-91. 
234. Krupnick, A.S., et al., Orthotopic mouse lung transplantation as 
experimental methodology to study transplant and tumor biology. Nat 
Protoc, 2009. 4(1): p. 86-93. 
235. Okazaki, M., et al., A mouse model of orthotopic vascularized aerated lung 
transplantation. American journal of transplantation : official journal of the 
American Society of Transplantation and the American Society of 
Transplant Surgeons, 2007. 7(6): p. 1672-9. 
236. Saito, H., et al., Pathogenesis of murine experimental allergic rhinitis: a 
study of local and systemic consequences of IL-5 deficiency. J Immunol, 
2002. 168(6): p. 3017-23. 
 
 
193 
237. Sanderson, C.J., D.J. Warren, and M. Strath, Identification of a 
lymphokine that stimulates eosinophil differentiation in vitro. Its 
relationship to interleukin 3, and functional properties of eosinophils 
produced in cultures. J Exp Med, 1985. 162(1): p. 60-74. 
238. Dyer, K.D., et al., Functionally competent eosinophils differentiated ex vivo 
in high purity from normal mouse bone marrow. J Immunol, 2008. 181(6): 
p. 4004-9. 
239. Iellem, A., et al., Unique chemotactic response profile and specific 
expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) 
regulatory T cells. J Exp Med, 2001. 194(6): p. 847-53. 
240. Tiffany, H.L., F. Li, and H.F. Rosenberg, Hyperglycosylation of eosinophil 
ribonucleases in a promyelocytic leukemia cell line and in differentiated 
peripheral blood progenitor cells. Journal of leukocyte biology, 1995. 
58(1): p. 49-54. 
241. Fischkoff, S.A., et al., Eosinophilic differentiation of the human 
promyelocytic leukemia cell line, HL-60. The Journal of experimental 
medicine, 1984. 160(1): p. 179-96. 
242. Ingram, D.A., et al., Hyperactivation of p21(ras) and the hematopoietic-
specific Rho GTPase, Rac2, cooperate to alter the proliferation of 
neurofibromin-deficient mast cells in vivo and in vitro. The Journal of 
experimental medicine, 2001. 194(1): p. 57-69. 
243. Hiatt, K.K., et al., Neurofibromin GTPase-activating protein-related 
domains restore normal growth in Nf1-/- cells. The Journal of biological 
chemistry, 2001. 276(10): p. 7240-5. 
244. Lu, L., et al., Detection of luxol-fast-blue positive cells in human 
promyelocytic leukemia cell line HL-60. Exp Hematol, 1981. 9(9): p. 887-
92. 
245. Johnson, G.R. and D. Metcalf, Detection of a new type of mouse 
eosinophil colony by Luxol-fast-blue staining. Exp Hematol, 1980. 8(5): p. 
549-61. 
246. Clutterbuck, E.J., E.M. Hirst, and C.J. Sanderson, Human interleukin-5 (IL-
5) regulates the production of eosinophils in human bone marrow cultures: 
comparison and interaction with IL-1, IL-3, IL-6, and GMCSF. Blood, 1989. 
73(6): p. 1504-12. 
247. Lozano, E., et al., PAK is required for the disruption of E-cadherin 
adhesion by the small GTPase Rac. J Cell Sci, 2008. 121(Pt 7): p. 933-8. 
248. Delorme-Walker, V.D., et al., Pak1 regulates focal adhesion strength, 
myosin IIA distribution, and actin dynamics to optimize cell migration. The 
Journal of cell biology, 2011. 193(7): p. 1289-303. 
249. Bates, M.E., et al., Human airway eosinophils respond to 
chemoattractants with greater eosinophil-derived neurotoxin release, 
adherence to fibronectin, and activation of the Ras-ERK pathway when 
compared with blood eosinophils. Journal of immunology, 2010. 184(12): 
p. 7125-33. 
 
194 
250. Lintomen, L., et al., Human eosinophil adhesion and degranulation 
stimulated with eotaxin and RANTES in vitro: lack of interaction with nitric 
oxide. BMC pulmonary medicine, 2008. 8: p. 13. 
251. Jia, G.Q., et al., Selective eosinophil transendothelial migration triggered 
by eotaxin via modulation of Mac-1/ICAM-1 and VLA-4/VCAM-1 
interactions. International Immunology, 1999. 11(1): p. 1-10. 
252. Nakajima, H., et al., Role of vascular cell adhesion molecule 1/very late 
activation antigen 4 and intercellular adhesion molecule 1/lymphocyte 
function-associated antigen 1 interactions in antigen-induced eosinophil 
and T cell recruitment into the tissue. J Exp Med, 1994. 179(4): p. 1145-
54. 
253. Walsh, G.M., et al., Integrin alpha 4 beta 7 mediates human eosinophil 
interaction with MAdCAM-1, VCAM-1 and fibronectin. Immunology, 1996. 
89(1): p. 112-9. 
254. Wittmann, T., G.M. Bokoch, and C.M. Waterman-Storer, Regulation of 
leading edge microtubule and actin dynamics downstream of Rac1. The 
Journal of cell biology, 2003. 161(5): p. 845-51. 
255. Adyshev, D.M., et al., Differential involvement of ezrin/radixin/moesin 
proteins in sphingosine 1-phosphate-induced human pulmonary 
endothelial cell barrier enhancement. Cellular signalling, 2011. 23(12): p. 
2086-96. 
256. Shamri, R., et al., CCL11 elicits secretion of RNases from mouse 
eosinophils and their cell-free granules. FASEB J, 2012. 26(5): p. 2084-
93. 
257. El-Shazly, A., et al., Human eotaxin induces eosinophil-derived neurotoxin 
release from normal human eosinophils. International Archives of Allergy 
and Immunology, 1998. 117 Suppl 1: p. 55-8. 
258. Zimmermann, N., J.J. Conkright, and M.E. Rothenberg, CC chemokine 
receptor-3 undergoes prolonged ligand-induced internalization. The 
Journal of biological chemistry, 1999. 274(18): p. 12611-8. 
259. Ro, J.Y., et al., Effects of 7,8-dihydro-8-oxo-deoxyguanosine on antigen 
challenge in ovalbumin-sensitized mice may be mediated by suppression 
of Rac. British journal of pharmacology, 2009. 158(7): p. 1743-52. 
260. Carstanjen, D., et al., Rac2 regulates neutrophil chemotaxis, superoxide 
production, and myeloid colony formation through multiple distinct effector 
pathways. Journal of immunology, 2005. 174(8): p. 4613-20. 
261. Reutershan, J., et al., Blocking p21-activated kinase reduces 
lipopolysaccharide-induced acute lung injury by preventing 
polymorphonuclear leukocyte infiltration. American journal of respiratory 
and critical care medicine, 2007. 175(10): p. 1027-35. 
262. Nakae, S., et al., Mast cell-derived TNF contributes to airway 
hyperreactivity, inflammation, and TH2 cytokine production in an asthma 
model in mice. J Allergy Clin Immunol, 2007. 120(1): p. 48-55. 
 
 
 
195 
263. McGlade, J.P., et al., Suppression of the asthmatic phenotype by 
ultraviolet B-induced, antigen-specific regulatory cells. Clinical and 
experimental allergy : journal of the British Society for Allergy and Clinical 
Immunology, 2007. 37(9): p. 1267-76. 
264. Sung, K.P., et al., Eotaxin induces a sustained reduction in the functional 
adhesive state of very late antigen 4 for the connecting segment 1 region 
of fibronectin. The Journal of allergy and clinical immunology, 2000. 
106(5): p. 933-40. 
265. Barthel, S.R., et al., Roles of integrin activation in eosinophil function and 
the eosinophilic inflammation of asthma. Journal of leukocyte biology, 
2008. 83(1): p. 1-12. 
266. Croker, B.A., et al., Rac2-deficient mice display perturbed T-cell 
distribution and chemotaxis, but only minor abnormalities in T(H)1 
responses. Immunology and cell biology, 2002. 80(3): p. 231-40. 
267. Insall, R.H. and L.M. Machesky, Actin dynamics at the leading edge: from 
simple machinery to complex networks. Developmental cell, 2009. 17(3): 
p. 310-22. 
268. Voermans, C., et al., SDF-1-induced actin polymerization and migration in 
human hematopoietic progenitor cells. Exp Hematol, 2001. 29(12): p. 
1456-64. 
269. Kim, C.H. and H.E. Broxmeyer, SLC/exodus2/6Ckine/TCA4 induces 
chemotaxis of hematopoietic progenitor cells: differential activity of ligands 
of CCR7, CXCR3, or CXCR4 in chemotaxis vs. suppression of progenitor 
proliferation. J Leukoc Biol, 1999. 66(3): p. 455-61. 
270. Weiner, O.D., et al., Spatial control of actin polymerization during 
neutrophil chemotaxis. Nat Cell Biol, 1999. 1(2): p. 75-81. 
271. Ichetovkin, I., W. Grant, and J. Condeelis, Cofilin produces newly 
polymerized actin filaments that are preferred for dendritic nucleation by 
the Arp2/3 complex. Current biology : CB, 2002. 12(1): p. 79-84. 
272. Yi, C., et al., Development of small-molecule inhibitors of the group I p21-
activated kinases, emerging therapeutic targets in cancer. Biochemical 
pharmacology, 2010. 80(5): p. 683-9. 
273. Fujisawa, T., et al., Chemokines induce eosinophil degranulation through 
CCR-3. The Journal of allergy and clinical immunology, 2000. 106(3): p. 
507-13. 
274. Ochkur, S.I., et al., The development of a sensitive and specific ELISA for 
mouse eosinophil peroxidase: assessment of eosinophil degranulation ex 
vivo and in models of human disease. Journal of Immunological Methods, 
2012. 375(1-2): p. 138-47. 
275. Adamko, D.J., et al., The induction of eosinophil peroxidase release: 
improved methods of measurement and stimulation. Journal of 
Immunological Methods, 2004. 291(1-2): p. 101-8. 
 
 
 
CURRICULUM VITAE 
Muithi Mwanthi 
Current Position: 
 2006  Student, NIH Medical Scientist Training Program 
   Indiana University School of Medicine (IUSOM) 
   Department of Microbiology and Immunology 
   Mentor/Advisor - D. Wade Clapp, MD 
Education: 
2005  B.S. - Pre-medicine Summa cum laude, Clearwater Christian 
College, Clearwater FL 
 
2013  Ph.D. - Microbiology and Immunology, Indiana University, 
Indianapolis IN 
 
2014 M.D. - Indiana University School of Medicine, expected 
 
Academic and Professional Honors and Fellowships: 
Undergraduate 
 
2002   Presidents’ Academic Fellowship, 2002-04 
 
2003  Alpha Chi academic chapter, National College Honor 
Scholarship Society Membership, 2003-04 
 
2003  Bailey Family Foundation Scholarship, 2003-04 
 
Graduate 
 
2006   University Fellowship, 2006-07 
 
2009  Edwin T. Harper Scholarship (R25 GM079657), 2009-10 
 
2010 Joint Best first-time presenter, Research in Progress, 
Department of Microbiology and Immunology,  
 
2010  1st place, Sigma Xi Graduate Biomedical Research 
Competition 
 
2010  Harold Raidt Department of Microbiology and Immunology 
Graduate Student Teaching Award 
 
 
 
2011 Ruth L. Kirschstein NRSA for Individual Predoctoral 
Fellowship to Promote Diversity in Health-Related Research 
- F31HL108569 PI: “Pak1's Role in Eotaxin-Mediated Murine 
Eosinophil Migration” National Heart Lung and Blood 
Institute, National Institutes of Health (NHLBI/NIH), 2011-13 
 
2011 Southern Regional Education Board (SREB) Doctoral 
Scholarship, Institute of Teaching and Mentoring, 2011-12 
 
2011 Abstract achievement travel award (MGSAAA), American 
Society of Hematology (ASH) 
 
Professional Experience: 
 
2004 Kaplan Test Prep and Admissions, Class Instructor and 
Tutor Indianapolis IN, and Tampa, Fl, 2004-09 
 
2005 Florida Department of Citrus, Research assistant, Lake 
Alfred, FL 
 
2005 Sun Orchards of Florida, Quality Assurance Technician 
Haines City, FL 
 
2008 IU School of Medicine MSMS MCAT Summer Prep Program, 
Tutor/Facilitator, Indianapolis, IN 
 
2009 IU School of Medicine Teaching Assistant & Lecturer J210, 
Principles in Microbiology, 2009-11 
  
Publications: 
 
1. Mwanthi, M., S. Chen, E. Michaels, K. Staser, Z. Sun, S. Sehra, D. 
Wilkes, M. Kaplan, S.Park, and D. W. Clapp. 2012. PAK1 regulates 
eosinophil migration in vivo and in vitro (In submission) 
 
2. Staser, KW, M. Shew, E. Michaels, M. Mwanthi, D. Clapp, and S. 
Park. 2011. A Pak1-PP2A-Ezrin signaling axis mediates IgE-
dependent F-actin rearrangement and degranulation in mast cells. 
Exp Hematology, 2012 
 
3. Zeng, Y., K. Staser, K. Menon, S. Park, M. Mwanthi, L. Jiang, and 
D. W. Clapp. 2012. Ezrin Regulates Hematopoietic Stem/Progenitor 
Cell Motility (In preparation) 
 
 
 
 
 
Abstracts and Presentations: 
 
1. Mwanthi MM, Micheals GE, Park SJ, Clapp DW. “PAK1’s regulation 
of eotaxin-mediated murine eosinophil migration” IUSM Medical 
Scientist Training Program (MSTP) retreat, July 2009, Lafayette, IN 
(Abstract and Poster) 
 
2. Mwanthi MM, Micheals GE, Yongqi Y, Tepper RS, Park SJ, Clapp 
DW. “PAK1 Modulates F-Actin Dynamics in Murine Eosinophil 
Migration and Tissue Infiltration”. Annual Biomedical Research 
Conference for Minority Students (ABRCMS), Nov 4-7 2009, 
Phoenix, AZ (Abstract and Poster) 
 
3. Mwanthi MM, Micheals GE, Yongqi Y, Tepper RS, Park SJ, Clapp 
DW. “PAK1 regulates eotaxin-mediated eosinophil migration and 
inflammation” American Society of Clinical Investigation 
(ASCI/AAP) 2010: April 17, 2010, Chicago, IL (Abstract and Poster) 
 
4. Mwanthi MM, Micheals GE, Yongqi Y, Tepper RS, Park SJ, Clapp 
DW. “PAK1 Regulates Eotaxin-Mediated Murine Eosinophil 
Migration and Tissue Infiltration”. Sigma Xi Research Day May 10, 
2010, Indianapolis, IN (Abstract and Oral Presentation) 
 
5. Mwanthi MM, Micheals GE, Staser KW, Yongqi Y, Tepper RS, Park 
SJ, Clapp DW. “PAK1 regulates eotaxin-mediated eosinophil 
migration” Regional conference, National Organization for the 
Professional Advancement of Black Chemists and Chemical 
Engineers (NOBCCHE), November 4, 2011, Indianapolis, IN 
(Abstract and Poster)  
 
6. Mwanthi MM, Micheals GE, Staser KW, Sehra S, Jander M, Chen 
S, Wilkes DS, Kaplan, MH, Park SJ, Clapp DW. Annual conference 
for American Society of Hematology: “PAK1 regulates eotaxin-
mediated eosinophil migration in vivo and in vitro” December 9, 
2011, San Diego, CA (Abstract and Oral Presentation) 
 
7. Mwanthi MM, Chen S, Micheals GE, Staser KW, Yongqi Y, Sehra 
S, Tepper RS, Kaplan, MH, Park SJ, Clapp DW. “PAK1 regulates 
eotaxin-mediated eosinophil migration” 10th Annual Midwest Blood 
Club Symposium, March 15, 2012, Indianapolis, IN (Abstract and 
Poster) 
 
 
 
 
 
 
8. Walline C, Benson H, Sehra S, Mwanthi M, Fisher A, Clapp DW, 
Brutkiewicz R, Kaplan M, Wilkes DS, and Blum, J. “Alterations in 
pulmonary immunity in response to vaccinia virus”  Immunology 
98th Annual Meeting May 14-15, 2011, San Francisco, CA 
(Abstract, Poster and Oral Presentation) 
 
9. Zeng, Yi, Staser KW, Menon KM, Park SJ, Mwanthi MM, Jiang L, 
and Clapp DW.  “Ezrin Regulates Hematopoietic Stem/Progenitor 
Cell Motility” Annual conference for American Society of 
Hematology, December 10, 2011, San Diego, CA (Abstract and 
Poster) 
